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Abstract
Aims:
To fully characterise the RGC-5 cell line and determine whether it would be a suitable
subsƟtute for primary RGC cell culture. To opƟmise a CNTF Nogo-P4 inhibitory assay and
establish whether (a) CNTF alone is capable of sƟmulaƟng RGC neurite outgrowth and
survival, or (b) an increase in intracellular cAMP is required for CNTF to be eﬀecƟve. To
determine whether recombinant AAV2 viral constructs were capable of producing de-
tectable levels of CNTF in HEK-293 transfected condiƟoned media. To opƟmise AAV2-
eGFP delivery and establish whether AAV2-CNTF-hrGFP and AAV2-CNTF-shRhoA-hrGFP
could promote RGC survival and regeneraƟon aŌer opƟc nerve crush surgery.
Methods:
The RGC-5 cell line was characterised using semi-quanƟtaƟve PCR, sequencing and im-
munocytochemistry. RGC-5 cells were screened for a selecƟon of neuronal, glial, progen-
itor, oligodendroglial lineages and cone photoreceptor cell markers to idenƟfy the cells
origin. ReƟnal cultures were treated with recombinant CNTF and/or Forskolin to pro-
mote RGC neurite outgrowth and survival - this was quanƟﬁed aŌer 3 d. ReƟnal whole-
mounts were prepared to assess GFP transducƟon and survival aŌer intravitreal delivery
of AAV2-eGFP. Axonal regeneraƟon and RGC survival were assessed through histological
examinaƟon of opƟc nerves and reƟnal secƟons.
Results:
The RGC-5 cell line predominantly expressed oligodendroglial lineage markers and only
weakly expressed ßIII-Tubulin mRNA. RGC-5 cells did not express mRNA for many of the
phenotypic markers of RGC. CNTF was eﬀecƟve at sƟmulaƟng RGC neurite outgrowth
without the need for cAMP elevaƟon - furthermore recombinant CNTF could disinhibit
Nogo-P4 treated RGC in vitro. GFP transducƟon was low when injected alone, however,
when administered with Pronase-E there was a signiﬁcant increase in GFP expression.
AAV2-CNTF-hrGFP and AAV2-CNTF-shRhoA-hrGFP did not promote RGC survival or re-
generaƟon 23 d post opƟc nerve crush.
Conclusions:
RGC-5 cells are not an appropriate subsƟtute for primary reƟnal cell culture in vitro as
they express many of the samemarkers as oligodendrocyte progenitors. CNTF is capable
of sƟmulaƟng RGC neurite outgrowth without an addiƟonal elevaƟon of cAMP. AAV2-
mediated GFP expression could be enhanced through the parƟal digesƟon of the inner
limiƟngmembrane - this seems to be themajor obstacle in achieving opƟmal AAV2 trans-
ducƟon.
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CHAPTER 1
GENERAL INTRODUCTION
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1.1 Anatomy of the visual system
The visual system has a single populaƟon of neurons within the reƟna (ReƟnal ganglion
cells) that extend their axons to form the opƟc nerves. The opƟc nerve (ON) decussates
at the opƟc chiasm to form the opƟc tracts which synapses at the lateral geniculate nu-
cleus (LGN) and superior colliculus (SC) (Berry, et al. 2008). Visual informaƟon is directed
from these structures to the visual neocortex for processesing, the motor nuclei in the
brain stem and cord for visually guided movement and the accessory oculomotor nu-
cleus for accommodaƟon reﬂexes (Berry et al. 2008). InteresƟngly, not all axons in the
ON originate from reƟnal ganglion cells (RGC). A small subpopulaƟon of reƟnopetal axons
originate from pepƟdernergic neurons in the hypothalamus (and other limbic structures)
and terminate in the reƟna (Vereczki, et al. 2006).
1.1.1 OrganisaƟon of the reƟna
The reƟna is a highly organised structure which can be described in terms of its layers
(see ﬁgure 1.1). The ganglion cell layer (GCL) contains the cell bodies of RGC, and their
unmyelinated axons make up the nerve ﬁbre layer (NFL) — this layer is also occupied
by astrocytes which become re-acƟve aŌer injury (Berry et al. 2008). The NFL layer is
isolated from the vitreous by an inner limiƟng membrane which is composed primarily
of basal lamina, plus Müller cell and astrocyte end feet (Berry et al. 2008). The inner
nuclear layer (INL) contains the cell bodies of amacrine, horizontal, bipolar and Müller
cells, whilst the outer nuclear layer (ONL) contains the cell bodies of both rods and cones
(Berry et al. 2008). The raƟo of rods to cones varies within the reƟna — there is a higher
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raƟo of rods to cones in the periphery as well as a higher proporƟon of photoreceptors to
ganglion cells. At the back of the reƟna there is a layer of reƟnal pigmented epithelium
which acts as a protecƟve barrier and prevents the reﬂecƟon of light striking the back of
the reƟna tomaintain image integrity. SynapƟc connecƟons between interneurons occur
in the inner plexiform and outer plexiform layers (Berry et al. 2008).
Figure 1.1: OrganisaƟon of the reƟna. The reƟna is a highly organised structure which can be
described in terms of its layers. RGC lie within the GCL and their unmyelinated axons lie within the
NFL. This layer also contains astrocytes which become reacƟve aŌer injury. The NFL is separated
from the vitreous by the inner limiƟng membrane. Bipolar, amacrine and horizontal cells reside
within the INL. Rod and cone photoreceptors occupy the ONL. SynapƟc connecƟons between
interneurons occur in the inner plexiform layer (IPL) and outer plexiform layer (OPL). (Reproduced
with permission from Prof. Ann Logan) (Berry et al. 2008).
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1.2 RGC structure funcƟon and development
The ON and eye are highly specialised central nervous system (CNS) structures which
are formed from the neural tube. Eye development in vertebrates is characterised by
bilateral evaginaƟon of the diencephalon (opƟc vesicle). The opƟc vesicle then makes
contact with the surface ectoderm and folds back on its self to form the opƟc cup. The
thin outer region of the opƟc cup forms the reƟnal pigmented epitheliumwhilst the inner
region forms the reƟna (Chow & Lang 2001).
In the reƟna, cell diﬀerenƟaƟon from reƟnal precursors occurs in the inner layer of the
opƟc cup and gradually expands out towards the peripheral edge of the reƟna. Cell dif-
ferenƟaƟon from reƟnal precursors tends to occur in a very speciﬁc order. In the rat
generaƟon of all the major cell types commences between Embryonic day 14 and 20
(E14-E20) (Reese & Colello 1992).
RGC diﬀerenƟaƟon commences at around E14, these cells then migrate towards the in-
ner limiƟng membrane (ILM) of the reƟna to form the GCL (Werner & Chalupa 2004).
Amacrine cells emerge shortly aŌerwards, although this process overlaps considerably
with RGC neurogenesis and does not occur sequenƟally (Reese & Colello 1992). At this
point, synapƟc connecƟons are established between the RGC and amacrine cells to form
the IPL of the reƟna (Werner & Chalupa 2004). Cone photoreceptors migrate at this
point, but do not diﬀerenƟate unƟl much later (Werner & Chalupa 2004). This is im-
mediately followed by the generaƟon and diﬀerenƟaƟon of bipolar cells and Müller glia
(Werner & Chalupa 2004). At this stage, cone and rod photoreceptors of the ONLmature
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and form synapƟc connecƟons with bipolar and horizontal cells in the OPL (Werner &
Chalupa 2004).
1.2.1 RGC cell fate
For the most part, the way in which cell fate is determined remains unclear — however,
there are some studies which have provided insight. Progenitor cells which are desƟned
to become RGC express transcripƟon factors such as brain-3 (Brn-3) and reƟna derived
POU-domain factor-1 (RPF-1) (Wang & Kim 2001). Sonic hedgehog (Shh) also appears
to be an important determinant of RGC cell fate – as its expression leads to the gener-
aƟon and diﬀerenƟaƟon of new RGC (Isenmann & Kretz 2003). Furthermore, Shh has
been shown to regulate paired box gene-6 (PAX-6) (a gene which plays a pivotal role in
eye development) gene expression, for example, downregulaƟon of PAX-6 directs reƟ-
nal progenitors towards an amacrine cell fate whilst overexpression of PAX-6 increases
the rate of RGC diﬀerenƟaƟon and decreases photoreceptor cell number (Isenmann &
Kretz 2003).
Like many other neuronal populaƟons, once diﬀerenƟated, RGC loose the property of
self renewal and can't be replaced aŌer death. Newly established RGC extend their axons
through the ON, decussate at the opƟc chiasm and conƟnues on through the opƟc tracts
to make contact with their midbrain targets (e.g. LGN and SC) (Berry et al. 2008).
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1.2.2 RGC morphology and classiﬁcaƟon
RGC can be sorted into subcategories based on their dendriƟc morphology, dendriƟc
ﬁeld, cell size and locaƟon of dendriƟc arborisaƟon. In 1974 BoycoƩ and Wassle pro-
posed a classiﬁcaƟon system for the cat. RGC of the cat were subdivided into alpha, beta,
gamma and delta types based on their size andmorphology (BoycoƩ &Wassle 1974). Al-
pha cells have large cell bodies and wide dendriƟc ﬁelds, making up approximately 3% of
cat RGC (Kolb 1981). In the centre of the reƟna the density of alpha cell bodies is high
and the dendriƟc ﬁeld is small, whilst in the periphery the reverse is true (Wassle 2004).
Alpha cells are not conﬁned to the reƟna of cats, they can also be found in a variety of
mammals (rats, ferrets, guinea pigs, mice and ox) cited in (Wassle 2004). Beta cells have
small dendriƟc ﬁelds making up approximately 50% of cat RGC (Kolb 1981).
Another commonly used classiﬁcaƟon system for the cat was based on their physiologi-
cal responses to visual sƟmuli (Y, X and W types). Since then it's been found that there
was a correlaƟon between alpha, beta, gamma and delta morphologies with Y, X and W
type physiological responses (Bear, et al. 2001). There are two addiƟonal classiﬁcaƟons
which should also be menƟoned, namely M-type (or Midget RGC) and P-type ganglion
cells (or Parasol RGC). These ganglion cell subtypes have been idenƟﬁed in the monkey
and human reƟna (Bear et al. 2001). M-type RGC are thought to be the human equiva-
lent of cat alpha cells and P-type RGC are thought to be the human equivalent of cat beta
cells(Wassle 2004). M-type RGC are typically larger and account for approximately 5% of
the total ganglion cell populaƟon, whilst P-type RGC are signiﬁcantly smaller making up
the majority (≈90%), of the total cell populaƟon (Bear et al. 2001). The remaining 5% of
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ganglion cells are made up of a completely diﬀerent class of ganglion cells (non-M and
non-P subtypes) (Bear et al. 2001).
The funcƟonal properƟes of each of these subtypes diﬀers considerably, for example,
M-type RGC have larger recepƟve ﬁelds, propagate acƟon potenƟals more rapidly and
are sensiƟve to low contrast sƟmuli (Bear et al. 2001). Furthermore, sƟmulaƟon of their
recepƟveﬁelds induces a transient burst of acƟonpotenƟals (Bear et al. 2001). In contrast
sƟmulaƟon of P-type RGC leads to the sustained ﬁring of acƟon potenƟals – in fact this
period of sustained acƟvity conƟnues unƟl the sƟmulus has ceased (Bear et al. 2001). As
a result, M-type RGC are thought to be important in terms of detecƟon of movement,
whilst P-type RGC are more important in terms of visual acuity (Bear et al. 2001).
1.2.3 RGC recepƟve ﬁelds
RGC can be further categorised based on their branching locaƟon, for example RGCs
which branch at diﬀerent depths of the sublamina. The sublamina of the reƟna can be
divided into (A) RGCwith ON recepƟve ﬁelds and (B) RGCwith OFF centre recepƟve ﬁelds
(Nelson & Famiglieƫ 1978). A recepƟve ﬁeld is an area of reƟna that can be sƟmulated to
ﬁre acƟon potenƟals (through changes in RGC membrane potenƟal) in response to light
(Bear et al. 2001). ON-centre RGC ﬁre acƟon potenƟals when light strikes the centre of
their recepƟve ﬁelds, whereas OFF-centre RGC are acƟvated when a shadow falls on the
centre of its recepƟve ﬁeld (Bear et al. 2001). The majority of RGC in the reƟna display
this property and have either ON or OFF centre recepƟve ﬁelds. The way in which this
characterisƟc distribuƟon is established is believed to occur through cell death. Axons
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compete for a limited number of trophic factors at their designated post-synapƟc targets
– those which receive more trophic support typically survive and those that are outcom-
peted die through apoptoƟc mechanisms (Sernagor & Eglen 2001). The overall purpose
of this type of conﬁguraƟon is so that RGC can respond to changes in light intensity.
1.2.4 Colour opponent RGC
A small populaƟon of RGC are also sensiƟve to speciﬁc wavelengths of light, namely
colour opponent RGC. This means that the response to one wavelength (e.g. red), strik-
ing the centre of the recepƟve ﬁeld can be cancelled out by the response of another (e.g.
green), striking the perimeter of the recepƟve ﬁeld (Bear et al. 2001). The central re-
gion of RGC recepƟve ﬁeld receives inputs from mainly red cones, whilst the periphery
receives inputs from green cones – therefore the response to red wavelengths can only
be cancelled out by the response of green wavelengths (Bear et al. 2001). This type of
conﬁguraƟon is typically seen in P-type RGC, whereas blue/yellow colour opponency is
oŌen found in non-M non-P type RGC (which works the same way). M-type RGC do not
exhibit this property, since the centre and periphery of the recepƟve ﬁeld are fed into by
mulƟple types of cones (Bear et al. 2001).
1.3 Histology of the opƟc nerve
The ON is occupied by four types of glia, namely: oligodendrocytes, astrocytes, microglia
and neuron-glial anƟgen 2 (NG2) glia. Within the reƟna RGC axons are unmyelinated,
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upon entering the lamina cribrosa these axons are myelinated by resident oligodendro-
cytes. RGC axons are separated by rows of myelinaƟng oligodendrocytes (Berry et al.
2008). These rows are occasionally interrupted by astrocytes, NG2 glia ormicroglia (Berry
et al. 2008).
Figure 1.2: DiagrammaƟc RepresentaƟon of the ON. The ON is predominantly composed of
myelinated RGC axons. These axons are separated by rows of myelinaƟng oligodendrocytes.
These rows are occasionally interrupted by astrocytes, NG2 glia and microglia. This diagram re-
produced with permission from Prof. Ann Logan (University of Birmingham) (Berry et al. 2008).
1.3.1 Anatomical diﬀerences between humans and rats
In animals with monocular visual ﬁelds, i.e. rats, 90% of RGC axons decussate at the
chiasm — whereas in mammals with stereoscopic vision, i.e. humans, 60% of ﬁbres
project contralaterally to the visual cortex (Berry et al. 2008). In rats the reƟnal artery
runs through the dural sheath, as such we can fully transect the ON whilst maintaining
the reƟnal blood supply.
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1.4 TheONas amodel system to studyCNS injury responses
The ON can be used as a model to study the cellular and molecular mechanisms under-
lying neuro-regeneraƟve failure. The anatomical simplicity and accessibility of the ON
allows us to dissect out basic mechanisms which inhibit or promote axon growth within
the CNS as a whole. With this model it is possible to completely transect RGC axonal pro-
jecƟons from their target cells. As the eye is a relaƟvely enclosed system, speciﬁc cells
can be targeted and drug dose can be regulated more eﬀecƟvely. Axon regeneraƟon can
be assessed by intravitreal injecƟon of anterograde tracers e.g. cholera toxin or through
growth-associated protein-43 (GAP-43) immunohistochemistry (IHC) (Berry et al. 2008).
Retrograde tracers e.g. Fluorogold, can be injected proximal to the crush to assess RGC
survival through the use of reƟnal wholemount preparaƟons. Furthermore, funcƟonal
recovery can be assessed through the measurement of visually evoked potenƟals, pupil-
lary reﬂexes and visually guided behaviour (Berry et al. 2008).
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1.4.1 The CNS injury response
The extent of CNS damage can vary depending on the type of injury, the spread of damage
and the extent of secondary reacƟons. CNS injuries typically sever axons, damagemyelin
sheaths and blood vessels and can cause catastrophic damage to the CNS through both
primary and secondary reacƟons. It is also important to note that cellular responses can
vary depending on damage locaƟon and developmental age.
The primary responses to CNS injuries are typically iniƟated by mechanical damage and
lead to apoptosis and necrosis of cells in the immediate vicinity, for example, mem-
branes and myelin sheaths may be injured leading to the release of myelin inhibitory
ligands (see secƟon 1.6.0.1) and other extracellular matrix molecules (see secƟon 1.6.4).
In addiƟon to this, the vasculature is commonly disrupted leading to inﬁltraƟon of a vari-
ety of haematogenous cells (macrophages, monocytes, neutrophils, platelets and serum)
(Berry 1998).
AŌer the iniƟal insult a whole host of secondary reacƟons occur. Platelets commence a
cloƫng reacƟon to stem the haemorrhage from severed blood vessels and monocytes
diﬀerenƟate into macrophages to phagocytose necroƟc debris and blood clots (Berry
1998). InﬁltraƟng neutrophils, monocytes and lymphocytes sƟmulate the release of a
whole host of chemokines which potenƟates the inﬂammatory response (Berry 1998)
andmacrophages sequester erythrocytes from the haemorrhagic core, reducing its over-
all volume (Berry 1998). The macrophages, monocytes and neutrophils secrete a whole
host of trophic cytokines (tumour necrosis factors, interleukins, TGFβ's, ﬁbroblast growth
factors and insulin-like growth factors) and sƟmulate the release of a variety of endoge-
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nous trophic factors from both neurons and glia (Berry 1998). Resident microglia also
play an important role in debris clearance by accumulaƟng around the injury site and
phagocytosing any cellular debris (Berry 1998). This is also accompanied by a change in
morphology and upregulaƟon of major histocompaƟbilty complex anƟgens (MHC I and
II), leukocyte common anƟgen (LCA), nucleoside diphosphatase (NDPase) and comple-
ment type 3 receptor (CR3) (Berry 1998).
ReacƟve astrocytes proliferate around the injury site and release axon growth inhibitory
molecules (CSPG, keraƟn sulphate proteoglycan and tenascin) which contribute towards
regeneraƟve failure (see secƟon 1.6.4). This gliosis is typically idenƟﬁed by a change
in cell morphology and upregulaƟon of glial ﬁbrillary acidic protein (GFAP) (Berry et al.
2008).
The numbers of haematogenous cells are reduced 3 to 8 days post-injury (dpi) as endoge-
nous gliosis is ampliﬁed. Wound margins are established and a basal lamina is formed at
the astrocyte end feet boundary (Berry 1998). This structure comprises the glia limitans
and forms a conƟnuous barrier against the inﬁltraƟon of unwanted cells and molecules
(Berry 1998). The lesion core conƟnues to shrink between 8 dpi to 20 dpi— this structural
change is accompanied by compacƟon of astrocyƟc processes and GFAP down regulaƟon
(Berry 1998).
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1.5 Glia
Glial cells make up approximately 90% of cells present within the CNS - although glial cells
were originally thought to purely have a structural role (Weigert 1895), it has become
increasingly clear that glial cells have a variety of diﬀerent funcƟons, and are essenƟal
for normal CNS funcƟon and development. Four populaƟons of glia exist in the CNS,
namely, astrocytes, microglia and NG2 glia and oligodendrocytes.
1.5.1 Astrocytes
Astrocytes have a stellate morphology consisƟng of mulƟple processes which interact
with numerous neurons to provide stability and support. Astrocytes have a number of
diﬀerent funcƟons in health and disease. Neuronal damage and changes in the extra-
celluar environment triggers the upregulaƟon of GFAP (Berry 1998). Astrocytes are a
major source of matrix and adhesion molecules e.g. laminin, ﬁbronecƟn, cytotacƟn-J1.
Astrocytes also secrete pro-survival factors such as nerve growth factor (NGF), cilliary
neurotrophic factor (CNTF) and S100-protein which have been shown to promote neu-
rite outgrowth (Berry 1998).
1.5.2 NG2 glia
NG2 glia or `synantocytes' are highly abundant in the CNS and are distributed evenly
throughout grey and white maƩer, making up approximately 8-9% of all white maƩer
cells and 2-3% of grey maƩer cells (Dawson & Polito 2003). NG2 glia has a stellate mor-
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phology and can be idenƟﬁed by their expression of platelet derived growth factor re-
ceptor alpha (PDGFRα), A2B5 and NG2 (Verkhratsky & BuƩ 2007). During development
NG2 glia generate myelinaƟng oligodendrocytes (Rivers, et al. 2008). NG2 glia persist in
adulthood and retain some stem cell characterisƟcs (Verkhratsky & BuƩ 2007).
1.5.3 Microglia
Microglial cells consƟtute the resident phagocyƟc cells of the CNS, making up approxi-
mately 10% of the total glial populaƟon (Hanisch & KeƩerman 2007, Barres 2008). Mi-
croglia are derived from blood borne monocytes and mesenchymal progenitor cells, to a
lesser extent (Guillemin & Brew 2003).
Under normal condiƟonsmicroglia are thought to act as environmental sensorswhich are
able to rapidly respond to extracellular cues (microbes, serum, intracellular components,
protein aggregates) induced by trauma or infecƟon (Hanisch & KeƩerman 2007). To fulﬁl
this role they conƟnuously rebuild their processes to allow them to eﬃciently monitor
the CNS environment (Hanisch & KeƩerman 2007).
AŌer injurymicroglial cells assume a `reacƟve' proﬁle and temporarily cease their surveil-
lance acƟvity. This change in reacƟve state can be idenƟﬁed morphologically (processes
become shorter and thicker) and histologically (through the up regulaƟon of phagocyƟc
makers such as CD68 and CD11b)(Ransohoﬀ & Perry 2009).
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1.6 Why doesn't the mammalian CNS regenerate?
Injury to the mammalian CNS has catastrophic funcƟonal consequences, oŌen resulƟng
in paralysis, loss of sensaƟon, chronic pain and loss of bladder control (Donovan 2007).
For many years the mammalian CNS was deemed to be incapable of regeneraƟon. As a
result, research in this area was impeded for almost a century (Cajal 1928). This assump-
Ɵon was ﬁrst challenged by a series of early experiments which demonstrated that some
injured axons were capable of regeneraƟng long distances in the permissive environment
of a PN graŌ (David & Aguayo 1981). Unfortunately regeneraƟon was short lived, with
axons being unable to re-enter the CNS environment. This phenomenon has also been
documented in the reƟna, where axons were unable to enter the ON head (McConnell
& Berry 1982) unless a PN implant was present (Cotman 1985, Berry, et al. 1986). Re-
generaƟon was halted when axons encountered CNS myelin. CNS myelin is formed by
oligodendrocytes and its primary purpose is to increase the speed at which acƟon poten-
Ɵals are propagated along myelinated ﬁbres by saltatory conducƟon – it is essenƟal for
normal CNS funcƟon (Zalc & Colman 2000). These observaƟons led researchers to inves-
Ɵgate the environmental factors which play an important role in regeneraƟve failure.
1.6.0.1 Myelin inhibitory ligands
CNS myelin was ﬁrst implicated as a potenƟal inhibitor of neurite outgrowth aŌer a se-
ries of experiments showed that dissociated neurons could invade and extend neurites
along sciaƟc nerve explants, but not ON explants (Schwab & Thoenen 1985). Further
evidence came from experiments performed by Huang et al which showed that mice im-
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munised with central myelin extract 3 weeks before spinal cord injury showed signiﬁcant
axonal regeneraƟon across the lesion site (Huang, et al. 1999). Success was aƩributed
to the producƟon of polyclonal anƟbodies which speciﬁcally blocked myelin associated
inhibitors and prevented growth cone collapse.
Myelin associated glycoprotein
Myelin associated glycoprotein (MAG) is a 100 kDa transmembrane glycoprotein which
is a member of the immunoglobulin (Ig) family of proteins. MAG has two isoforms, large
MAG (L-MAG) and smallMAG (S-MAG), each ofwhich have diﬀerent cytoplasmic domains
(Filbin 2003).
S-MAG L-MAG
V-set Ig domain
4 Ig-like domains
Figure 1.4: DiagramaƟc RepresentaƟon of MAG
Structure. DiagramaƟc representaƟon of the
two MAG isoforms. Diagram modiﬁed from
(Profyris et al. 2004)
MAGhas ﬁve extracellular Ig-like domains,
a V-set Ig domain which binds to sialic acid
and an intracellular C-terminus (Profyris
et al. 2004, Filbin 2003). The primary func-
Ɵon of MAG is to maintain axon-myelin
stability and cytoskeletal integrity and al-
though MAG has many roles in axon-
myelin maintenance, it is not required
for myelinaƟon (Schnaar & Lopez 2009).
Found in both PNS and CNS myelin, MAG
has a relaƟvely low abundance, making up
only 1% of CNS myelin and 0.1% of PNS myelin (Schnaar & Lopez 2009). Despite its
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low abundance, MAG has potent inhibitory properƟes and is capable of inducing growth
cone collapse both in vitro (Huang et al. 1999, Filbin 2003) and in vivo (Mukhopadhyay,
et al. 1994). These inhibitory properƟes were ﬁrst revealed in 1994 when MAG was iso-
lated from PNS myelin extract and applied to neuronal cells to inhibit neurite outgrowth
(Mukhopadhyay et al. 1994, McKerracher, et al. 1994). InteresƟngly, the inhibitory prop-
erƟes of MAG are cyclic adenosine monophosphate (cAMP) dependent, being inhibitory
in the mature CNS where cAMP levels are low, and permissive in the embryonic CNS
where cAMP levels are elevated (Cai, et al. 2001).
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Oligodendrocyte myelin glycoprotein
LRR
Ser/Thr rich
domain
GPI anchor
OMgp
Figure 1.5: Structure of oligodendrocyte
myelin glycoprotein (OMgp). OMgp has 8
leucine rich repeat (LRR) domains followed
by a serine/threonine rich domain and is at-
tached to the membrane through a glyco-
syl phosphaƟdylinositol (GPI) anchor. Fig-
ure modiﬁed from (Profyris et al. 2004)
OMgp is a 120 kDa GPI linked protein. It was
ﬁrst idenƟﬁed as aminor component of myelin
and is expressed by both neurons and oligo-
dendrocytes. Expression is localised primar-
ily to the paranodal loops next to the Nodes
of Ranvier where it is ideally placed for ax-
onal interacƟon (Filbin 2003). OMgp has 8 LRR
domains at its N-terminus, followed by a ser-
ine/threonine rich domain which is required
for nogo receptor (NgR) binding (Profyris et al.
2004). Like both MAG and neurite outgrowth
inhibitor (Nogo), OMgp is capable of inhibiƟng
neurite outgrowth in vitro (Filbin 2003).
Neurite outgrowth inhibitor
Nogo is a member of the reƟculon family of
proteins and is localised primarily to the endo-
plasmic reƟculum (Filbin 2003). The ﬁrst indi-
caƟon that Nogo was inhibitory came from studies performed by Schwab et al in the late
1980 s (Caroni & Schwab 1988). In this study, the IN-1 monoclonal anƟbody was raised
against a fracƟon of CNS myelin which was known to inhibit neurite outgrowth. Appli-
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caƟon of this anƟbody resulted in disinhibited neuronal growth both in vitro (Caroni &
Schwab 1988) and in vivo (Schnell & Schwab 1990). Despite this breakthrough, it was
not unƟl the year 2000 that the anƟgen for this anƟbody was cloned and idenƟﬁed
(Prinjha 2000, Chen, et al. 2000, GrandPre, et al. 2000). Nogo exists in three isoforms,
(Nogo-A, Nogo-B and Nogo-C) all of which share a common carboxyl (C) terminal do-
main (Filbin 2003). The inhibitory properƟes of Nogo are aƩributed to two extracellular
domains: Nogo-66, which is common to all three isoforms, and amino-Nogo, which is
speciﬁc to Nogo-A (Filbin 2003). The topology of Nogo-A remains unclear, but two struc-
tural conformaƟons have been proposed. The ﬁrst proposal places Nogo-66 in the extra-
cellular compartment and amino-Nogo in the cytoplasm, whilst the alternaƟve sugges-
Ɵon places amino-Nogo in the extracellular compartment and Nogo-66 in the cytoplasm
(Filbin 2003). Numerous studies have suggested that both topologies may co-exist in the
CNS environment (Chen et al. 2000, GrandPre et al. 2000).
Figure 1.6: Structural Arrangement of Nogo-A, Nogo-B and Nogo-C. Nogo exists as 3 isoforms –
Nogo-66 is common to all three isoforms, however amino-Nogo is speciﬁc to Nogo-A. There has
been some debate over the structural conformaƟon of Nogo-A, one proposal places amino-Nogo
in the extracellular compartment whilst the other places it in the cytoplasm. Figure reproduced
from (Filbin 2003).
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1.6.0.2 Myelin inhibitory ligand receptors
Nogo-66 Receptors
MAG, Nogo and OMgp all bind to the Nogo-66 receptor (NgR1+2) to elicit their Rho me-
diated biological eﬀects. A member of the LRR superfamily (Fournier, et al. 2001), NgR1
is a glycosyl phosphaƟdylinositol-linked membrane protein which is expressed primar-
ily by neurons of the CNS (Fournier et al. 2001). As this receptor is GPI-linked it does
not possess an intracellular signalling domain and requires a co-receptor to transduce
inhibitory signals. This prompted researchers to idenƟfy NgR and several co-receptors,
namely: low-aﬃnity p75 neurotrophin receptor (p75NTR), tumour necrosis factor (TNF)
receptor 19 , and LRR and Ig domain containing 1.
p75NTR, Tumour necrosis factor receptor 19 (Troy) and Lingo-1
p75NTR is a glycosylated membrane protein and a member of the TNF receptor super-
family. In addiƟon to its role as a low aﬃnity neurotrophin receptor, numerous lines of
study have idenƟﬁed p75NTR as a co-receptor for NgR1 (Yamashita, et al. 2002, Wong,
et al. 2002). p75NTR was ﬁrst implicated as an interacƟng partner of NgR1 aŌer neurons
isolated from p75NTR knockout mice only exhibited a limited response to MAG, Nogo and
OMgp treatment (Yamashita et al. 2002, Wang, et al. 2002). This was followed by co-
immunoprecipitaƟon studieswhich revealed that p75NTR formed a receptor complexwith
NgR1 (Wong et al. 2002, Wang et al. 2002). InteresƟngly p75NTR is not expressed univer-
sally, being present in only a small subpopulaƟon of neurons (Park, et al. 2005). It may be
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that p75NTR has amore prominent role in the developing CNS, as messenger RNA (mRNA)
expression rapidly declines with maturity (Shao, et al. 2005).
In contrast, Troy mRNA is broadly expressed in the mature CNS and may act as the pre-
dominant co-receptor postnatally (Shao et al. 2005). Its funcƟon as an NgR1 co-receptor
was conﬁrmed aŌer a series of binding and co-immunoprecipitaƟon assays (Shao et al.
2005). COS-7 cells were treated with OMgp, MAG and Nogo aŌer transfecƟon with var-
ious combinaƟons of Troy, NgR1 and leucine rich repeat and Ig domain containing 1
(Lingo-1). Rho acƟvaƟon was used as a funcƟonal readout of receptor acƟvaƟon (Shao
et al. 2005). They found that only the combinaƟon of Troy, NgR1 and Lingo-1 acƟvated
Rho, and concluded that Troy could be used as a subsƟtute for p75NTR (Shao et al. 2005).
As Troy alone was incapable of transducing the inhibitory signalling, the requirement for
an NgR1 receptor complex was also conﬁrmed (Shao et al. 2005). Neurons isolated from
Troy knockoutmice only exhibited a limited response toMAG, OMgp andNogo, andwere
able to extendneurites overmyelin inhibitory ligand (MIL) coated slides (Shao et al. 2005).
Higher concentraƟons were able to inhibit neurite outgrowth, but this was aƩributed to
the presence of p75NTR (Shao et al. 2005).
To form a funcƟonal receptor complex with NgR, Lingo-1 is also required. Lingo-1 belongs
to the TNF receptor superfamily and is expressed exclusively by neuronal Ɵssue (Mi, et al.
2004). Lingo-1 has a 12 leucine-rich repeat domain which commences at the N terminus.
This is followed by an Ig and transmembrane domain, as well as a short cytoplasmic tail
(Mi et al. 2004). COS-7 cells transfectedwith NgR1 are able to directly interact with Lingo-
1 fusion proteins (Mi et al. 2004). However, cells transfected with NgR1 and p75NTR were
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insensiƟve to OMgp treatment. Only cells triple transfectedwith NgR1, p75NTR and Lingo-
1 were capable of acƟvaƟng Rho and transducing the inhibitory signal (Mi et al. 2004).
1.6.1 The growth cone
To be able to understand how these inhibitorymolecules induce growth cone collapse it is
important to ﬁrst describe the molecular machinery which underlies axon guidance. The
growth cone is a specialised structure (see ﬁgure 1.7) at the end of an axon which senses
environmental cues and guides the axon through the developing CNS to its correct target.
The leading edge (or peripheral domain) of the growth cone contains ﬁnger-like struc-
tures called ﬁlopodiawhich are separated bymembrane sheets of lamellipodia (Lowery&
Vactor 2009). Long ﬁlamentous-acƟn (F-acƟn) bundles reside beneath this structure and
make up the ﬁlopodia whilst branched F-acƟn networks make up the lamellipodia. The
transiƟon domain (T-domain) resides between the central and peripheral regions of the
growth cone and is ﬂanked by an F-acƟn arc. Peripheral domain (P-domain) microtubules
are thought to act as guidance sensors, whilst central domain (C-domain) microtubules
provide stability to the overall structure (Lowery & Vactor 2009).
Growth cone protrusion and advancement is highly reliant on the dynamic properƟes
of acƟn. F-acƟn bundles are elongated through polymerisaƟon at the leading edge of
the growth cone — this process eﬀecƟvely pushes the plasma membrane forward. Con-
comitantly, polymerised secƟons of F-acƟn are severed at the proximal end of ﬁlopo-
dia/lamellipodia and recycled as monomers. Growth cone advancement requires a care-
ful balance between F-acƟn polymerisaƟon and recycling.
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F-actin arc
F-actin bundle
F-actin
network
Lamellipodia-like veil
Filopodium
Dynamic
microtubule
Stable
microtubule
Axon shaft
T zone
P domain
C domain
Nature Reviews | Molecular Cell Biology
Actin treadmilling
The process by which the 
continual addition of actin 
subunits at the barbed end  
of an actin polymer and 
disassembly of the polymer  
at the pointed end ensures 
that the polymer stays of 
constant length, but individual 
subunits move along.
Filopodium
A thin, transient actin 
protrusion that extends from 
the cell surface and is formed 
by the elongation of bundled 
actin filaments in its core.
Lamellipodia-like veil
A thin, sheet-like extension of 
cytoplasm between filopodia 
that is formed by branched 
actin networks.
F-actin bundle
Long actin filaments that are 
crosslinked together in parallel, 
forming the core of filopodia.
spatially and to achieve accurate steering. In fact, 
the steering and drivetrain are intimately connected 
at a physical level. Therefore, if we are to fully grasp 
how guidance occurs, it is essential to understand the 
underlying cytoskeletal mechanisms that propel 
the vehicle forward and have the potential to be affected 
asymmetrically.
Turning on the engine: F-actin retrograde flow. Growth 
cone motility and protrusion of the leading edge mem-
brane depend on the dynamic properties of actin (BOX 3). 
Although actin might not be the only engine that powers 
axon elongation per se (axons that lack actin poly mer-
ization can still move forward, albeit with abnormal 
growth cone morphology and substratum selectivity)15, 
actin is a central part of the mechanism that controls 
growth cone exploration. A combination of filamen-
tous (F)-actin treadmilling and F-actin retrograde flow 
(the continuous movement of F-actin from the leading 
edge towards the centre of the growth cone) provide 
the ‘motor’ that keeps the growth cone engine idling 
(FIG. 2a) and available to drive movement in response 
to directional cues16. Following increased technological 
advances in live cell imaging, the past few years have 
seen substantial improvements in our molecular under-
standing of F-actin retrograde flow and how it relates to 
growth cone motility and protrusion.
It has been convincingly demonstrated that F-actin ret-
rograde flow is driven both by contractility of the motor 
protein myosin II, which seems to be tethered through 
protein–protein interactions in the transition (T) zone 
(the region between the peripheral (P) and central (C) 
domains of the growth cone), and the ‘push’ from F-actin 
polymerization in the P domain (the region of the growth 
cone that includes filopodia and lamellipodia-like veils)17. 
Myosin II-driven compression across the T zone cir-
cumference causes buckling of the F-actin bundles (FIG. 2a), 
which might be enhanced by pushing from leading edge 
actin polymerization17. This leads to bundle severing 
near the proximal ends17 and probably involves actin 
filament-severing proteins of the actin-depolymerizing 
factor (ADF)/cofilin family18. A recent paper suggests 
that myosin II might also actively depolymerize actin fila-
ments19. After severing, the actin fragments are recycled 
into individual actin subunits and are available for trans-
port to the periphery for further actin polymerization at 
the leading edge20 (FIG. 2a).
Engaging the clutch and forming traction to push ahead. 
How does the growth cone use the actin engine to move 
forward? Mitchison and Kirschner first proposed the 
‘clutch’ hypothesis21, also called the substrate–cytoskeletal 
coupling model22, which links growth cone protru-
sion to actin dynamics16,23. They suggested that growth 
cone receptor binding to an adhesive substrate leads 
to the formation of a complex that acts like a mole-
cular clutch, mechanically coupling the receptors and 
F-actin flow, thus anchoring F-actin to prevent retro-
grade flow and driving actin-based forward protrusion 
of the growth cone on the adhesive substrate (FIG. 2a). 
Indeed, growth cone–substrate adhesions have long 
been shown to be important for growth cone migra-
tion24 and, in fact, the generation of traction also 
requires myosin II25.
Filopodia, in particular, are considered to be guid-
ance sensors at the front line of the growth cone and 
might have a major role in establishing growth cone–
substrate adhesive contacts during environmental explo-
ration26. Studies show that filopodia function as points 
of attachment to the substrate and produce tension that 
is used for growth cone progression27,28. Whereas earlier 
studies that blocked filopodia formation using general 
F-actin inhibitors showed abnormal growth cone steer-
ing29,30, a recent study that specifically targeted filopodial 
F-actin suggests that filopodia are dispensible for accu-
rate growth cone guidance but are indeed required for 
normal growth cone motility31, supporting their role in 
forming adhesive contacts.
Accumulating evidence in recent years supports the 
clutch model, in particular in vitro live growth cone 
imaging experiments that use APCAM, a neural CAM 
(NCAM) orthologue in Aplysia californica32, a model 
system with large growth cones that allow the high 
resolution imaging of their cytoskeletal dynamics33. 
Following APCAM-mediated growth cone–substrate 
Box 1 | The structure of the growth cone
The structure of the growth cone is fundamental to its function. The leading edge  
consists of dynamic, finger-like filopodia that explore the road ahead, separated by 
sheets of membrane between the filopodia called lamellipodia-like veils (see the figure). 
The cytoskeletal elements in the growth cone underlie its shape, and the growth cone 
can be separated into three domains based on cytoskeletal distribution14. The peripheral 
(P) domain contains long, bundled actin filaments (F-actin bundles), which form the 
filopodia, as well as mesh-like branched F-actin networks, which give structure to 
lamellipodia-like veils. Additionally, individual dynamic ‘pioneer’ microtubules (MTs) 
explore this region, usually along F-actin bundles. The central (C) domain encloses stable, 
bundled MTs that enter the growth cone from the axon shaft, in addition to numerous 
organelles, vesicles and central actin bundles. Finally, the transition (T) zone sits at the 
interface between the P and C domains, where actomyosin contractile structures (termed 
actin arcs) lie perpendicular to F-actin bundles and form a hemicircumferential ring33.  
The dynamics of these cytoskeletal components determine growth cone shape and 
movement on its journey during development.
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Figure 1.7: Growth cone structure. Growth cone advancement is mediated by the conƟnuous
polymerisaƟon and movement of F-acƟn. PolymerisaƟon of F-acƟn occurs at the leading edge
of the gr wth cone, the growing chain is event ally severed in the transiƟon zone, where it
is eventually ecycled and transported ck to the leading edge for re-use. Protrusion occurs
when the F-acƟn polymerisaƟon occurs at a higher rate than F-acƟn depolymerisaƟon. P-domain
microtubules explore the ﬁlopodial environment and are thought to act as guidance sensors
whilst C-domain microtubules stabilise the overall structure. Figure reproduced from (Lowery
& Vactor 2009).
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When the rate of F-acƟn polymerisaƟon is higher than that of F-acƟn recycling, the lead-
ing edge of the growth cone advances. On the other hand, if the rate of acƟn depoly-
merisaƟon is higher than that of acƟn polymerisaƟon, the leading edge of the growth
cone retracts. However, when F-acƟn monomers are polymerised and recycled at the
same rate, protrusion at the leading edge does not occur and the growth cone is said to
be arrested (Lowery & Vactor 2009).
When F-acƟn polymerisaƟon occurs predominantly at the front of the growth cone, the
axon advances in a relaƟvely straight line. However, if F-acƟn depolymerisaƟon occurs
locally at one side of the growth cone, the axon turns in the opposite direcƟon.
The last process that will be discussed is growth cone collapse. Importantly, growth cone
retracƟon and growth cone collapse are two enƟrely separate enƟƟes. Whilst growth
cone retracƟon is characterised by F-acƟn depolymerisaƟon and lamellipodia shortening,
growth cone collapse occurs as a result of lamellipodial disassembly (Gallo & Letourneau
2004). Growth cone collapse oŌen occurs aŌer CNS injury, where it encounters a variety
of inhibitory ligands and is mediated by a number of diﬀerent receptors and signalling
molecules — which is discussed in secƟon 1.6.2.
1.6.2 Myelin inhibitory signalling cascade
Rho GTPases are small (≈21 kDa) G proteins which regulate a whole host of cellular pro-
cesses (gene transcripƟon, vesicle traﬃcking, cell morphology and acƟn polymerisaƟon)
(Ellenbroek & Collard 2007). RhoA belongs to this family of proteins and is a key medi-
ator of myelin based inhibiƟon and growth cone collapse (Yamashita et al. 2002). RhoA
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acƟvity is regulated by guanine nucleoƟde exchange factors, GTPase acƟvaƟng proteins
and guanosine diphosphate (GDP) dissociaƟon inhibitors (GDI). GDP-bound (inacƟve) Rho
is sequestered in the cytoplasm by GDI and prevented from interacƟng with guanine
nucleoƟde-exchange factor (GEF) (Ellenbroek& Collard 2007). Upon phosporylaƟon, Rho
is released from GDI induced inhibiƟon and allowed to translocate to the plasma mem-
brane where it can interact with GEF (Ellenbroek & Collard 2007). Upon interacƟon with
GEF, Rho is able to exchange GDP (inacƟve) for GTP (acƟve) and interact with a variety
of downstream eﬀectors. GEF induced signalling is terminated by GTPase-acƟvaƟng pro-
tein (GAP) which renders Rho inacƟve once more through GTP hydrolysis (Ellenbroek &
Collard 2007). Rho-associated kinase (ROCK), a serine threonine kinase, is a major down-
stream eﬀector of GTP-bound Rho. AcƟvaƟon of ROCK and LIM kinase-1 leads to F-acƟn
disassembly, inhibiƟon of lamellipodea extension and growth cone collapse (see ﬁgure
1.8 for an overview of inhibitory signalling) (Yang, et al. 1998).
1.6.3 TargeƟng the inhibitory signalling cascade
Over the years various strategies have been used to overcome myelin induced growth
cone collapse. The inhibitory signalling cascade can be targeted at mulƟple levels and
since all myelin derived ligands signal through a common receptor complex, this is an
obvious place to start. The NgR receptor complex can be targeted through the admin-
istraƟon of anƟbodies or pepƟdes to prevent ligand binding and/or receptor interac-
Ɵon (Chaudhry & Filbin 2006). However, targeƟng the inhibitory signalling pathway at
this level is problemaƟc since there is a degree of funcƟonal redundancy in the system
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Figure 1.8: Inhibitory Signalling Diagram. Myelin derived inhibitory ligands, namely, MAG, Nogo
and OMgp bind to NgR to elicit their biological response. As NgR lacks an intracellular signalling
domain, associaƟon with p75NTR/Troy and Lingo-1 are required to potenƟate the signal. The in-
hibitory signalling cascade impinges on both Rho and ROCK and ulƟmately leads to growth cone
collapse through F-acƟn disassembly, inhibiƟon of lamellipodea extension and growth cone col-
lapse. (Diagram adapted from version provided by Prof. Ann Logan, University of Birmingham).
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(Filbin 2003), meaning targeƟngmyelin inhibitory ligands is ineﬃcient; as youwould need
to target mulƟple myelin derived elements (Filbin 2003). Furthermore knockdown of any
one of these components may lead to a compensatory increase in protein expression –
this is certainly true in the case of Nogo (Simonen, et al. 2003).
Nogo knockout experiments revealed that when Nogo-A was knocked down there was a
compensatory increase in Nogo-B expression (Simonen et al. 2003). Furthermore the in-
jured CNS environment is also liƩered with other inhibitory molecules (e.g. ChondroiƟn
sulphate proteoglycans (CSPGs), semaphorins) which could induce growth cone collapse
(Berry et al. 2008). TargeƟng the NgR receptor complex is also problemaƟc since it as-
sociates with mulƟple proteins (Lingo-1, p75NTR/Troy), as a result, it is possible that any
inhibiƟon (or knockdown) of Troy may result in a compensatory upregulaƟon in p75NTR
(Mandemakers & Barres 2005). It is also possible that NgR has some, as of yet, unidenƟ-
ﬁed interacƟng partner which could also transduce the inhibitory signal (Mandemakers
& Barres 2005).
An alternaƟve would be to target signalling molecules which lie downstream of the NgR
receptor complex. Since both Rho and ROCK are integral to the inhibitory signalling
pathway their potenƟal as a therapeuƟc target has received much aƩenƟon (Dergham,
et al. 2002, Lehmann, et al. 1999). For example C3-transferase (a bacterial enzyme de-
rived from Clostridium Botulinum) can be used to speciﬁcally inhibit Rho acƟvity and
promote signiﬁcant RGC neurite outgrowth in the presence ofMIL (Lehmann et al. 1999).
It has been shown that C3-transferase suppresses Rho acƟvity through ADP-ribosylaƟon
(the addiƟon of ADP-ribosemoieƟes to a protein) of asparagine-41 (Paterson, et al. 1990).
Moreover, treatmentwith the ROCK inhibitor Y-27632 enabled corƟcal neurons to extend
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neurites on a myelin or chondroiƟn sulphate proteoglycan (CSPG) substrate (Dergham
et al. 2002). Treatment with each of these inhibitors also resulted to improved funcƟonal
recovery following spinal cord injury (Dergham et al. 2002).
1.6.4 ChondroiƟn sulphate proteoglycans and the glial scar
AŌer injury, matrix molecules (ﬁbronecƟn, collagen, laminin, tenascin and chondroiƟn
sulphate proteoglycans) are deposited by reacƟve astrocytes at the lesion site (Berry
1998). In the developing CNS, CSPGs are expressed at glial boundaries such as the dorsal
root entry zone (DREZ) (Pindzola, et al. 1993), opƟc tectum and spinal cord roof plate
(Snow, et al. 1990). AŌer injury, scar deposiƟon appears to serve a similar purpose
through the formaƟon of the glia limitans accessories (Berry 1998). CSPG rich scar Ɵssue
was previously thought to act as a physical barrier to axon regeneraƟon (Berry et al. 2008)
— however this is not enƟrely the case. Neurons do not lack the intrinsic capability to
regenerate axons as previously thought (Berry et al. 2008) — in fact if you can sƟmulate
neurons to grow they can modulate their surrounding environment to dissolve scar Ɵs-
sue (Ahmed, et al. 2005a). This event is thought to occur by the upregulaƟon of matrix
metalloproteases (MMPs) and concomitant downregulaƟon of Ɵssue inhibitors of MMP
(TIMP) (Ahmed et al. 2005a).
CSPGs comprise of a large family of glycosylated core proteins aƩached to a long chain
of polysaccharides, namely, N-acetylgalactosamine and glucoronic acid. Members of this
family include neurocan, brevican, versican, NG2, phosphocan and aggrecan, all of which
have been shown to inhibit neurite outgrowth (Morgenstern, et al. 2002). The inhibitory
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properƟes of CSPGs are mediated primarily by glycosaminoglycan chain (GAG) chains
and in some instances by their core proteins (e.g. NG2) (Ughrin, et al. 2003). This in-
hibiƟon can be parƟally reversed, and neurite outgrowth promoted in vitro and in vivo
by ChondroiƟnase ABC treatment (an enzyme which cleaves sugar chains) (Bradbury,
et al. 2002, Houle, et al. 2006). Although the CSPG receptor has recently been idenƟﬁed
as PTPσ (a heparin sulphate proteoglycan (HSPG) receptor) (Shen, et al. 2009), its precise
signalling mechanism remains unclear. However, there is some evidence to suggest that
CSPG signalling may exert its acƟons through the Rho inhibitory pathway (see ﬁgure 1.8)
(Monnier, et al. 2003). In this study they found that treatment with C3 transferase or
Y-27632 disinhibited RGC neurite outgrowth (Monnier et al. 2003).
1.7 Cell death
AŌer ON injury, axotomized RGC iniƟates a transitory sprouƟng reacƟon, however this
growth ulƟmately fails (Cajal 1928), leading to RGC death through both apoptoƟc and
necroƟc mechanisms. During necrosis cells swell and burst, releasing their cellular con-
tents into the surrounding environment – this can lead to a potenƟally damaging inﬂam-
matory responses (Alberts 2002). In contrast, cells undergoing apoptosis die in a regu-
lated way – cells shrink and condense, the cytoskeleton collapses and the nuclear enve-
lope loses structural integrity (Alberts 2002). As a result of this, nuclear deoxyribonucleic
acid (DNA) is exposed to endogenous DNases and RNases and DNA fragmentaƟon occurs
(Alberts 2002). The apoptosome is then phagocytosed by surrounding cells before any of
the cellular contents can be released into the surrounding environment (Alberts 2002).
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This process is regulated by a highly conserved family of proteases known as Caspases
(Cysteine-dependent Aspartate-directed protease). Caspases are iniƟally manufactured
as inacƟve precursors (pro-caspases) which require cleavage by other caspases to be-
come acƟve (Alberts 2002). Once acƟvated these caspases interact with adaptor proteins
to bring about acƟvaƟon of iniƟator pro-caspases (Alberts 2002).The apoptoƟc signalling
pathways are typically acƟvated through either an intrinsic or extrinsic mechanism (see
ﬁgure 1.9).
1.7.1 The extrinsic pathway
The extrinsic signalling pathway is typically acƟvated by a receptor mediated process.
Upon ligand binding (Fas) death receptors of the of the TNF receptor superfamily aggre-
gate and recruit intracellular adaptor proteins (FADD, NRAGE) (Fulda & DebaƟn 2006).
These adaptor proteins bind and aggregate pro-caspase 8 molecules, which cleave and
acƟvate one another (Alberts 2002). Once acƟvated these molecules iniƟate apoptosis
through the direct cleavage of downstream eﬀector caspases, such as Caspase-3 (Alberts
2002).
1.7.2 The intrinsic pathway
When a cell is damaged or stressed the intrinsic signalling pathway is acƟvated. Stress
signals induce the release of pro-apoptoƟc factors (cytochrome c, apoptosis inducing fac-
tor (AIF) (apoptosis inducing factor), second mitochondria-derived acƟvator of caspase
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Figure 1.9: DiagrammaƟc representaƟon of the intrinsic and extrinsic apoptoƟc signalling path-
ways. The intrinsic signalling pathway is acƟvated by stress signals, these signals induce the re-
lease of cytochrome (as well as others) from the mitochondria into the cytosol. Once released
cytochrome c binds to and acƟvates Apaf-1. Pro-caspase-9 is bound by Apaf-1 to trigger its aggre-
gaƟon and cleavage. In contrast the extrinsic signalling pathway is acƟvated through a receptor
mediated process. Once acƟve these death receptors recruit addiƟonal adaptor proteins. These
adaptor proteins bind to aggregate pro-caspase-8 molecules which cleave and acƟvated one an-
other. Once acƟve these molecules iniƟate apoptosis through the direct cleave of downstream
eﬀector caspases. Diagram reproducedwith permission from Prof. Ann Logan (University of Birm-
ingham).
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(Smac) (second mitochondria-derived acƟvator of caspase)/DIABLO (direct inhibitor of
apoptosis (IAP) binding protein with low PI) or Omi/HtrA2 (high-temperature require-
ment protein A2)) from the mitochondria into the cytosol (Alberts 2002). Once released
cytochrome c binds to and acƟvates an adaptor protein called Apaf-1 (Alberts 2002). Pro-
caspase-9 is then bound by Apaf-1, to trigger its aggregaƟon and cleavage. Smac/DIABLO
and Omi/HtrA2 regulates caspase acƟvity through an alternaƟve mechanism. Upon mi-
tochondrial release Smac/DIABLO binds to and counteracts the inhibitory eﬀects of IAPs
(Alberts 2002).
1.7.3 Regulators of apoptosis
Apoptosis is regulated, in part, by the Bcl-2 family of proteins (Alberts 2002). This family
contains pro- (e.g. Bax, Bak) and anƟ-apoptoƟc members (e.g. Bcl-2, Bcl-XL), each of
which controls mitochondrial protein release by altering the permeability of the outer
mitochondrial membrane (Alberts 2002). Another level of regulaƟon is performed by
inhibitors of apoptosis, these proteins bind to pro-caspases to prevent their acƟvaƟon,
or interact directly with caspases to inhibit their acƟvity (Alberts 2002).
1.8 Neurotrophins
Neurotrophins have numerous funcƟons, both in the developing and mature CNS. They
have roles in cell survival, synaptogenesis, growth cone guidance, synapƟc plasƟcity, neu-
rotransmiƩer turnover and diﬀerenƟaƟon (Tuszynski 2007). Members of this family in-
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clude brain derived neurotrophic factor (BDNF) NGF, neurotrophin 3 (NT3), and Neu-
rotrophin 4/5(NT4/NT5) (Tuszynski 2007). Neurotrophins are iniƟally synthesized as pro-
proteins (30-35kDa), which are proteolyƟcally cleaved by convertases (convertase 1 and
2) to produce mature proteins (12-13kDa)which exist as non-covalently bound homod-
imers (Tuszynski 2007).
1.8.1 Neurotrophin receptors
tropomyosin receptor kinase (Trk) receptors are type I transmembrane proteinswhich are
members of the receptor tyrosine kinase superfamily. Each neurotrophin binds with high
aﬃnity to their respecƟve tropomyosin-related kinase receptor – NGF to tropomyosin re-
ceptor kinase A (TrkA), BDNF and NT4/NT5 to tropomyosin receptor kinase B (TrkB), and
NT3 to tropomyosin receptor kinase C (TrkC) (Tuszynski 2007). Binding of neurotrophins
to their corresponding Trk receptors causes receptor dimerisaƟon and autophosphory-
laƟon of tyrosine residues within the acƟvaƟon loop, which leads to the phosphoryla-
Ɵon of seven addiƟonal tyrosine residues (Roux & Barker 2002). These phosphotyrosine
residues act as docking sites for SH2 containing secondarymessengerswhich regulate cell
growth and survival through Ras/MAPK, phospholipase C (PLC) and phosphaƟdylinositol
3-kinase / Akt signalling pathways.
As previously discussed in secƟon 1.6.0.2, p75NTF is not solely a co-receptor for NgR1 and
also plays an important role in neurotrophin signalling. In fact all neurotrophins (NGF,
BDNF, and NT4/NT5) bind to p75NTF with almost equal aﬃnity. Although p75NTF has
been shown to bind to all neurotrophins with low aﬃnity, its' exact funcƟon has been
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the subject of much debate. There is substanƟal evidence to suggest that p75NTF en-
hances the responsiveness of Trk receptors to their corresponding ligands (Hantzopoulos
& Suri 1994). For example Yancopoulus et al found that a truncated form of p75NTF sig-
niﬁcantly enhanced the ability of each of the Trks to respond to their cognate receptors
(Hantzopoulos & Suri 1994). p75NTF may play a role in neuronal apoptosis, since neu-
rotrophin pro-proteins are not have been found to bind to p75NTF with high aﬃnity to
iniƟate apoptosis (Volosin, et al. 2008).
1.8.2 p75NTF and apoptosis
The ﬁrst indicaƟon that p75NTF had a role in inducing apoptosis came from the work of
Rabizadeh et al. A selecƟon of neuronal cell lines (CSM 14.1 and R2) were transfected
with p75NTF and cultured in serum free or serum supplemented media. Cells which were
cultured in serum free media had an increased rate of apoptoƟc cell death, however
when these cells were cultured in serum supplementedmedia there was no eﬀect on cell
death. WhenNGFwas added to the serumdeprived cells the negaƟve eﬀect of the p75NTF
transfected cells was abolished (Rabizadeh, et al. 1993). A similar eﬀect was achieved by
treaƟng these cells with amonoclonal anƟbody targeted against p75NTF. Since neither the
R2 nor CSM 14.1 cell lines endogenously expressed detectable levels of TrkA or p75NTF,
the apoptoƟc eﬀect was thought to be mediated by the p75NTF receptor (Rabizadeh et al.
1993).
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Figure 1.10: Neurotrophic factor signalling through Trk receptors. Neurotrophins signal through
their corresponding Trk receptors to acƟvate a number of interacƟng intracellular signalling path-
ways (PI3k/Akt, Ras/MAPK PLCɣ), ulƟmately leading to axon growth (through Rac/cdc42) and neu-
ron survival. Figure modiﬁed with permission from Prof. Ann Logan (University of Birmingham).
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1.8.3 Neurotrophin signalling pathways
1.8.3.1 Ras/MAPK signalling
Ras is a 21 kDa small GTPase which essenƟally acts as a molecular switch for a whole host
of cellular processes (e.g. cell growth, diﬀerenƟaƟon, cytoskeletal organisaƟon, mem-
brane traﬃcking and apoptosis) (Huang & Reichardt 2003). Its role as a mediator of neu-
rotrophin signalling was iniƟally idenƟﬁed in 1986 (Huang & Reichardt 2003). AnƟbodies
raised against Ras were micro-injected into PC12 cells, this resulted in neurite inhibiƟon
and parƟal reversal of neurite outgrowth following NGF treatment (Hagag, et al. 1986).
Ras signalling is typically iniƟated through the acƟvaƟon of cell surface receptor tyrosine
kinases (e.g. Trk receptors) (Ray 2009). Ligand binding induces receptor dimerizaƟon
and autophosphorylaƟon of three sites in the intracellular domain. SH2 containing pro-
tein (SHC) is phosphorylated at one of these sites, creaƟng a binding site for growth fac-
tor receptor binding protein 2 (Grb2) (Huang & Reichardt 2003). This in turn interacts
with son of sevenless (SOS) to acƟvate Ras through the exchange of GDP for GTP (Huang
& Reichardt 2003). Ras acƟvaƟon sƟmulates translocaƟon of Raf (a 68 kDa to 72 kDa
cytosolic protein) to the cell membrane where it can acƟvate map kinase kinase (MEK)
(Huang & Reichardt 2003). MEK then phosphorylates mitogen-acƟvated protein kinase
(MAPK) (ERK1 and ERK2) which translocates to the nucleus to acƟvate a variety of tran-
scripƟon factors (e.g. c-Fos, Jun, acƟvator protein-1 (AP-1), cAMP responsive binding ele-
ment binding protein (CREB), c-myc, and signal transducers and acƟvators of transcripƟon
1 (STAT1) / 3 (STAT1/STAT3) which modulate gene expression (Huang & Reichardt 2003).
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1.8.3.2 Phospholipase C
PLC is recruited to an alternaƟve site of the intracellular domain aŌer TrK receptor phos-
phorylaƟon (Huang&Reichardt 2003). PLC catalyzes the formaƟonof inositol-trisphosphate
anddiaglycerol (DAG) through the cleavageof phosphaƟdylinositol-4,5-bisphosphate (PIP2)
(Huang&Reichardt 2003). DAGacƟvates protein kinase C (PKC)whilst inosital-trisphosphate
(IP3) induces the release of calcium from intracellular stores (Huang & Reichardt 2003).
Cytosolic calcium can then go on to sƟmulate a variety of downstream enzymes (e.g ac-
ƟvaƟon of calmodulin-dependent protein kinases), whilst PKC can acƟvate the Erk-1 sig-
nalling pathway (Huang & Reichardt 2003).
1.8.3.3 PI3K/Akt signalling
PhosphoinosiƟde 3-kinases (PI3K) are a family of highly conserved lipid kinases that phos-
phorylate the 3’hydroxyl (3’-OH) group of phosphaƟdylinosiƟdes. Class 1 PI3Ks are het-
erodimeric molecules which contain a regulatory (p85) and a catalyƟc (p110) subunit
(Vanhaesebroeck & Guillermet-Guibert 2010).
This class of PI3Ks can be further subdivided into class 1A and class 1B. Class 1A PI3Ks
are typically acƟvated by growth factors and their associated receptors (e.g. Trk recep-
tors) whilst class IB PI3Ks are usually acƟvated by G protein coupled receptors (GPCR)
(Vanhaesebroeck & Guillermet-Guibert 2010).
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PI3K/Akt signalling pathway
Trk receptor acƟvaƟon leads to receptor autophosphorylaƟon of tyrosine residues and
subsequent recruitment of PI3K to the plasmamembrane. The regulatory subunit of PI3K
interacts with the receptor through its SH2 containing domains leading to subsequent
acƟvaƟon of its catalyƟc subunit (Vanhaesebroeck & Guillermet-Guibert 2010). This ulƟ-
mately leads to the generaƟon of phosphoinositol-3, 4, 5-triphosphate (PtdIns(3,4,5)P3)
and PtdIns-3,4-bisphosphate (PtdIns-(3,4)P2) at the inner side of the cell membrane. Akt
is then recruited to the cell membrane where it is phosphorylated by PDK1 and PDk2
(Vanhaesebroeck & Guillermet-Guibert 2010). Akt then translocates to the cell nucleus
where it can interact with a variety of transcripƟon factors to bring about changes in gene
expression to inﬂuence a whole host of cellular processes (e.g. cell proliferaƟon, growth
and survival).
1.9 Cilliary neurotrophic factor
CNTF is a 22 kDa cytosolic protein which belongs to the interleukin-6 family of cytokines.
This family consists of interleukin-6 (IL-6) together with leukemia inhibitory factor (LIF),
interleukin-11 (IL-11), oncostaƟnM (OSM) and cardiotrophin-1 (CT-1) (DuƩa, et al. 2007).
Some more recent members include cardiotrophin like cytokine (CLC) and neuropoieƟn
(NP) (Rousseau, et al. 2008).
CNTF has a terƟary structure which is similar to that of other cytokines and consists of a
four alpha helix bundle (Inoue, et al. 1996). CNTF does not possess a classical secretory
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signal sequence and it's unclear how the protein is released from cells. One potenƟal ex-
planaƟon is that it is released from cells (e.g. astrocytes) through an induced mechanism
(Sleeman, et al. 2000).
CNTFwas ﬁrst described as a proteinwhich could enhance chick cilliary ganglionic neuron
survival in vitro (Adler, et al. 1979). Further research has revealed that CNTF has a much
broader eﬀect and is capable of promoƟng sensory, motor, cerebral and hippocampal
neuron survival (cited in (Sleeman et al. 2000)).
In the reƟna, CNTF is endogenously expressed by astrocytes and Müller glia while it's
corresponding receptor, CNTFRα, can be found on RGC, horizontal cells and a subpopu-
laƟon of amacrine cells (Adel, et al. 2005). It is generally believed that CNTF is an injury
inducible factor which is released by glia, in response to trauma or cellular stress, to pro-
tect neurons from cell death (Adler 1993). Several lines of evidence indicate that this
is the case. AŌer injury, endogenous levels of CNTF, CNTFR α and leukemia inhibitory
factor receptor β (LIFRβ) are substanƟally elevated (Adel et al. 2005). This compensatory
up regulaƟon of CNTF, CNTFR α and LIFRβ may be in place to enhance neuronal survival
through JAK-STAT signalling and/or other neuroprotecƟve signalling pathways e.g. MAPK
and PI3K . Exogenous applicaƟon of CNTF at this point may further enhance RGC survival,
since more receptors are available for protein binding and propagaƟon of the extracellu-
lar signal (Adel et al. 2005).
CNTF mediated acƟvaƟon of these pathways may also protect RGC from glutamate in-
duced excitotoxic damage through modiﬁcaƟon and/or downregulaƟon of glutamate re-
ceptors (Petersén & Brundin 1999). This is important since excitotoxic damage has been
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shown to be a major contributor of RGC cell death aŌer axotomy (cited in (Adel et al.
2005)).
AlternaƟvely, CNTF may protect neurons from injury through an indirect mechanism, for
example, CNTF release from glia can be sƟmulated through the applicaƟon of exoge-
nous protein (Adel et al. 2005). Several studies shown that exogenous CNTF can directly
acƟvate glia (Müller glia, astrocytes) to bring about changes in gene expression via the
Ras-MAPK and JAK-STAT signalling pathways (Adel et al. 2005).
Intravitreal injecƟon of CNTF has a neuroprotecƟve eﬀect aŌer ON transecƟon and —
aŌer mulƟple injecƟons — promotes RGC axon regeneraƟon through both the ON and a
PN graŌ (Cui & Harvey 2000, Cui, et al. 2003). Long term CNTF gene expression has also
been demonstrated using Adenoviral vectors. In 2000, Weise et al found that intravitreal
injecƟon of Ad-CNTF rescued approximately 31% of RGC from cell death 14 d aŌer opƟc
nerve crush (ONC) injury (Weise, et al. 2000). InteresƟngly, Ad-CNTF was more eﬀecƟve
at rescuing RGC from cell death when Ad-CNTF was applied to the severed end of the
transected ON – this resulted in a 41% increase in RGC survival. Although Ad-CNTF pro-
moted signiﬁcant RGC survival, axon regeneraƟon was not evident(Weise et al. 2000).
LenƟviral and AAV2 vectors have also been used to deliver CNTF to the visual system –
this ulƟmately resulted in RGC survival and axonal regeneraƟon (Leaver, et al. 2006b, van
Adel, et al. 2003, Leaver, et al. 2006a).
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1.9.1 CNTF Receptor Complex
CNTF binds to a triparƟte receptor complex to elicit its biological eﬀects. IniƟally it binds
to the GPI-linked CNTFɑ receptor (CNTFRɑ), which in turn associates with gp130 and LIF
receptor β to form a triparƟte receptor complex (Tuszynski 2007). Ligand binding ulƟ-
mately leads to acƟvaƟon of the JAK-STAT, PI3-Akt and Ras-MAPK signalling pathways
(see ﬁgure 1.10).
1.9.2 The JAK-STAT signalling pathway
The JAK-STAT signalling pathway can be acƟvated by a variety of cytokines (IL-6, IL-11,
CNTF) and growth factors. Cytokines such as CNTF, IL-6, IL-11, bind to their respecƟve
receptors (CNTFRɑ, IL-6Rɑ, IL-11Rɑ) which sƟmulates associaƟon with co-receptors such
as gp130 and LIF to form a triparƟte receptor complex (Tuszynski 2007). Receptor acƟva-
Ɵon leads to tyrosine phosphorylaƟon of Janus kinase – the acƟvated receptor complex
provides docking sites for SH2 containing signalling molecules such as signal-transducer
and acƟvator of transcripƟon (STAT) (Signal Transducer and AcƟvator of TranscripƟon)
and Grb2 (Tuszynski 2007) (to acƟvate the JAK-STAT and Ras/MAPK signalling pathways
respecƟvely). Once docked STAT proteins are phosphorylated by JAKS and undergo a
process of homo- or heterodimerisaƟon (Aaronson & Horvath 2002). At which point
STAT dimers translocate to the nucleus and interact with speciﬁc DNA sequences to bring
about changes in gene expression (Tuszynski 2007, Aaronson & Horvath 2002). CNTF
signalling through this receptor complex has also been shown to acƟvate the PI3k/AKt,
Ras/MAPKand PLCɣ signalling pathways (Boulton, et al. 1994). The JAK-STAT signalling
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pathway can interact with a variety of diﬀerent signalling pathways. Cross-talk between
these signalling pathways is complex and can occur at mulƟple points throughout the
JAK-STAT signalling cascade.
1.10 Non-viral mediated gene transfer
1.10.1 Naked DNA
Delivering naked, unpackaged plasmid DNA to the visual system is extremely ineﬃcient.
The ability to transfect mammalian cells using naked, unpackaged plasmid DNA is ex-
tremely limited. Naked DNA is unable to cross biological membranes (e.g. plasma, en-
dothelium and nuclear membranes) -this is thought to be a result of the repulsive forces
generated between the negaƟvely charged cell surface and the naked DNA (Niidome &
Huang 2002). Another contribuƟng factor to their poor eﬃcacy is that endonucleases
present within the extracellular space can rapidly degrade naked, unpackaged DNA ren-
dering them ineﬀecƟve (Niidome & Huang 2002). Several techniques have been devel-
oped to tackle the problem of poor DNA uptake.
1.10.2 ElectroporaƟon and shotgun gene delivery
ElectroporaƟon is a techniquewhich is commonly used in vitro to facilitate DNA uptake—
it has also been used in vivo with varying degrees of success. An electric pulse is applied
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to temporarily permeabilise the cell membrane and overcome the repulsive forces by
driving the negaƟvely charged DNA into the cell (Vry, et al. 2010).
In vivo delivery is achievedwhen the electric ﬁeld is applied directly aŌer a bolus injecƟon
of DNA. The eﬀecƟveness of this techniquewas ﬁrst demonstrated in vivo by Titomirov et
al. In this study electroporaƟon was successfully used to deliver plasmid DNA (containing
a neomycin resistant casseƩe) into the skin of newborn mice (Titomirov, et al. 1991).
Since then electroporaƟon has been extensively used as a method of gene transfer. Its
usefulness has also been demonstrated in the eye to transduce RGC (Mo & Yokoyama
2002), pigmented epithelial cells (RPE cells) and the cornea (Mo& Yokoyama 2002). ReƟ-
nal transducƟon was achieved by placing a hemisphere cathode on the cornea and a
hemisphere anode around the ON. This technique was used to successfully transduce
RGC with a plasmid encoding BDNF aŌer an intravitreal injecƟon, and rescued ≈38.7% of
RGC from cell death 6 weeks aŌer ON transecƟon. Despite this promising outcome, this
technique has a number of limitaƟons (Mo & Yokoyama 2002).
One of the limitaƟons of electroporaƟon is that the electric pulse needs to be carefully
calibrated to ensure that the pulse is strong enough to temporarily permeabilise the cell
membrane, but not so strong that it causes irreversible cell damage (Niidome & Huang
2002). It is also very diﬃcult to target speciﬁc cell types since electroporaƟon increases
the permeabilisaƟon of all cell membranes. As a result, electroporaƟon doesn't seem to
be a very translatable technique in terms of delivery therapeuƟcs to paƟents.
Gene gun can be used as an alternaƟve to electroporaƟon. Gold parƟcles are coated
with DNA and shot into the Ɵssue or cell of interest. As a result DNA penetrates the
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cell membrane and is transported directly into the cell cytoplasm or nucleus (Niidome
& Huang 2002). One of the limiƟng factors of this technique is that the level of Ɵssue
penetraƟon is oŌen poor (Niidome & Huang 2002).
1.10.3 CaƟonic polymers
CaƟonic polymers are oŌen used to increase the transducƟon eﬃciency of non-viral me-
diated gene transfer. Some caƟonic polymers (e.g. poly-L-lysine) form linear chains,
whilst others have a highly branched structure (e.g. poly (ethyleneimine), fractured den-
drimers) (Smedt & Demeester 2000). CaƟonic polymers are able to accommodate larger
genes (Smedt & Demeester 2000). In the presence of caƟonic polymers and mulƟvalent
caƟons, plasmid DNA condenses to occupy a much smaller space (Smedt & Demeester
2000). This process is thought to protects DNA from degradaƟon by extracellular nucle-
ases and prolongs their half-life (Bielinska & Kukowska-Latallo 1997).
1.11 Viral mediated gene transfer
A variety of viral vectors have been tested for their ability to transfect RGC of the visual
system. To be an eﬀecƟve therapeuƟc, the viral vector needs to be able to transduce
postmitoƟc cells without eliciƟng a harmful immune response. This can be accomplished
directly through the transducƟon of RGC or indirectly through the transducƟon of other
reƟnal cell types. One of the main advantages of using a viral mediated gene transfer
Page | 45
strategy is that long term transgene expression can be achieved from a single injecƟon of
virus.
1.11.1 Adenoviruses
Adenoviruses (Ad) are polyhedral, non-enveloped viruseswhich contain a double-stranded
DNA genome (Harvey, et al. 2006). Although Ad infecƟon has been linked to a number
of human diseases (Chanock 1974), Adenoviral vectors have become a popular choice
for delivering therapeuƟc genes to the visual system. Ad exhibit a high degree of cellular
tropism, in fact over 50 types of Ad has been idenƟﬁed in recent years.
One of the advantages of using Ad as a viral vector is that it is able to transduce both
dividing and non-dividing cells – as a result both neuronal and glial cell populaƟons can
be targeted using this kind of viral vector (Harvey et al. 2006). Moreover infecƟon can
be achieved without incorporaƟon of viral DNA into the host cells genome reducing the
likelihood of causing random oncogenic events. Ads can also accommodate much larger
inserts (≈8 kb), making it possible to deliver a wider range of therapeuƟc transgenes
(Harvey et al. 2006).
Another important factor to consider when developing therapeuƟc gene vectors is the
ease of producƟon and puriﬁcaƟon. In the case of Ad this does not appear to be a prob-
lem, as high viral Ɵtres can be achieved through well established manufacturing tech-
niques (Harvey et al. 2006).
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Although the onset of gene expression is rapid, transgene expression is oŌen short-lived
and is rapidly cleared by the immune system (Isenmann, et al. 2001). As a result, ade-
noviral vectors are not typically suitable for long term therapeuƟc regimes and may be
more suitable for short term use. Another important factor to consider is the impact of
using such an immunogenic viral vector, as this may cause harmful adverse eﬀects. To
overcome this problem, several groups have developed ways to evade the immune re-
sponse e.g. by encapsulaƟng viral parƟcles in polymers (Fasbender & Zabner 1997) or
gold parƟcles (Sims, et al. 2009).
1.11.2 LenƟviruses
Like other retroviruses, lenƟvirus (LV) has an RNA genome that is surrounded by core
proteins and a lipid envelope (Verma & Weitzman 2005). Once the vector is taken up
by the cell the RNA strand is reverse transcribed and incorporated randomly into the
host genome (Verma & Weitzman 2005). As a result the transgene can be inherited
by the cells progeny allowing long term gene expression to occur in dividing cells (e.g.
glia) without the need for repeat administraƟon (Davidson & Breakeﬁeld 2003). In ad-
diƟon to this, LenƟviral vectors can transduce non-dividing cells making it possible to
also transduce neuronal cell populaƟons. Although random integraƟon is advantageous
in some respects (see above) it can also increase the likelihood of gene inacƟvaƟon or
oncogene acƟvaƟon. LV has similar packaging capabiliƟes to that of Ad and can accom-
modate an insert of approximately 8 kb (Davidson & Breakeﬁeld 2003). Furthermore LV
does not typically induce a signiﬁcant immune response (Davidson & Breakeﬁeld 2003).
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A number of lenƟviral variants are currently available for use as therapeuƟc vectors in-
cluding the human immunodeﬁciency virus (HIV), equine infecƟous anaemia virus (ELAV),
simian immunodeﬁciency virus (SIV) and feline immunodeﬁciency virus (FIV) (Verma &
Weitzman 2005).
1.12 Structure of wild type adeno-associated virus
Wild type adeno-associated virus (AAV)was iniƟally idenƟﬁed as a contaminant of adeno-
virus preparaƟons (Atchison, et al. 1965). Wild type AAV has a single stranded DNA
genome consisƟng of ≈4700 bases which is ﬂanked by idenƟcal 145base inverted ter-
minal repeats (ITR) (Vasileva & Jessberger 2005). Wild type AAV contains REP and CAP
genes which are responsible for replicaƟng and packaging viral DNA and producing the
capsid proteins needed for successful infecƟon (Vasileva & Jessberger 2005). The virus
can enter either a lyƟc (see secƟon 1.13) or lysogenic (see secƟon 1.14) pathway aŌer
host cell infecƟon.
1.13 The lyƟc pathway
The lyƟc pathway occurs when the virus infects a cell in the presence of a helper virus
such as Ad or herpes simplex virus (HSV). The virus enters the cell via a receptor medi-
ated process (e.g. HSPG or laminin receptor), replicates and packages its viral genome
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(Vasileva & Jessberger 2005). The host cell then undergoes helper virus induced cell lysis
followed by the release of infecƟve virion parƟcles (Vasileva & Jessberger 2005).
1.14 The lysogenic pathway
The virus enters the lysogenic pathway when the virus infects the cell in the absence
of a helper virus. If this occurs gene expression is repressed and the AAV integrates its
genome into the host cell at chromosome 19 (Vasileva & Jessberger 2005). The viral DNA
remains there latently unƟl a helper virus comes along. If a latently infected cell is then
infected with a helper virus, viral gene expression is acƟvated, viral DNA is excised from
the chromosome and the cell enters the lyƟc pathway (Vasileva & Jessberger 2005) (see
secƟon 1.13).
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Figure 1.11: Structure ofWild Type AAV.Wild type AAV has a single stranded DNA genomewhich
is ﬂanked by palindromic ITRs. It also contains two open reading frameswhich encode rep and cap
genes which are required for packaging viral DNA and producing the capsid proteins needed for
infecƟon. In the absence of a helper virus (e.g. Ad or HSV) AAV integrates at chromosome 19 of
the host cells genome and resides there unƟl a helper virus comes along. The lyƟc pathway occurs
when AAV infects a host cell in the presence of a helper virus. The virus enters the cell through
a receptor mediated process, replicates and packages its viral genome. The host cell undergoes
helper virus induced cell lysis and virion parƟcles are released. Figure modiﬁed from (Vasileva &
Jessberger 2005).
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1.15 Recombinant AAV virus as a gene delivery vector
The replicaƟon defecƟve and non-pathogenic nature of this virus prompted researchers
to rapidly develop recombinant vectors. These recombinant vectors exhibit many of the
desirable features of wild type AAV (low pathogenicity and immunogenicity) whilst pre-
venƟng the undesirable properƟes of chromosomal integraƟon, and the requirement of
a helper virus. The REP and CAP genes are replaced with a gene of interest (e.g. CNTF)
together with a strong promoter (Cytomegalovirus, CMV) and a reporter gene, such as
green ﬂuorescent protein (GFP) (Vasileva & Jessberger 2005). The REP and CAP genes,
together with Ad elements (Ad Va, E2A, E4), are supplied on separate plasmids (pAAV RC
and pHelper plasmids, Stratagene) which contain all the genes required for the produc-
Ɵon of infecƟve recombinant AAV parƟcles (rAAV). Since these plasmids do not share any
homology with the REP/CAP gene the risk of producing wild type virus (through recom-
binaƟon) is reduced. Triple transfecƟon of these plasmids enables rAAV parƟcles to be
produced and released from the host cell. AŌer puriﬁcaƟon and ƟtraƟon these viruses
can then be used to deliver shRhoA and/or CNTF to RGC of the reƟna.
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Co-infection with
E2A, E4 and VA RNA 
genes (pHelper plasmid)
E1 gene (host cells)
REP/CAP genes (pAAV
RC)
VECTOR PRODUCTION
CELL LYSIS
ITR CMV Promoter CNTF hrGFP ITR
ITR U6 Promoter shRhoA CMV Promoter CNTF hrGFP ITR
TRANSDUCTION
rAAV particles
Figure 1.12: Recombinant AAV Virus. The REP and CAP genes of wild type AAV are replaced
with a gene of interest (e.g. CNTF). This insert contains a strong promoter (CMV) to drive gene
expression and a reporter gene which allows the visualisaƟon of AAV2 transfected cells. Like the
wild type virus, the transgene insert is ﬂanked by ITR to allow viral replicaƟon to occur. Figure
modiﬁed from (Vasileva & Jessberger 2005).
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1.15.1 Advantages and disadvantages of using AAV as a viral vector
AAV viruses are ideal for reƟnal gene transfer since they are able to transduce both di-
viding and non-dividing cells. Furthermore they exert low pathogenicity and immuno-
genicity, in fact approximately 80% of the human populaƟon test seroposiƟve for AAV2
without any overt pathology (Goncalves 2005). Moreover, rAAV vectors are parƟcularly
eﬀecƟve at promoƟng long term gene expression in the eye (Dudus, et al. 1999), making
the requirement for repeƟƟve protein injecƟons redundant. One of the major limiƟng
factors of using rAAV2 as a gene delivery vector is the transducƟon process. First AAV2
needs to be able to enter the cell of interest through a receptormediated process (Surace
& Auricchio 2008), this is problemaƟc when virus is administered through an intravitreal
injecƟon and is discussed in secƟon 5.1.1. Once internalised the AAV virus needs to be
traﬃcked to the nucleus where it can iniƟate second strand DNA synthesis and express
the desired transgene (Surace & Auricchio 2008). All of these processes are very Ɵme
consuming; in the case of AAV2 it can take up to 30 d for transgene expression to be seen
aŌer delivery (Surace & Auricchio 2008, Zincarelli, et al. 2008). Furthermore AAV has a
limited packaging capacity and is only able to accommodate a ≈4:7 kb insert (Surace &
Auricchio 2008) — however this is suﬃcient to house our gene of interest.
1.16 RNA interference
RNA interference (RNAi) is a highly conserved mechanism that co-ordinates the degra-
daƟon of double-stranded RNA (dsRNA) molecules (Davidson & McCray 2011). This nat-
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urally occurring defencemechanismhas been observed in a number of organisms, includ-
ing single cell fungi (Cogoni, et al. 1996), plants (Bernstein, et al. 2001), frogs (Oelgeschlager,
et al. 2000) and insects (Kennerdell & Carthew 1998). The process of RNAi was iniƟally
observed in transgenic plants (Bernstein et al. 2001). Transgenes coding for chalcone
synthase were introduced into pertunia plants to enhance petal pigmentaƟon (Bernstein
et al. 2001); in spite of this they found that many of the plants had white or variegated
petals — this outcome was indicaƟve of gene silencing (Bernstein et al. 2001). Subse-
quent work on caenorhabdiƟs elegans (C.elegans) (Fire, et al. 1998) revealed that the
presence of double stranded RNA was a prerequisite for RNAi. They found that injecƟon
of single stranded sense or anƟsense RNAs led to moderate mRNA suppression, whilst
introducƟon of dsRNA resulted in signiﬁcant mRNA knockdown (Fire et al. 1998). Inter-
esƟngly, many of the phenotypic changes associated with mRNA knockdown were dis-
played by injected adults, and inherited by their respecƟve progeny (Fire et al. 1998).
This was the ﬁrst indicaƟon that RNAi could be used to cause heritable changes. This
phenomenon was later recognised in a variety of mammalian cell lines (Human embry-
onic kidney-293, HeLa, COS-7 and NIH/3T3) (Elbashir, et al. 2001). They found that trans-
fecƟon of dsRNA caused signiﬁcant mRNA knockdown without producing an interferon
response. The outcome of this study brought with it the realisaƟon that short-interfering
RNA (siRNA) technology could be used to produce ``gene-speciﬁc'' therapeuƟcs (Elbashir
et al. 2001).
The mechanisƟc acƟon of RNAi has recently been demonstrated in humans (during a
phase I clinical trial) (Davis, et al. 2010). siRNA was administered systemically, using a
nanoparƟcle delivery system, to treat paƟents with solid tumours. Analysis of paƟent
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biopsies revealed a dose dependent accumulaƟon of nanoparƟcles, together with mRNA
cleavage and protein suppression (Davis et al. 2010).
1.16.1 Mechanisms of RNA interference
RNAi can be triggered by the presence of exogenous dsRNA (e.g. derived from viruses
or transposable elements) and leads to the Dicer dependent generaƟon of small (20 to
24 nucleoƟde pairs) siRNAs (Davidson & McCray 2011). AlternaƟvely siRNAs can arise
from endogenous loci that contain direct or indirect ITR (Davidson &McCray 2011). Tran-
scripts arising from these loci form short hairpin loops which are cleaved by Dicer to pro-
duce siRNAs (Davidson &McCray 2011). The resultant siRNA duplex consists of two RNA
strands, each of which has a 5ʹ phosphate group and a 3ʹ hydroxyl group (Davidson &
McCray 2011). These strands are paired together to produce a 2 nucleoƟde overhang at
each end (Davidson & McCray 2011). Once synthesized, one strand of the siRNA duplex
(the guide strand) binds to the endonuclease Argonaut (AGO) and is incorporated into
the RNA-induced silencing complex (RISC), whilst the other strand (the passenger) is dis-
carded (Davidson & McCray 2011). The guide strand directs the RISC complex to a com-
plementary region ofmRNA. Gene silencing is achieved through the subsequent cleavage
of the targeted mRNA, ulƟmately leading to mRNA degradaƟon and translaƟonal arrest
(Davidson & McCray 2011).
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CHAPTER 2
MATERIALS AND METHODS
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2.1 In vitro Techniques
Unless otherwise stated reagents were obtained from Sigma-Aldrich (Poole, UK).
2.1.1 ReƟnal culture
Adult Sprague-Dawley rats (150 g to 250 g) were killed by cervical dislocaƟon, the eyes
were removed and placed on ice in sterile phosphate buﬀered saline (PBS) (Gibco, Pais-
ley, UK). ReƟnae were dissected from each eye and dissociated using a papain dissocia-
Ɵon kit (Worthington Biochemicals, New Jersey, USA). The papain soluƟon was prepared
by adding 5ml of earle's Balanced Salt SoluƟon (EBSS) with bicarbonate and phenol red
together with 20Uml 1 papain and 100Uml 1 deoxyribonuclease I (DNase I). ReƟnae
were placed in this soluƟon and incubated at 37 C in a humidiﬁed atmosphere contain-
ing 5% CO2 for 90min. During this Ɵme, ovomucoid inhibitor was reconsƟtuted in 32ml
EBSS to give a ﬁnal concentraƟon of 10mgml 1 ovomucoid inhibitor and 10mgml 1 al-
bumin. AŌer 90min, any remaining Ɵssue fragments were broken up by trituraƟng with
a 5ml pipeƩe, the soluƟon was then centrifuged at 300 x g for 5min at room temper-
ature (RT). The supernatant was discarded and the remaining pellet was resuspended
in a soluƟon containing 1:35ml EBSS, 150 µl reconsƟtuted albumin ovomucoid inhibitor
and 125 µl DNase. The cell suspension was then layered on top of a disconƟnuous den-
sity gradient (containing 2:5ml of albumin ovomucoid inhibitor) to separate intact reƟnal
cells from cell membrane components. The cell suspension was then passed through this
gradient by centrifugaƟon (70 x g for 6min). The supernatant (containing cell membrane
components) was discarded and the remaining cell pellet (containing reƟnal cells) was
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resuspended in 1ml of supplemented Neurobasal-A. Cell suspension (10 µl) was mixed
with 10 µl of trypan blue and added to a haemocytometer. The number of live cells in
the 25 squares located in the centre of the haemocytometer were counted, reƟnal cell
number was calculated and the appropriate number of cells plated. Cells were plated on
laminin coated chamber slides (BD Biosciences, Oxford, UK) and incubated at 37 C in a
humidiﬁed atmosphere containing 5% CO2 for 3 d.
2.1.1.1 ReƟnal culture quanƟﬁcaƟon
RGC were visualised by βIII-Tubulin immunostaining and idenƟﬁed by their disƟncƟve
morphology (see secƟon 4.3.1). ReƟnal cultures were prepared as in secƟon 2.1.1 and
plated on laminin-coated chamber slides at a density of 130 000 reƟnal cells per well
(0:7 cm2).
Each well was divided into a grid of 9 squares. Within each grid square, 4 random ﬁelds
of view were captured using an upright microscope (Carl Zeiss Meditec, Dublin CA) —
36 images/well were captured in total. RGC cell number was determined by counƟng
βIII-Tubulin posiƟve cells and neurite length was measured using Image Pro® 6.2 (Media
CyberneƟcs, MD, USA). Neurites were classiﬁed as projecƟons that originated at the cell
body and were at least the diameter of the cell soma in length.
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Figure 2.1: DiagrammaƟc representaƟon of sampling technique. Each well was divided into
a grid of 9 squares. 4 random ﬁelds of view were captured within each grid square. Diagram
reproduced from (Morrison 2011).
2.1.2 RGC-5 cell culture
RGC-5 cells were kindly provided by Dr. Neeraj Agarwal (Department of Pathology and
Anatomy, The University of north Texas Health Science Centre, Fort Worth, Texas, USA).
RGC-5 cells were grown in dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented
with 100Uml 1 penicillin/streptomycin (P/S) and10%heat-inacƟvated foetal bovine serum
(FBS). RGC-5 cells were incubated at 37 C in a humidiﬁed environment containing 5%CO2
and were passaged at a raƟo of 1:20. The RGC-5 cells were grown in T175 ﬂasks during
general cell maintenance.
2.1.2.1 Morphological analysis of RGC-5 cells
RGC-5 cells were treated with Staurosporine using concentraƟons ranging from 0 nÃ to
3:16 µÃ for 24 h to induce diﬀerenƟaƟon. The extent of process outgrowth, expression
and branching were assessed aŌer 24 h exposure to the reagent. The extent of process
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expression and branching per cell were expressed as mean ± standard error of the mean
(SEM) from 60 cells. The length of each process was measured from soma to end using
Image Pro® 6.2 (Media CyberneƟcs, MD, USA). Mean process length and longest process
per cell were expressed as ± SEM from 60 cells. For the purpose of quanƟﬁcaƟon a pro-
cess was deﬁned as any cellular projecƟon longer than the diameter of one cell soma.
2.1.3 Immunocytochemistry and Immunohistochemistry
IHC and immunocytochemistry are techniques which can be used to visualise parƟcular
anƟgens on Ɵssues/cells of interest. This is accomplished by the applicaƟon of a primary
anƟbody targeted against a speciﬁc anƟgen, followed by addiƟon of a secondary anƟbody
conjugated to a ﬂuorescent label — this allows visualisaƟon when examined microscop-
ically. The locaƟon of ﬂuorescent label gives an indicaƟon as to the cellular locaƟon of
the anƟbody-anƟgen interacƟons.
2.1.3.1 Immunocytochemistry
Cells were ﬁxed with 4% formaldehyde (TAAB Laboratories, Berkshire, UK) in PBS (Oxoid,
Ltd, Basingstoke, UK) at RT for 10min. The formaldehyde soluƟon was then removed
with a pasteur pipeƩe and the wells were washed three Ɵmes with rinsing buﬀer. Block-
ing buﬀer was then added to each of the wells to eliminate non-speciﬁc binding. Primary
anƟbody (200 µl) was then added to each of the wells and incubated at RT for 1 h. Pri-
mary anƟbodies were then removed by inverƟng chamber slides onto paper towels and
the wells were washed three Ɵmes with rinsing buﬀer. Secondary anƟbodies (200 µl)
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were added to each of the wells and incubated for 1 h at RT in a dark environment to pre-
vent bleaching. Secondary anƟbodies were removed by inverƟng chamber slides onto
paper towels and each of the wells were washed three Ɵmes in rinsing buﬀer. When
the last wash was removed, the well dividers were removed from the chamber slides
and coverslips were mounted using vectashield withʹ,6-diamidino-2-phenylindole (DAPI)
(Vector Labs, Peterborough, UK). The slideswere then viewedwith an uprightmicroscope
(Carl Zeiss Meditec, Dublin, CA) and images were captured using the Axiovision soŌware
(Axiovision; Carl Zeiss Meditec).
2.1.3.2 Immunohistochemistry
ON and eye secƟons were removed from the freezer, thawed for 30min and washed in
rinsing buﬀer (3 x 5min). Excess rinsing buﬀer was aspirated and a hydrophobic pen
was used to draw around each secƟon. Blocking soluƟon (100 µl) was then applied to
each of the secƟons and slides were subsequently placed in a humidiﬁed chamber at RT
for 1 h. AŌer this, blocking buﬀer was removed and 100 µl of primary anƟbody was ap-
plied to each secƟon and incubated in a humidiﬁed chamber for 1 h at RT. Slides were
then washed in rinsing buﬀer (3 x 5min) before applying the appropriate secondary an-
Ɵbody. SecƟons were then incubated in a humidiﬁed chamber at RT for 1 h in the dark
to prevent bleaching of ﬂuorescence. SecƟons were washed in rinsing buﬀer (3 x 5min)
and coverslips mounted using vectashield with DAPI (vector labs, Peterborough, UK). The
slides were then viewed with an upright microscope (Carl Zeiss Meditec, Dublin CA) and
images were captured using the Axiovision soŌware (Axiovision; Carl Zeiss Meditec).
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Table 2.1: Immunocytochemistry / immunohistochemistry reagents.
Reagents Eye & opƟc nerve sec-
Ɵons
ReƟnal culture & RGC-5
cell culture
10mÃ PBS, ph
7.4
PBS tablets in milli-Q wa-
ter
PBS tablets in milli-Q wa-
ter
Rinsing buﬀer 0.1% Triton X-100 in PBS 0.1% Triton X-100 in PBS
Blocking buﬀer 10% NGS and 3% BSA in
rinsing buﬀer
5% NGS and 3% BSA in
rinsing buﬀer
Primary anƟ-
body diluƟon
buﬀer
3% BSA in rinsing buﬀer Prepared in blocking
buﬀer
Secondary an-
Ɵbody diluƟon
buﬀer
3% BSA in rinsing buﬀer Prepared in blocking
buﬀer
2.1.3.3 AnƟbodies
AnƟbody details for immunocytochemistry and immunohistochemsitry are listed in table
2.2.
Table 2.2: AnƟbody details for immunocytochemistry and immunohistochemsitry.
AnƟbody Speciﬁcity Source &
LocaƟon
Species Stock Con-
centraƟon
DiluƟon
βIII-Tubulin RGC somata,
axons and
neurites
Sigma-
Aldrich,
Poole, UK
Mouse N/A (As-
cites)
1/500
(IHC/ICC)
βIII-Tubulin RGC somata,
axons and
neurites
Sigma-
Aldrich,
Poole, UK
Rabbit 200 µgml 1 1/500
(IHC/ICC)
GAP-43 RegeneraƟng
RGC axons
Invitrogen
Ltd, Paisley,
UK
Mouse 0:5 µgml 1 1/500 (IHC)
ConƟnued on next page ...
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Table 2.2 -- conƟnued from previous page
AnƟbody Speciﬁcity Source &
LocaƟon
Species Stock Con-
centraƟon
DiluƟon
NG2 NG2 posiƟve
glia
Abcam,
Cambridge,
UK
Rabbit 1mgml 1 1/500 (ICC)
Carbonic an-
hydrase II
(CAII)
Oligoden-
drocytes
GiŌ from
Prof. Wilkin-
son, Univer-
sity College
London, UK
Rabbit N/A
(Serum)
1/4000 (ICC)
eGFP eGFP posi-
Ɵve cells
Abcam,
Cambridge,
UK
Rabbit 0:5mgml 1 1/1000 (IHC)
hrGFP hrGFP posi-
Ɵve cells
Agilent
Tech., Wok-
ingham, UK
Rabbit N/A (AnƟ-
serum)
1/1000 (IHC)
Alexa Fluor
488
Mouse IgG Invitrogen
Ltd, Paisley,
UK
Goat 2 µgml 1 1/500 (IHC,
ICC)
Alexa Fluor
594
Mouse IgG Invitrogen
Ltd, Paisley,
UK
Goat 2 µgml 1 1/500 (IHC,
ICC)
Alexa Fluor
488
Rabbit IgG Invitrogen
Ltd, Paisley,
UK
Goat 2 µgml 1 1/500 (IHC,
ICC)
Alexa Fluor
594
Rabbit IgG Invitrogen
Ltd, Paisley,
UK
Goat 2 µgml 1 1/500 (IHC,
ICC)
2.1.4 Haematoxylin and Eosin staining of frozen reƟnal secƟons
Frozen reƟnal secƟons were washed in several changes of PBS (3 x 5min) to remove OCT.
All secƟonswere then immersed inMayer's Haematoxylin for 1min to stain the cell nuclei
and idenƟfy the GCL, INL and IPL of the reƟna. Slides were then washed for 20min under
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running water to remove excess Haematoxylin. ReƟnal secƟons were then submerged
in Eosin for 5min to counterstain, the secƟons were then washed in disƟlled water to
prevent streaking. The reƟnal secƟons were then immersed in 50%, 70%, 90%, 100%
and 100% ethanol for 1min each. Immediately aŌer this, the secƟons were transferred
into 2 changes of histoclear for 1min and 3min respecƟvely. Slides were then mounted
using vectamount. Cover slips were applied to each slide and bright ﬁeld images were
captured.
2.1.5 AAV2 constructs
The four constructs used (AAV2-eGFP, AAV2-CNTF-hrGFP, AAV2-CNTF-shRhoA-hrGFP and
AAV2-CNTF-FLAG) were kindly provided by Dr Mike Douglas (Molecular Neuroscience
Group, University of Birmingham). All constructs were produced using the AAV Helper
Free system (Stratagene). The gene of interest, CNTF,was cloned into themulƟple cloning
site of the pAAV-IRES-hrGFP plasmid. Prior to this, the CNTF sequence was modiﬁed to
include an NGF signal sequence — this was achieved by fusing a sequence encoding of
the ﬁrst 20 amino acids from rat prepro-Nerve growth factor (ppNGF) to the rat CNTF
sequence. This would allow CNTF to be released from RGC and dispersed throughout
the reƟna. The pAAV-IRES-hrGFP plasmid allowed us to produce FLAG-tagged CNTF as it
contains a 3x FLAG sequence at the C terminus of the mulƟple cloning site. Untagged
CNTF was produced by inserƟng a stop codon aŌer the CNTF sequence, but before the
FLAG encoding region. Importantly this plasmid contains an internal ribosome entry site
(IRES) which allows mulƟple genes (e.g. CNTF and hrGFP) to be translated from a single
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plasmid. IRES sequences allow translaƟon iniƟaƟon to occur in the middle of an mRNA
sequence by a cap-independent mechanism. As a result Ribosomes bind to the AUG
start codon without scanning the 5ʹ non-translated region of the transcript (Mizuguchi,
et al. 2000). AAV2 viruses were manufactured, concentrated and Ɵtred by Gene Vector
Core (University of Iowa). For a more complete explanaƟon of this process (see secƟon
1.15).
14 AAV Helper-Free System 
pAAV-IRES-hrGFP Vector 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Non-unique sites used to release the expression cassette for subcloning fragments from pCMV-MCS 
 
 
 
Feature Nucleotide Position 
left AAV-2 inverted terminal repeat (ITR) 1–141 
CMV promoter 150–812 
E-globin intron 820–1312 
multiple cloning site 1392–1420 
3× FLAG tag 1421–1492 
internal ribosome entry site (IRES) 1528–2114 
hrGFP ORF 2112–2828 
human growth hormone (hGH) polyA signal 2886–3364 
right AAV-2 inverted terminal repeat (ITR) 3404–3544 
f1 origin of ss-DNA replication 3636–3942 
ampicillin resistance (bla) ORF 4461–5318 
pUC origin of replication 5469–6136 
Not I cleavage sites for subcloning from pCMV-MCS 143, 3397 (additional site at 1373) 
FIGURE 2 The pAAV-IRES-hrGFP cloning vector 
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(sequence shown 1392–1432)
GG ATC CGA ATT CGC ATG CGT CGA CTC GAG GAC TAC AAG GAT 
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BamH I EcoR I Hinc II
Acc I
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start of FLAG tag
Figure 2.2: pAAV-IRES-hrGFP expression plasmid supplied in the AAV Helper Free System.
Reproduced from http://www.chem.agilent.com/Library/usermanuals/Public/
240071.pdf
2.1.6 Lipofectamine 2000 TransfecƟon
Human embryonic kidney 293 cells (HEK-293) were plated in DMEM media at a density
of 500 000 cells well 1 in a 6-well plate (Nunc, Loughborough, UK) to ensure that the
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cells were 90-95% conﬂuent at the Ɵme of transfecƟon. The following day, transfecƟon
samples and reagents were prepared in separate tubes. In one tube, plasmid DNA was
diluted in OpƟ-MEM media (2mlwell 1) to give a DNA concentraƟon of 4 µgwell 1. In
the second tube, 10 µl of Lipofectamine 2000 (Invitrogen, Ltd, Paisley, UK) was diluted
in OpƟ-MEM media (Invitrogen, Ltd, Paisley, UK) (2mlwell 1) — both soluƟons were in-
cubated at RT for 5min. To form complexes, diluted plasmid DNA was combined with
the diluted Lipofectamine soluƟon, mixed gently and incubated at RT for 20min. AŌer
this, 2ml of complexes were added to each well and mixed gently. Cells were then incu-
bated at 37 C in a humidiﬁed atmosphere containing 5% CO2 for 5 h, at which point the
media was changed with DMEM (+ 100Uml 1 P/S + 10% FBS). Treatment groups com-
prised of AAV2-hrGFP, AAV2-CNTF-hrGFP, AAV2-CNTF-FLAG, AAV2-CNTF-shRhoA-hrGFP,
untreated control and Lipofectamine 2000 only. CondiƟoned media was collected 5 d
aŌer transfecƟon.
2.1.7 Enzyme linked immunosorbent assay
A sandwich enzyme-linked immunosorbent assay (ELISA) was used to measure CNTF lev-
els in HEK-293 condiƟoned media. The CNTF ELISA (R&D Systems) was performed in ac-
cordance with manufacturer's instrucƟons and all reagents were supplied with the kit. A
sterile 96-well plate (Nunc, Loughborough, UK) was coated with capture anƟbody, sealed
with paraﬁlm and incubated at RT overnight for 17 h. Following anƟbody removal, each
well was rinsed three Ɵmes with wash buﬀer (≈400 µl well 1). AŌer each wash step the
buﬀer was removed by inverƟng the plate and bloƫng with clean paper towels.
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To block, reagent diluent (300 µl) was added to each well and incubated at RT for 1 h. Af-
ter repeaƟng the aspiraƟon wash step, CNTF standards and samples were prepared and
added to each well (100 µl). The iniƟal CNTF standard was diluted with reagent diluent
to give a ﬁnal concentraƟon of 2000 pgml 1. A series of 1:2 diluƟons (i.e. 1000 pgml 1,
500 pgml 1, 250 pgml 1 etc) was then performed so that a standard curve could be con-
structed (each sample was iniƟally diluted 1:5 to ensure that the concentraƟonwould fall
within the standard curve). A series of 1:2 diluƟons were then performed for each sam-
ple, as with the CNTF standard.
The plate was then coveredwith an adhesive strip and incubated at RT for 2 h on a shaker.
AŌer another round of washing, detecƟon anƟbody (100 µl) was added to each of the
wells. The plate was then covered with a new adhesive strip and incubated at RT for a
further 2 h. Another aspiraƟon wash step was performed and then a working soluƟon
of streptavidin-HRP was prepared and added to each well. The plate was incubated at
RT for 20min and covered with foil to avoid being placed in direct light – this was then
followed by another aspiraƟon wash step.
Substrate soluƟon (100 µl) was added to each well and incubated at RT for 20min. Stop
soluƟon (50 µl) was then applied to each well and mixed gently on a shaker. The opƟcal
density was measured using a microplate reader set to 450 nm (Victor3, Perkin Elmer).
A standard curve of absorbance vs CNTF concentraƟon was then ploƩed using MicrosoŌ
Excel. This curve was then used to determine the relaƟve concentraƟon of CNTF present
within each sample.
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Table 2.3: Reagents for CNTF ELISA.
SoluƟon Reagents
10mÃ PBS, pH 7.4 PBS tablets in milli-Q water
Wash buﬀer 0.05% Tween-20 in PBS
Reagent diluent 1% BSA in PBS
Substrate soluƟon 1:1 mixture of colour reagent A (H2O2) and
colour reagent B (Tetramethylbenzidine)
Stop soluƟon 2N H2SO4
Capture anƟbody 2 µgml 1 prepared in PBS
DetecƟon anƟbody 200 ngml 1 prepared in reagent diluent
Streptavidin-HRP Prepared in reagent diluent
2.1.8 Cell viability assay
The viability of RGC-5 cellswas determinedby theuse of Cell Titer-Glo (Promega, Southamp-
ton, UK). The assay is based on a luciferase reacƟon which is used to measure the ATP
levels of metabolically acƟve cells. The Cell Titer-Glo reagent acts by lysing cell mem-
branes to release ATP, inhibiƟng endogenous ATPase acƟvity and providing the luciferin
and luciferase needed to measure ATP in a bioluminescent reacƟon. The amount of ATP
present following cell lysis is directly proporƟonal to cell number.
Thismethodof determining cell viability has a number of advantages over othermethods.
It takes a relaƟvely short Ɵme to perform the assay and is incredibly sensiƟve at detect-
ing intracellular ATP levels. The assay is performed in a single plate and does not involve
any cell transfer or wash steps which could result in cell loss and inaccuracies. Further-
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more, this assay gives reproducible bioluminescent readouts resulƟng in low standard
deviaƟon/error values.
One of the limitaƟons of using this method is that it requires cells lysis to isolate and
measure cellular ATP content. As a result, conclusions can only be drawn from whole
populaƟons of cells rather than from individual cells. Another potenƟal limitaƟon of hav-
ing a cell lysis step is that it prevents further analysis from being carried out on the same
populaƟon of cells (e.g.immunocytochemistry, PCR e.t.c.). This method relies on mea-
suring the metabolic acƟvity of cells (through ATP content) to determine cell viability. As
a result this assay is potenƟally suscepƟble to addiƟonal factors which may rapidly in-
ﬂuence ATP cell content (e.g. oxygen availability). Consequently, analysis is limited to
gross changes in ATP content and does not allow for the analysis of contribuƟng factors.
It is also important that the right equipment is used to carry out these assays: Biolumi-
nescent reacƟons require the use of a specialised microplates (opaque sides with a clear
ﬂat boƩom) to prevent luminescent interference between wells. It's also essenƟal that
phenol red is not present within the media as it can reduce the luminescent signal.
RGC-5 cellswere plated in a 96-wellwhite opaqueplate at a seeding density of 2500 cells well 1
in 180 µl of medium containing 10% FBS for 2 h at 37 C in a humidiﬁed environment con-
taining 5% CO2. The CellTiter-Glo luminescent substrate was reconsƟtuted with CellTiter-
Glo buﬀer and equilibrated to RT. Cells were leŌ at RT for 30min before 100 µl of lumines-
cent substrate was added. To ensure eﬃcient cell lysis the plate was placed on a shaker
for 5min at RT and then leŌ to stabilise for 10min. The luminescencewas thenmeasured
using a 96-well plate reader (Victor3, Perkin Elmer, MA, USA).
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2.1.9 RNA extracƟon
RNA was extracted using the RNeasy mini kit (Qiagen) according to manufacturer's pro-
tocols.
2.1.9.1 RGC-5 cell RNA extracƟon
DMEM was removed from Ɵssue culture ﬂasks and cells were washed twice with sterile
PBS. Trypsin (Gibco) in PBS (0.25%)was then added to detach cells from the ﬂask—media
(DMEM + 10% FBS + 1% P/S) was then added to inacƟvate the trypsin. The cell suspen-
sion was then transferred into a 50ml Falcon tube and centrifuged at 300 x g for 5min.
The supernatant was carefully aspirated leaving the remaining cell pellet. The pellet was
then re-suspended in denaturing buﬀer RLT (containing guanidine-thiocyanate) and ho-
mogenized using a rotor stator homogenizor. One volume of 70% ethanol was added to
the homogenate to facilitate membrane binding. The soluƟon was then transferred to a
spin column and centrifuged at 8000 x g for 15 s, the ﬂow through was collected in the
tube supplied and discarded. Buﬀer RW1 (700 µl) was added to the spin column and cen-
trifuged at 8000 x g for 15 s to wash the membrane. The membrane was then washed
a further two Ɵmes with buﬀer RPE (discarding the ﬂow through each Ɵme) to remove
contaminants. RNA was then eluted from the column in 50 µl of RNase free water. A
Nanodrop was then used to measure RNA concentraƟon.
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2.1.9.2 Mouse brain RNA extracƟon
Mouse brain was dissected out and snap frozen in liquid nitrogen, ≈30mg of brain Ɵs-
sue was disrupted in 600 µl buﬀer RLT using a rotor stator homogeniser (IKA ® T10 basic
Ultra-Turrax) for 20 s to 40 s. The homogenate was centrifuged at full speed for 3min
and the supernatant was carefully removed using a pipeƩe. The supernatant was then
transferred into a clean eppendorf tube and one volume of 70% ethanol was added to
aid membrane binding. The soluƟon was then transferred to a spin column and cen-
trifuged at 8000 x g for 15 s, the ﬂow through was collected in the tube supplied and
discarded. Buﬀer RW1 (700 µl) was added to the spin column and centrifuged at 8000 x
g for 15 s to wash the membrane. The membrane was then washed a further two Ɵmes
with buﬀer RPE (discarding the ﬂow through each Ɵme) to remove contaminants. RNA
was then eluted from the column in 50 µl of RNase free water. A Nanodrop was then
used to measure RNA concentraƟon.
2.1.9.3 Mouse eye RNA extracƟon
RNA was extracted from 2 mouse eyes using the RNeasy mini kit as previously described
(see secƟon 2.1.9.2).
2.1.10 RNA quanƟﬁcaƟon
RNA concentraƟons were determined by loading 2 µl of RNA soluƟon into a Nanodrop
spectrophotometer (ND-1000; Wilmington, DE, USA) and measuring the absorbance of
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each sample at 260 nm. The Nanodropmachine was also used to esƟmate sample purity;
this was achieved by measuring the 260 nm/280 nm absorbance raƟo. RNA with a purity
value of >1.8 was used in all experiments. RNA integrity was determined by gel elec-
trophoresis — RNA samples were resolved in a 1% agorose gel, idenƟﬁed by ethidium
bromide (EtBr) (EtBr) staining and analysed using mulƟgenius imaging. RNA was deemed
to be intact when sharp bands of 18 s and 28 s ribosomal RNA subunits were present at
≈2 kb and ≈4 kb.
2.1.11 cDNA Libraries
Puriﬁed RNA was reverse transcribed into single-stranded complementary DNA (cDNA)
using the high capacity cDNA archive kit (Applied Biosystems). The RT master mix was
prepared using the reagent volumes shown in table 2.4 and placed on ice. Once prepared,
50 µl 2 x RTmaster mix was combined with 50 µl of RNA (26:48 ng µl 1) in a PCR tube (for
each 100 µl reacƟon). PCR tubes were then transferred to the thermal cycler for reverse
transcripƟon to commence (for reacƟon condiƟons see table 2.5).
Table 2.4: 2 x RT master mix (100 µl reacƟon volume).
Component Volume (µl) per
ReacƟon
Volume (µl) per
31 ReacƟons
10X Reverse TranscripƟon Buﬀer 10 310
25X dNTPs 4 124
10X Random Primers 10 310
MulƟscribe Reverse Transcriptase, 50U/µl 5 155
Nuclease-free H2O 21 651
Total per ReacƟon 50 1550
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Table 2.5: Thermal cycler seƫngs used for reverse transcripƟon.
Step 1 2 3 4
Temperature (C) 25 37 85 4
Time 10min 120min 5 s 1
2.1.12 Primer Design
Primers (Alta Bioscience) were designed with the help of Dr. Mike Douglas using the
Primer 3 soŌware package. Table 2.6 shows the DNA sequences of the forward and re-
verse primers used. All primers, with the excepƟon of rat CNTF, were between 20 and
22 nucleoƟdes in length. The rat CNTF primers were 31 nucleoƟdes in length - although
signiﬁcantly longer than those generally believed to be opƟmal (18 to 24 nucleoƟdes in
length), these primers had previously been used and opƟmised by Dr. Mike Douglas.
Primers were matched, as far as possible, for melƟng temperature (Tm) and PCR product
size (see table 2.6). Care was taken to avoid primers which form stable secondary struc-
tures (hairpin loops) and primer dimers - this was done to ensure that cDNA ampliﬁcaƟon
would be successful and speciﬁc. An annealing temperature of 55 C was selected aŌer
visual inspecƟon of ampliﬁed PCR products (see ﬁgure 3.8). An annealing temperature
of 50 C produced a high degree of smearing and non-speciﬁc ampliﬁcaƟon, whilst an
annealing temperature of 55 C produced signiﬁcantly cleaner PCR products.
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Table 2.6: RGC-5 primer list.
Cell Marker Forward Primer Tm (C) Reverse Primer Tm (C) Accession No.
βIII-Tubulin 5ʹ-TGA GGC CTC CTC TCA CAA GT-3ʹ 56.8 5ʹ-CGC ACG ACA TCT AGG ACT GA-3ʹ 56.7 NM_023279.2
Neuroﬁlament-H 5ʹ-AGC CCA AGG ACT CTA CAG CA-3ʹ 57.4 5ʹ-CTT TGG CTT TTC CGT CTC TG-3ʹ 57.7 NM_010904
Neuroﬁlament-L 5ʹ-GCC GAA GAG TGG TTC AAG AG-3ʹ 57.2 5ʹ-TGT CTG CAT TCT GCT TGT CC-3ʹ 56.7 GI:76573285
Neuroﬁlament-M 5ʹ-GTC AGA CCA GGC AGA AGA GG-3ʹ 56.8 5ʹ-GAT TTG GGC ATA GGG GAT TT-3ʹ 58.2 NM_008691
Tau 5ʹ-CAG TCT CCA CAC CCC AGT TT-3ʹ 56.8 5ʹ-ACA AGC TAA CAG GGC GAA GA-3ʹ 57.8 M18776
Thy-1 5ʹ-AAG GCC TCT GCC TGT AGT GA-3ʹ 57.4 5ʹ-GAA GAG GCA GGT TGC AAG AC-3ʹ 57.3 NM_009382
NesƟn 5ʹ-AGG AAC CAA AAG AGG CAG GT-3ʹ 57.9 5ʹ-TTG GGA CCA GGG ACT GTT AG-3ʹ 57.2 GI:38173717
NeuroD 5ʹ-CAA AGC CAC GGA TCA ATC TT-3ʹ 57.6 5ʹ-CCC GGG AAT AGT GAA ACT GA-3ʹ 57.4 NM_010894.2
Neurogenin-1 5ʹ-CGC TTC GCC TAC AAC TAC ATC-3ʹ 58.0 5ʹ-CTG AAG CCG AGG GAC TAC TG-3ʹ 57.3 U67776
Neurogenin-2 5ʹ-GAT GCC AAG CTC ACG AAG AT-3ʹ 57.7 5ʹ-ACG TGG AGT TGG AGG ATG AC-3ʹ 56.6 GI:1666909
SOX1 5ʹ-CAC AGT TCA GCC CTG AGT GA-3ʹ 56.3 5ʹ-GAT CAG CCC AGA GAG ACT GG-3ʹ 56.7 NM_009233.3
SOX2 5ʹ-AAG GGT TCT TGC TGG GTT TT-3ʹ 58.1 5ʹ-AGA CCA CGA AAA CGG TCT TG-3ʹ 57.4 NM_011443.3
Mouse CNTF 5ʹ-GAT GGC TTT CGC AGA GCA AAC-3ʹ 55.38 5ʹ-TCT GAT GAG AAG AAA TGA CAC G-3ʹ 50.47 NM_170786
Rat CNTF 5ʹ-GAT CGG ATC CTA GGG GAT GGC TTT CGC
AGA G-3ʹ
64.51 5ʹ-GAT CCT CGA GCT ACA TCT GCT TAT CTT
TGG C-3ʹ
60.21 NM_013166
RALDH2 5ʹ-TTG CAG ATG CTG ACT TGG AC-3ʹ 56.7 5ʹ-TCT GAG GAC CCT GCT CAG TT-3ʹ 56.8 BC075704
ConƟnued on next page ...
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Table 2.6 -- conƟnued from previous page
Cell Marker Forward Primer Tm (C) Reverse Primer Tm (C) Accession No.
CD11b 5ʹ-CAT CTG CCA AGA CGA TCT CA-3ʹ 56.5 5ʹ-TTC TGG CTT GCT GAA TCC TT-3ʹ 57.6 NM_001082960.1
CD68 5ʹ-TTC TGC TGT GGA AAT GCA AG-3ʹ 57.2 5ʹ-AGA GGG GCT GGT AGG TTG AT-3ʹ 57.7 NM_009853.1
SOX1 5ʹ-CAC AGT TCA GCC CTG AGT GA-3ʹ 56.3 5ʹ-GAT CAG CCC AGA GAG ACT GG-3ʹ 56.7 NM_009233.3
CD44 5ʹ-GGC AGA AGA AAA AGC TGG TG-3ʹ 57.7 5ʹ-GGA ATG ACG TCT CCA ATC GT-3ʹ 56.9 BC005676
CD133 5ʹ-GAA AAG TTG CTC TGC GAA CC-3ʹ 57.7 5ʹ-TCT CAA GCT GAA AAG CAG CA-3ʹ 57.3 GI:20271425
ChAT 5ʹ-CCT GCC AGT CAA CTC TAG CC-3ʹ 57.4 5ʹ-ATA CAG AGA GGC TGC CCT GA-3ʹ 57.2 NM_009891.2
Pax6 5ʹ-AAC AAC CTG CCT ATG CAA CC-3ʹ 57.7 5ʹACT TGG ACG GGA ACT GAC AC-3ʹ 56.8 NM_013627.4
GFAP 5ʹ-CAC GAA CGA GTC CCT AGA GC-3ʹ 57.3 5ʹ-ATG GTG ATG CGG TTT TCT TC-3ʹ 57.4 NM_001131020.1
GalC 5ʹ-TGC GCA GTT TGA CAA CTT TC-3ʹ 57.3 5ʹ-AGG ATC CAG CAA AAA TGC AC-3 57.7 NM_008079
NG2 5ʹ-TGG GCT CAG GAG ATG CTA GT-3ʹ 57.2 5ʹ-CTG CGA TGT CTG GCT CAT AA-3ʹ 57.1 NM_001081249
Olig1 5ʹ-CTT GCT CTC TCC AGC CAA AC-3ʹ 57.5 5ʹ-GCG AGC CTG AAA AAC AGA AC-3ʹ 57.7 NM_016968.4
Olig2 5ʹ-ATA TGG GAA CCG AAG CAA TG-3ʹ 57.6 5ʹ-CAG GAA GTT CCA GGG ATG AA-3ʹ 57.1 NM_016967.2
MBP 5ʹ-CTT CAA AGA CAG GCC CTC AG-3 57.3 5ʹ-CCT GTC ACC GCT AAA GAA GC-3ʹ 57.8 NM_001025251
CNPase 5ʹ-ACA CAG TGG CTA CCC TCC AC-3ʹ 56.9 5ʹ-GTA CGC CTC GGA GAA GTC TG-3ʹ 57.3 AF332056.1
Blue sensiƟve opsin 5ʹ-GCC TCA GTA CCA CCT TGC TC-3ʹ 57.1 5ʹ-CTG GCG ATG AAG ACT GTG AA-3ʹ 56.6 NM_007538
GAPDH 5ʹ-AAT-GCA-TCC-TGC-ACC-ACC-AA-3ʹ 55.3 5ʹ-GTA-GCC-ATA-TTC-ATT-GTC-ATA-3ʹ 45.37 NM_017008Page|75
2.1.13 Semi-quanƟtaƟve PCR and densitometry
For each gene, six PCR tubes were prepared. One tube was removed every 3rd cycle,
starƟng from either the 16th or 25th cycle— these cycles were previously determined as
the cycles where the exponenƟal phase of the PCR reacƟon occurred (see appendix A).
The intensity of the resultant PCR bands, resolved on agarose gels and stained with EtBr,
were analysed using the MulƟgenius Gel DocumentaƟon System (Syngene, Cambridge,
UK). The PCR thermal cycler condiƟons are shown in table 2.8 and the reacƟon volumes
can be found in table 2.7.
Table 2.7: PCR reacƟon volumes.
40 µl ReacƟon
Reagent Volume (µl)
Biomix 20
H2O 14
Mouse brain cDNA 2
Forward primer 2
Reverse primer 2
MgCl 1:5mÃ
Table 2.8: PCR thermal cycler seƫngs.
Step 1 2 (30 or 40 cycles) 3 4
Temperature (C) 96 96 50 72 72 4
Time 2min 30 s 30 s 30 s 5min 1
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2.1.13.1 Densitometry
EtBr stained DNA bands from all genes that tested posiƟve in the RGC-5 groupwere quan-
Ɵﬁed by densitometry using the PhoreƟx 1D SoŌware (Nonlinear Dynamics, Newcastle-
upon-Tyne, UK) and normalised to the density of a glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) loading control. Unless otherwise stated, each experiment was per-
formed on 3 independent occasions. Densitometry valueswere averaged for each primer
and cycle number. The exponenƟal phase of each PCR reacƟon was determined by plot-
Ɵng the densitometry readings on a line chart (see ﬁgure 2.3). This enabled me to es-
tablish which cycles fell within the exponenƟal phase of the PCR reacƟon. A cycle was
chosen where both PCR products fell within the exponenƟal phase of the reacƟon (e.g.
cycle 25 for mouse brain GalC and RGC-5 GalC), an example of this is shown below. Mean
densitometry values at the selected cycle number were normalised by dividing the tar-
get gene (e.g. GalC) densitometry value by the GAPDH (internal control) densitometry
value. The relaƟve signal intensiƟes could then be compared and ploƩed on a bar chart
(see ﬁgure 2.3).
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Figure 2.3: Example of how the exponenƟal phase of the PCR reacƟon was determined. Mean
desitometry readings were ploƩed on a line chart to determine which cycles fell within the ex-
ponenƟal phase of the PCR reacƟon. A cycle was then chosen where both PCR products (RGC-5
mRNA and mouse brain posiƟve control) fell within the exponenƟal phase of the reacƟon. Mean
densitometry readings at the selected cycle number (cycle 25 in this example) were then nor-
malised by dividing the target gene densitometry value (GalC) by the internal control densitome-
try value. RelaƟve signal intensiƟes were then ploƩed on a bar chart (see ﬁgure 3.13).
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2.1.14 Sample preparaƟon for sequencing
PCR reacƟons were performed to prepare CD44, NG2 and GAPDH cDNA for sequencing.
PCR reacƟons were performed using the Phusion high-ﬁdelity DNA polymerase. This en-
zyme was selected because of its 3ʹ → 5ʹ exonuclease acƟvity — as a result, fewer errors
should bemade during the ampliﬁcaƟon process. For reacƟon volumes see table 2.9 and
for thermal cycler condiƟons see table 2.8.
Table 2.9: PCR reacƟon volumes used to prepare samples for sequencing.
Reagent Volume (µl)
Forward primer 2
Reverse primer 2
cDNA 4
dNTP 5
5x phusion HF buﬀer 10
Phusion DNA polymerase 0.5
H2O 27
2.1.14.1 Gel extracƟon
Upon compleƟon of the PCR reacƟon, each sample was resolved on a 0.7% agarose gel
and visualised by EtBr staining. DNA bands were isolated using the QIAquick gel extrac-
Ɵon kit (Qiagen). Protocols were performed in accordance with manufacturer's instruc-
Ɵons — all reagents were supplied with the kit. Brieﬂy: DNA bands were excised using a
scapel blade and excess agarose was removed. Gel slices were weighed in a tube and 3
volumes of buﬀer QG was added to each sample. The tubes were incubated for 10min
Page | 79
at 50 C to dissolve the gel samples and 1 volume of isopropanol was added to each tube
and mixed. Samples were then transferred into a QIAquick spin (with accompanying col-
lecƟon tube) and centrifuged for 1min. The ﬂow through was discarded and the spin
column was placed back within the same collecƟon tube. 500 µl of buﬀer QG was then
added to the spin column and centrifuged for 1min to remove all trace of agarose. Buﬀer
PE (750 µl) was then added to the column and allowed to stand for 5min, the columnwas
then washed by centrifugaƟon for 1min. The ﬂow through was discarded and the col-
umn was spun for an addiƟonal 1min. The spin column was then placed within a new
collecƟon tube and the DNA was eluted by adding 50 µl of buﬀer EB and centrifuging for
1min at maximum speed.
2.1.14.2 DNA quanƟﬁcaƟon
DNAconcentraƟonsweredeterminedby loading 2 µl of DNA into aNanodrop spectropho-
tometer (ND-1000; Wilmington, DE, USA) and measuring the absorbance of each sample
at 260 nm. The Nanodrop machine was also used to esƟmate sample purity — this was
achieved by measuring the 260 nm/280 nm absorbance raƟo. DNA with a purity value of
<1.8 was used in all experiments.
2.1.14.3 Sample preparaƟon
Two samples of each of the PCR products were made up with 50 ng of DNA (volume re-
quired to give 50 ngwas calculatedwith the concentraƟonmeasured using the Nanodrop
machine). For each of the PCR product sample pairs, 1 µl of forward primer (10 pmol) was
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added to one sample, and 1 µl reverse primer (10 pmol) to the other — water was then
added to make a total volume of 12 µl (as shown in table 2.10).
Table 2.10: Sample preparaƟon.
Sample 50 ng DNA
template
volume
(µl)
H2O (µl) 10 pmol
Forward
Primer (µl)
10 pmol Re-
verse Primer
(µl)
Total Vol-
ume (µl)
NG2 6.3 4.7 1 — 12
NG2 6.3 4.7 — 1 12
CD44 3 8 1 — 12
CD44 3 8 — 1 12
GAPDH 3.5 7.5 1 — 12
GAPDH 3.5 7.5 — 1 12
2.1.14.4 Sequencing
All sequencing reacƟons were performed by the genomics lab sequencing service (Uni-
versity of Birmingham) using the Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Carlsbad, CA, USA), running a sequencing reacƟon, purifying samples and
analysing the results on a 3700 DNA Analyzer.
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2.2 In vivo techniques
2.2.1 Animal surgery
Adult male Sprague Dawley rats (150 g to 250 g) were used for AAV2 experiments to as-
sess transfecƟon rates, RGC survival and axon regeneraƟon. All procedures were per-
formed in accordance with the regulaƟons of the UK Animals (ScienƟﬁc Procedures) Act
1986 under a Home Oﬃce Licence. Surgeries were performed by Professor MarƟn Berry
— anaesthesia and analgesia were administered by myself.
InhalaƟon anaesthesia was induced with an iniƟal dose of 4% isoﬂurane (AbboƩ Labo-
ratories Ltd, Kent, UK) and maintained at 3% during surgery. Animals received a sub-
cutaneous injecƟon of the analgesic Buprenorphine (NaƟonal VeƟnary Supplies, Stoke-
on-Trent, UK) at the start of the procedure at a dose of 0:03mg kg 1. An ocular lubricant
(Lacri-Lube, AlleganHighWycombe, UK)was also applied to prevent corneal dehydraƟon.
2.2.1.1 OpƟc nerve crush
A midline cutaneous incision was made to access the ON intraorbitally, the skin was re-
ﬂected over the upper lid to expose the orbital margin and the superﬁcial fascia was
removed. A verƟcal incision was made through the temporalis fascia and temporalis
muscle and extended rostrally over the orbital margin without damaging the supraor-
bital vessels. The supraorbital neurovascular bundle was clamped using forceps and the
Harderian gland exposed by making an incision in the orbital fascia between the clamp
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sites. The gland was reﬂected rostrally to expose the superior and lateral rectus mus-
cles. Retractors were placed between the superior rectus and ON as well as between
the lateral rectus muscle and ON to allow easy access. The ON was exposed by excising
the retractor bulbi muscle, dural sheath, and arachnoid. Care was taken not to sever the
central reƟnal artery which runs through the dural sheath medially. The ON was crushed
2mm from the laminal cribrosa using blunt forceps to transect all axonswhilst leaving the
sheath intact. The retractor bulbi, rectus muscles and Harderian gland were reposiƟoned
around the nerve and the skin margins sutured.
2.2.2 Intravitreal injecƟons
A glass micropipeƩe was loaded with a 10 µl volume of test reagent and inserted into
the vitreous body via the sclera immediately posterior to the ora serrata. The pipeƩe
was posiƟoned so that the Ɵp was inserted between the lens and the reƟna. The mi-
cropipeƩe was connected to a syringe before slowly injecƟng the appropriate soluƟon
into the vitreous. The pipeƩe was then withdrawn slowly to prevent reﬂux — care was
taken throughout the procedure not to damage the lens.
2.2.3 AAV2-CNTF-hrGFP,AAV2-eGFP andAAV2-CNTF-shRhoA-hrGFP de-
livery and RGC survival counts
Rats received an intravitreal injecƟon of 1 1011 vg/10µlAAV2-CNTF-hrGFP,AAV2-CNTF-
shRhoA-hrGFP or AAV2-eGFP in combinaƟon with 0.0002% Pronase-E 30 d prior to ONC
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(see secƟon 2.2.1.1). Eyes were prepared for histological examinaƟon as in secƟon 2.2.4.
To determine whether intravitreal injecƟon of AAV2-CNTF-hrGFP or AAV2-CNTF-shRhoA-
hrGFP could protect RGC from cell death, 10 reƟnal secƟons were randomly selected
for histological examinaƟon. ReƟnal secƟons were stained with haematoxylin and eosin
(H&E) and images were captured using an upright microscope (Carl Zeiss Meditec, Dublin
CA). The number of RGC occupying a 550 µm  500 µm ﬁeld of view was counted and
compared against an uninjured control. n = 3 for each treatment group (30 secƟons in
total for each treatment group).
2.2.4 Tissue PreparaƟon for Histology
Animals were killed by rising concentraƟons of CO2 and the Ɵssue ﬁxed by perfusion with
4% paraformaldehyde (PFA) (TAAB Laboratories, Berkshire, UK). Eyes and opƟc nerves
were removed and post ﬁxed in PFA for 2 h at 4 C. Tissue was then washed in PBS for
10min and then passed sequenƟally through sucrose gradients (overnight at 4 C in 10%,
20% and 30% sucrose in PBS) to cryoprotect. Eyes and ON were then bloƩed with ﬁlter
paper (to remove excess PBS), embedded in OCT Embedding Medium (R.A. Lamb Labo-
ratory), frozen rapidly on dry ice and stored at 80 C. Eye and ON cryosecƟons (15 µm)
were cut on a cryostat (Bright Instrument Company, HunƟngdon, UK) and mounted on
either Superfrost Plus or Extra Adhesive slides microscope slides.
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2.2.5 ReƟnal wholemount counts
To assess survival, RGC were retrogradely labelled with a 4% soluƟon of ﬂourogold (FG)
(FG, hydroxysƟlbamidine, Cambridge Bioscience, Cambridge, UK). The ON was accessed
intraorbitally and a 2 µl volume of tracer was injected into the ON proximal to the crush
site 48 h prior to Ɵssue harvesƟng. AŌer the eyes had been harvested, the reƟna was ex-
posed by carefully removing the cornea, iris diaphragm, lens and aƩached vitreous. The
remaining eye cup was then submerged in 4% PFA for 2 h to post ﬁx the Ɵssue. The reƟna
was then removed from the eye cup, cut into 4 quadrants and ﬂaƩened out onto a slide
using dry paintbrushes. Coverslips were mounted with Vectamount (without DAPI) to
preserve immunoﬂourescence. Wholemounted reƟnae were viewed with an Axioplan-2
ﬂuorescent microscope (Carl Zeiss Meditec, Dublin CA) and images were captured using
Axiovision soŌware (Axiovision; Carl Zeiss Meditec). The radial centre was determined
for each quadrant and 4 images were captured along this axis. FG-posiƟve RGC were
counted and averaged per wholemount. Results were expressed as the mean number of
RGC/mm2 ± SEM of 3 reƟnae for each treatment group. For a diagrammaƟc representa-
Ɵon of this sampling technique see ﬁgure 2.4.
2.2.6 ReƟnal ganglion cell transducƟon
To determine whether the addiƟon of Pronase-E could increase AAV2 transducƟon eﬃ-
ciency, animals received a 10 µl intravitreal injecƟon of AAV-GFP (1 1011 vg/10µl) with
and without 0.0002% Pronase-E (see secƟon 2.2.2). AŌer the eyes had been harvested
the reƟna was exposed by carefully removing the cornea, iris diaphragm, lens and at-
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Figure 2.4: Image (not to scale) illustraƟng the sampling technique used to calculate RGC
survival and GFP transducƟon eﬃciency. ReƟnal wholemount diagram modiﬁed from http:
//goo.gl/Sq8Iy
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tached vitreous. The remaining eye cup was then submerged in 4% PFA for 2 h to post
ﬁx the Ɵssue. The reƟna was then removed from the eye cup, cut into 4 quadrants and
ﬂaƩened out onto a slide using dry paintbrushes. Coverslips were mounted with Vecta-
mount (without DAPI) to preserve immunoﬂourescence. Wholemounted reƟnae were
viewed with an Axioplan-2 ﬂuorescent microscope (Carl Zeiss Meditec, Dublin CA) and
images were captured using Axiovision soŌware (Axiovision; Carl Zeiss Meditec). The
radial centre was determined for each quadrant and 4 images were captured along this
axis. GFP posiƟve RGC were counted and averaged per wholemount. Results were ex-
pressed as the mean number of RGC/mm2 ± SEM of 3 reƟnae for each treatment group.
For diagrammaƟc representaƟon of this sampling technique see ﬁgure 2.4.
2.2.7 QuanƟﬁcaƟon of RGC axon regeneraƟon in vivo
QuanƟﬁcaƟon of RGC axon regeneraƟon was based upon a method described by others
(Leon, et al. 2000, Lorber, et al. 2005). The number of GAP-43 posiƟve axons extending
100 µm, 200 µm, 400 µm, 800 µm and 1200 µm from the lesion core was counted. The
cross secƟonal width of the ON was measured at the point at which the counts were
taken. This was used to calculate the number of axons/mm width. Unless otherwise
stated, this value was averaged over 3 secƟons.
P
ad (the total number of axons extend-
ing distance d in an ON with radius r) was calculated and results were expressed as the
mean from 3 opƟc nerves per treatment group ± SEM.
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X
ad = r2  average number of axons/mmwidth
t
(t = secƟon thickness (15 µm))
Figure 2.5 shows a diagrammaƟc explanaƟon of the above formula.
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2.2.8 StaƟsƟcal Analysis
All staƟsƟcal analysis was performed using the SPSS (IBM) soŌware package. StaƟsƟcal
analysis was performed to ascertainwhether diﬀerences seen between treatment groups
were real, due experimental error or random chance. An independent t-test was used to
compare data from 2 experimental treatment groups. A one-way analysis of variance
(ANOVA) in combinaƟon with the Gains Howell post-hoc test was used to compare data
from mulƟple treatment groups. This test was performed to determine if the mean of 2
or more treatment groups was signiﬁcantly diﬀerent from that of the untreated controls.
Parametric tests were chosen based on the assumpƟon that the data followed a normal
distribuƟon. Data was considered to be staƟsƟcally signiﬁcant if the probability (p) was
less than the speciﬁed signiﬁcance levels (where *p ≥ 0.05, **p ≥ 0.05, ***p ≥ 0.001).
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CHAPTER 3
CHARACTERISATION OF THE RGC-5 CELL
LINE
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3.1 The use of cell lines in biological research
Cell lines have many advantages over primary cell cultures. Cell lines tend to represent
a homogeneous populaƟon of cells — giving them the advantage of generaƟng more
reproducible results. As cell lines aremitoƟcally acƟve they are relaƟvely easy tomaintain
and can be passaged for a long, or indeﬁnite, amount of Ɵme. This provides us with the
means to produce and harvest high yields of cells. The use of cell lines can also limit
the cost of using animals as a source of material which in turns minimises the variability
inherent in using such animals.
Cell lines also have some disadvantages — they need to be fully characterised before
they can be used as a subsƟtute for primary cells. This involves determining whether the
cells express the same transcripƟon factors, signallingmolecules, receptors, neurotrophic
factors and proteins present in the primary cells. A further disadvantage is that with
increasing Ɵme and passage number, cell lines may incur morphological changes as well
as changes in gene expression.
3.2 RGC-5 cell line
The use of in vitro assays is an important tool for elucidaƟng the mechanisms involved in
regeneraƟve failure. Primary reƟnal cultures are commonly used to achieve this, however
RGC are notoriously diﬃcult to purify making it diﬃcult to disƟnguish between neuronal
and glial based acƟons. The use of an RGC cell line would eliminate this complicaƟon and
facilitate the analysis of neuronal speciﬁc responses.
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The RGC-5 cell line was ﬁrst introduced in 2001 as an immortalised cell line generated
by isolaƟng RGC from postnatal day 1 Sprague Dawley rats and transforming them us-
ing ψ2EIA virus (R.R.Krishnamoorthy, et al. 2000). The cell line was deemed to be of
reƟnal ganglion cell origin based upon it tesƟng posiƟve for a number of markers associ-
ated with RGC e.g. Thymocyte diﬀerenƟaƟon anƟgen 1 (Thy-1), Brn-3C, NeuriƟn, NMDA
receptor, GABA-B receptor, synaptophysin, neurotrophic factors and their respecƟve re-
ceptors (R.R.Krishnamoorthy et al. 2000). They were not found to express GFAP which is
a marker of astrocytes (R.R.Krishnamoorthy et al. 2000).
Since their introducƟon, more than 100 research reports have used RGC-5 cells as a
subsƟtute for primary RGC. Many of these reports use RGC-5 cells to model apoptoƟc
events induced by hypoxia (Li, et al. 2011, Sato, et al. 2010), serum deprivaƟon (Charles,
et al. 2005), oxidaƟve stress (Jung, et al. 2010, Koriyama, et al. 2009), glutamate excito-
toxicity (Harper, et al. 2009, Bergen, et al. 2009, Tchedre & Yorio 2008) and hydrostaƟc
pressure (Agar, et al. 2006). Other publicaƟons have used RGC-5 cells to invesƟgate dif-
ferenƟaƟon (R.R.Krishnamoorthy et al. 2000, Tchedre & Yorio 2008, FrasseƩo, et al. 2006,
Lieven, et al. 2007, Schwechter, et al. 2007), calcium signalling (Tchedre& Yorio 2008, Luo,
et al. 2005) and neuroprotecƟon (Koriyama et al. 2009, Harper et al. 2009, Tchedre &
Yorio 2008).
The purpose of this study was to characterise the RGC-5 cell line to determine whether
it would be a suitable subsƟtute for primary reƟnal cultures.
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3.3 Aims
1. Characterise the RGC-5 cell line.
2. Establish whether the RGC-5 cell line can be used as a subsƟtute for primary RGC.
3. Determine whether Staurosporine could be used to diﬀerenƟate the RGC-5 cell
line.
4. Look at the morphological dynamics of Staurosporine mediated RGC-5 diﬀerenƟa-
Ɵon.
3.4 Results
The use of cells lines in biological research can be a very useful tool for invesƟgaƟng the
molecularmechanismswhich underlie CNS injury. However, comparisonsmade between
mitoƟc cell lines (e.g. the RGC-5 cell line) and post-mitoƟc neuronal cell populaƟons (e.g.
primary RGC) are oŌen problemaƟc, since they oŌen don’t have the same characterisƟcs
as primary neurones.
As a result it would be useful to ﬁnd a means of diﬀerenƟaƟng the RGC-5 cell line so that
more accurate comparisons can be made between these two cell populaƟons. In recent
years, several diﬀerenƟaƟng agents have been tested on the RGC-5 cell line. One such
reagent is Staurosporine, a broad spectrum kinase inhibitor which is reported to cause
cell cycle arrest, somal rounding and process extension (FrasseƩo et al. 2006). In addiƟon
to this, Staurosporine treated RGC-5 cells are believed to take on a more neuronal phe-
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notype as evidenced by an increased expression of neuronal markers and establishment
of outward recƟfying channels (FrasseƩo et al. 2006).
To achieve this, a Staurosporine dose response experiment was performed and RGC-
5 morphological measurements were taken (see secƟon 2.1.2.1). The purpose of this
was to ﬁnd out which concentraƟon was opƟmal in terms of process extension, process
length (ﬁgures 3.1a and 3.1b), process number (ﬁgure 3.2), process branching (ﬁgure 3.3)
and toxicity (ﬁgure 3.4). The evaluaƟon of toxicity was parƟcularly important since Stau-
rosporine is commonly used to iniƟate apoptosis at high doses (Manns, et al. 2011).
3.4.1 Staurosporine treatment induces process extension
Approximately 5000 RGC-5 cells per well were plated and given 2 h to adhere. Once the
2 h had passed the reagents were added and leŌ for a further 24 h to induce diﬀerenƟa-
Ɵon, ﬁnally the cells were ﬁxed and analysed.
For the purpose of quanƟﬁcaƟon a process was deﬁned as any cellular projecƟon greater
than one soma in length. The length of each cellular projecƟon was measured using
Image Pro® and expressed for each treatment group as ± SEM from 60 cells.
Results demonstrate that increasing the concentraƟon of Staurosporine led to increases
in the length of the longest process (and processes length/cell), with a concentraƟon
of Staurosporine between 100 nÃ and 1:78 µÃ favouring opƟmum process outgrowth.
There was a staƟsƟcal signiﬁcance between Staurosporine treatment groups and con-
trols, ***p ≤ 0.001. Dimethyl Sulfoxide (DMSO) treatment did not induce process out-
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growth and there was no staƟsƟcal signiﬁcance between DMSO treatment groups and
control.
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(a)Mean length of longest process aŌer Staurosporine treatment
Figure 3.1: Staurosporine treatment induces process extension. RGC-5 cells (5000 cells well 1)
were treated (aŌer being leŌ to adhere for 2 h) with increasing concentraƟons of Staurosporine
for 24 h. All concentraƟons induced similar levels of process extension, increasing mean length
of longest neurite and process length/cell. All Staurosporine treatment groups are staƟsƟcally
signiﬁcant from controls, ***p ≤ 0.001. n = 3 for all groups. Error bars represent the SEM from 3
independent experiments. † indicates ***p ≤ 0.001 when compared to 0 nÃ control. ● indicates
***p ≤ 0.001 when compared to DMSO controls (0.1%, 1% and 2% DMSO). ***p ≤ 0.001 and *p
≤ 0.05. ConƟnued on next page.
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(b)Mean process length per cell aŌer Staurosporine treatment
Figure 3.1: Staurosporine treatment induces process extension. ConƟnued from previous page.
Error bars represent the SEM from 3 independent experiments. † indicates ***p ≤ 0.001 when
compared to 0 nÃ control. ● indicates ***p ≤ 0.001 when compared to DMSO controls (0.1%, 1%
and 2% DMSO).
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3.4.2 The impact of Staurosporine treatment on process number
Increasing Staurosporine concentraƟon led to an increase in process number, with maxi-
mal process number being achieved at 562 nÃ. Process number declined between 1 µÃ
to 3:16 µÃ, this may have been a result of increased cytoxicity (see ﬁgure 3.2). There
is a staƟsƟcal signiﬁcance between Staurosporine treatment groups and control, ***p ≤
0.001. DMSO treatment did not induce process outgrowth. There is no staƟsƟcal signiﬁ-
cance between DMSO treatment groups and control.
Figure 3.2: Process Number aŌer Staurosporine Dose Response. RGC-5 cells (5000 cells well 1)
were treated with increasing concentraƟons of Staurosporine for 24 h (aŌer being leŌ for 2 h to
adhere to the plate). Process number (a process was deﬁned as any cellular projecƟon greater
than one soma in length) was signiﬁcantly enhanced by applicaƟon of 100 nÃ to 562 nÃ Stau-
rosporine. This eﬀect declined between 1 µÃ to 3:16 µÃ, presumably as a result of cytoxicity. All
Staurosporine treatment groups are staƟsƟcally signiﬁcant from controls, ***p ≤ 0.001. Error bars
represent the SEM from 3 independent experiments. † indicates ***p ≤ 0.001 when compared
to 0 nÃ control. ● indicates ***p ≤ 0.001 when compared to DMSO controls (0.1%, 1% and 2%
DMSO). ***p ≤ 0.001, **p ≤ 0.01 and *p ≤ 0.05.
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3.4.3 Process branching is dose dependent
Results demonstrate that increasing concentraƟons of Staurosporine led to a dose de-
pendent increase in process branching. Maximal branching was achieved at a dose of
1 µÃ to 1:78 µÃ, the extent of process branching was dramaƟcally reduced by concentra-
Ɵons higher than this, presumably as a result of cytotoxicity (see ﬁgure 3.3). There was a
staƟsƟcally signiﬁcant diﬀerence between Staurosporine treatment groups and controls.
Branching was not observed in the untreated control and DMSO treatment groups.
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Figure 3.3: Process Branching is Dose Dependent. RGC-5 cells (5000 cells well 1) were exposed
to increasing concentraƟons of Staurosporine for 24 h (aŌer being leŌ for 2 h to adhere to the
plate). The extent of process branching was posiƟvely correlated with Staurosporine concentra-
Ɵon. Process branching (where a process was deﬁned as any cellular projecƟon longer than one
soma) drasƟcally declines aŌer exposure to 3:16 µÃ. Branching is absent from the untreated con-
trol and DMSO groups. All Staurosporine treatment groups are staƟsƟcally signiﬁcant from con-
trols. Error bars represent the SEM from 3 independent experiments. † indicates ***p ≤ 0.001
when compared to 0 nÃ control. ● indicates ***p ≤ 0.001 when compared to DMSO controls
(0.1%, 1% and 2% DMSO). ‼ indicates ***p ≤ 0.001 when compared to 100 nÃ Staurosporine
treatment group. ***p ≤ 0.001, **p ≤ 0.01 and *p ≤ 0.05.
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3.4.4 RGC-5 cell viability assay aŌer Staurosporine treatment
A cell viability assay was performed on RGC-5 cells to determine the extent of toxicity
caused by increasing concentraƟons of Staurosporine.
At the start of the experiment, 2500 cells well 1were plated in a 96well plate. RGC-5 cells
were allowed to adhere for 2 h, at which point the appropriate amount of Staurosporine
(100 nÃ, 178 nÃ, 316 nÃ or 562 nÃ) was added. Cell viability assays were performed (as
in secƟon 2.1.8) 24 h later.
Treatmentwith 1 µÃ, 1:78 µÃand 3:16 µÃ caused a staƟsƟcally signiﬁcant (***p ≤ 0.001)
reducƟon in mean ATP content aŌer 24 h compared to all other treatment groups. Al-
though this is indicaƟve of RGC-5 cell death an accurate comparison can't be made with-
out addiƟonal quanƟtaƟve data (e.g. direct cell counts, BrdU and or Tunnel staining).
There was no signiﬁcant diﬀerence between DMSO treated controls (0.1%, 1% and 2%)
and the untreated control group (0 nÃ) (see ﬁgure 3.4). DMSO controls were added to
account for the small amount of compound present within the Staurosporine prepara-
Ɵons.
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Figure 3.4: RGC-5 Cell Viability Assay. RGC-5 cells were plated, leŌ 2 h to adhere and then treated
with Staurosporine using concentraƟons ranging from 0µÃ to 3:16 µÃ to induce diﬀerenƟaƟon.
Cells were ﬁxed and analysed 24 h aŌer the reagent was added. Treatment with 1 µÃ, 1:78 µÃ
and 3:16 µÃ caused a signiﬁcant reducƟon in mean ATP content aŌer 24 h compared to all other
treatment groups. There was no signiﬁcant diﬀerence between DMSO treatment groups and the
untreated control group. Error bars represent the SEM from 3 independent experiments. † indi-
cates ***p ≤ 0.001 when compared to 0 nÃ control. ***p ≤ 0.001, **p ≤ 0.01 and *p ≤ 0.05.
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3.4.5 RepresentaƟve images of the Staurosporine dose response ex-
periment
RGC-5 cells were plated (5000 cells well 1) onto chamber slides (BD Biosciences, Oxford,
UK) and allowed to adhere for 2 h. The cells were then treated with increasing concen-
traƟons (0 nÃ, 100 nÃ, 178 nÃ, 562 nÃ, 1 µÃ, 1:78 µÃ, 3:16 µÃ) of Staurosporine to de-
termine an opƟmal dose for diﬀerenƟaƟon. AŌer 24 h the cells were ﬁxed and visualised
by βIII-Tubulin immunostaining (shown in ﬁgure 3.5 as green). Somal rounding and pro-
cess extension was evident in all Staurosporine treatment (see ﬁgure 3.5B-H and ﬁgures
3.2, 3.3, 3.4 for quanƟﬁcaƟon) groups aŌer 24 h. In contrast, fewer processes (examples
highlighted with a red arrow in ﬁgure 3.5) were present in all control groups (ﬁgure 3.5A,
3.5I-K) and the cell soma of these cells (examples highlighted with a white arrow in ﬁgure
3.5) were markedly ﬂaƩer – DMSO was included as a control to account for the small
amount of compound present within the Staurosporine soluƟon. Increasing concentra-
Ɵons of Staurosporine led to a dose dependent increase in process branching (see ﬁgure
3.5A-H and ﬁgure 3.3, where a process was deﬁned as any cellular projecƟon which was
longer than one cell soma. Fewer cells were present at higher Staurosporine concentra-
Ɵons - this was likely a result of toxicity. As expected no background staining was evident
in the no primary control group (see ﬁgure 3.5L).
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Figure 3.5: RepresentaƟve images of Staurosporine dose response experiment. RGC-5 cells
were treated with increasing concentraƟons of Staurosporine (0 nÃ, 100 nÃ, 178 nÃ, 562 nÃ,
1 µÃ, 1:78 µÃ, 3:16 µÃ) to determine an opƟmum dose for diﬀerenƟaƟon. 24 h later cells were
ﬁxed and visualised by βIII-Tubulin immunostaining (green). Process extension (red arrow) and
somal rounding (white arrow) was evident in all Staurosporine treatment groups (A-H). Process
branching becamemore apparent with increasing concentraƟons of Staurosporine. Controls con-
sisted of 0.1% DMSO, 1% DMSO, 2% DMSO and an untreated control. DMSO was included as a
control to account for the small amount present within Staurosporine preparaƟons. Fewer pro-
cesses were evident in all RGC-5 control groups and the cell soma was considerably ﬂaƩer. DAPI
stained nuclei are shown in blue. ConƟnued on next page.
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Figure 3.5: RepresentaƟve images of Staurosporine dose response experiment. ConƟnued from
previous page. Red arrows point to process extensions, white arrows point to somal rounding.
DAPI stained nuclei are shown in blue.
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3.5 The RGC-5 cell line is derived from Mus musculus and
not RaƩus norvegicus
The primary aim of this chapter was to characterise the RGC-5 cell line and to determine
whether the cells would be a suitable subsƟtute for primary RGC.
In 2009 several batches of RGC-5 cellswere found to bederived fromMusmusculus rather
than RaƩus norvegicus (Bergen et al. 2009). Although all RGC-5 cells used in the studies
listed in secƟon 3.2 were derived from a common source, held by the Agarwal laboratory
(R.R.Krishnamoorthy et al. 2000, Agarwal, et al. 2007), their originwas challengedwhen it
was found that a number of batches were not derived from rats and were phenotypically
unlike RGC (Bergen et al. 2009). Furthermore, a study re-characterised the RGC-5 cell line
as a derivaƟve of a mouse cone photoreceptor lineage (Wood, et al. 2010).
In light of this, all experiments from this point onwards were performed in the knowledge
that this batch of cells may not be of rat origin as originally thought. As a result a new set
of aims were planned:
3.5.1 New aims
1. Design and opƟmise primers for PCR and sequencing reacƟons.
2. Determine whether the RGC-5 cell line is derived from RaƩus norvegicus or Mus
musculus.
Page | 107
3. Establish whether the RGC-5 cell line expresses neuronal, glial or developmental
cell markers.
Sequencing was performed to determine whether the RGC-5 cell line was derived from
Mus musculus or RaƩus norvegicus. PCR was performed on RGC-5 and rat brain cDNA
using primers speciﬁc for rat CNTF. PCR products were run on a 0.7% agarose gel and
visualised using EtBr staining. No band was present in the RGC-5 sample, whilst a band
of the expected size (≈550 bp) was present within the control lane (see ﬁgure 3.6).
The primers were then re-designed to target the mouse CNTF sequence and included
a GAPDH control for both rat brain and RGC-5 cDNA samples. The PCR reacƟon was
repeated a second Ɵme, on this occasion no bands were present in the CNTF groups,
but GAPDH posiƟve bands (≈473 bp) were present in the control group (see ﬁgure 3.6).
As the purpose of this exercise was not speciﬁcally to sequence CNTF, but to ascertain
whether the RGC-5 cells were of mouse origin I decided to go ahead and sequence the
GAPDH posiƟve samples. Subsequent sequence alignments (see ﬁgure 3.6) conﬁrmed
that the RGC-5 cDNA was of mouse (Mus musculus) not rat (RaƩus norvegicus) origin.
Sequence alignment revealed that the GAPDH mouse homologue shared 97% idenƟty
with the RGC-5 sequence whilst the rat homologue shared 96% idenƟty.
To conﬁrm that RGC-5 cells were of mouse origin, a region of the NG2 and CD44 genes
were selected for sequencing (see ﬁgure 3.7). Sequences were aligned using ClustalX and
compared against published sequences for both NG2 (RaƩus norvegicus:
NM_001170558.1; Mus musculus: Mm: NM_001081249.1) and CD44 (RaƩus norvegi-
cus: M61875.1; Mus musculus: NM_009851.2). Sequence alignments revealed that the
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NG2 mouse homologue was 99% idenƟcal to the RGC-5 sequence, whereas the rat ho-
mologue was only 87% idenƟcal. The CD44 sequence alignment revealed that the RGC-
5 sequence was 100% idenƟcal to Mus musculus and shared 93% idenƟty with RaƩus
norvegicus (see ﬁgure 3.7). All sequence alignments conﬁrm that the RGC-5 cells in our
possession are derived from mouse (Mus musculus) and not rat (RaƩus norvegicus).
PCR and sequencing experiments were not performed on diﬀerenƟated RGC-5 cells be-
cause this had already been invesƟgated by Wood et al in 2010 (Wood et al. 2010). A full
comparison between their results and mine is discussed in secƟon 3.6.3.
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gi|37590766_Rn    GTCATCCATGACAACTTTGGCATCGTGGAAGGGCTCATGACCACAGTCCATGCCATCACT 
Rat_brain_GAPDH   GTCATCCATGACAACTTTGGCATCGTGGAAGGGCTCATGACCACAGTCCATGCCATCACT 
gi|126012538_Mm   GTCATCCATGACAACTTTGGCATTGTGGAAGGGCTCATGACCACAGTCCATGCCATCACT 
RGC5              GTCATCCATGACAACTTTGGCATTGTGGAAGGGCTCATGACCACAGTCCATGCCATCACT 
 
gi|37590766_Rn    GCCACTCAGAAGACTGTGGATGGCCCCTCTGGAAAGCTGTGGCGTGATGGCCGTGGGGCA 
Rat_brain_GAPDH   GCCMCTCARAAGACTGTGGATGGCCCCTCTGGAAAGCTGTGGCGTGATGGCCGTGGGGCA 
gi|126012538_Mm   GCCACCCAGAAGACTGTGGATGGCCCCTCTGGAAAGCTGTGGCGTGATGGCCGTGGGGCT 
RGC5              GCCACCCARAAGACTGTGGATGGCCCCTCTGGAAAGCTGTGGCGTGATGGCCGTGGGGCT 
 
gi|37590766_Rn    GCCCAGAACATCATCCCTGCATCCACTGGTGCTGCCAAGGCTGTGGGCAAGGTCATCCCA 
Rat_brain_GAPDH   GCCCAGAACATCATCCCTGCATCCACTGGTGCTGCCAAGGCTGTGGGCAAGGTCATCCCA 
gi|126012538_Mm   GCCCAGAACATCATCCCTGCATCCACTGGTGCTGCCAAGGCTGTGGGCAAGGTCATCCCA 
RGC5              GCCCAGAACATCATCCCTGCATCCACTGGTGCTGCCAAGGCTGTGGGCAAGGTCATCCCA 
 
gi|37590766_Rn    GAGCTGAACGGGAAGCTCACTGGCATGGCCTTCCGTGTTCCTACCCCCAATGTATCCGTT 
Rat_brain_GAPDH   GAGCTGAACGGGAAGCTCACTGGCATGGCCTTCCGTGTTCCTMCCCCCAATGTATCCGTT 
gi|126012538_Mm   GAGCTGAACGGGAAGCTCACTGGCATGGCCTTCCGTGTTCCTACCCCCAATGTGTCCGTC 
RGC5              GAGCTGAACGGGAAGCTCACTGGCATGGCCTTCCGTGTTCCTACCCCCAATGTGTCCGTC 
 
gi|37590766_Rn    GTGGATCTGACATGCCGCCTGGAGAAACCTGCCAAGTATGATGACATCAAGAAGGTGGTG 
Rat_brain_GAPDH   GTGGATCTGACATGCCGCCTGGAGAAACCTGCCAAGTATGATGACATCAAGAAGGTGGYG 
gi|126012538_Mm   GTGGATCTGACGTGCCGCCTGGAGAAACCTGCCAAGTATGATGACATCAAGAAGGTGGTG 
RGC5              GTGGATCTGACGTGCCGCCTGGAGAAACCTGCCAAGTATKATGACATCWAGAAGGTGGTG 
 
gi|37590766_Rn    AAGCAGGCGGCCGAGGGCCCACTAAAGGGCATCCTGGGCTACAC 
Rat_brain_GAPDH   AA------------------------------------------ 
gi|126012538_Mm   AAGCAGGCATCTGAGGGCCCACTGAAGGGCATCTTGGGCTACAC 
RGC5              AAKCAKGCWTCTGASGKCCCACTGAATGGY-TCTTGTSCTAC-- 
 
C 
Figure 3.6: Rat CNTF primers do not anneal to RGC-5 cDNA. (A.) Rat CNTF primers were used
to amplify rat brain and RGC-5 cDNA in a PCR reacƟon and samples were run on a 0.7% agarose
gel. No band was present in the RGC-5 sample. However a band of the expected size (≈550 bp)
was present within the rat brain posiƟve control lane. (B.) Primers were re-designed and the ex-
periment repeated to include GAPDH controls for both rat brain and RGC-5 samples. No bands
were present within the CNTF groups — however bands (≈473 bp) were present in the GAPDH
control groups. (C.) RGC-5 and rat brain PCR products were sequenced and aligned using ClustalX
alignments for GAPDH. The sequence alignment also included the published genes for RaƩus
norvegicus (Rn) GAPDH (gi: 37590766) and Mus musculus (Mm) GAPDH (gi: 126012538). Areas
highlighted in green indicate areas of rat homology, whereas regions highlighted in pink signify
areas of mouse homology. Sequence alignments conﬁrm that the RGC-5 cell line was not derived
from rat.
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Mm: NM_001081249.1 CTTACTTTTAACACCAGAATTAGAAAGTTCAAATGTAGATGCATCTAGTGATTTGGCTACCTGGGAAGGTTTTATTC 
RGC5               CTTACTTTTA-CACCAGAATTAGAAAGTTCAAATGTAGATGCATCTAGTGATTTGGCTACCTGGGAAGGTTTTATTC 
Rn: NM_001170558.1 CTTACTCTTAACTTCAGAATTAGAAAGTTCAAATGTGGCTGCATCTAGTCCTTTGGACACCTGGGAAGGTTTTGTGC 
 
Mm: NM_001081249.1 TAGAGACAACACCCACAGAGTCTGAAAAGGAAATGGCAAATTCAACTCCTGTTTTTAGAGAAACAATTGGTGTAGCC 
RGC5               TAGAGACAACACCCACAGAGTCTGAAAAGGAAATGGCAAATTCAACTCCTGTTTTTAGAGAAACAATTGGTGTAGCC 
Rn: NM_001170558.1 CAGAGACAACATCAACAGTGTCCGAAAAGGAAATGGCAAACACAACTCCTGTTTTTACAGAAACAAGTGATGTAGCC 
 
Mm: NM_001081249.1 AATGTGGAGGCACAGCCCTTTGAGCATAGCAGTAGTAGTCATCCCAGGGTTCAGGAAGAGCTGACCACTCTCTCAGG 
RGC5               AATGTGGAGGCACAGCCCTTTGAGCATAGCAGTAGTAGTCATCCCAGGGTTCAGGAAGAGCTGACCACTCTCTCAGG 
Rn: NM_001170558.1 AATTTGGAGACACAGTCTTTTGAGCATAGTAGTAGCAGTCAGCCCAGGGTACAGGAAGAGCTGACCACTCTCTCAGG 
 
Mm: NM_001081249.1 AAATCCCCCCTCTCTTTTTACGGACCTGGGCTCAGGAGATGCTAGTACTGGTATGGAACTCATCACTGCTTCTTTAT 
RGC5               AAATCCCCCCTCTCTTTTTACGGACCTGGGCTCAGGAGATGCTAGTACTGGTATGGAACTCATCACTGCTTCTTTAT 
Rn: NM_001170558.1 AAAGCCCCCCTTGATTTTTATGGACCTGGGTTCAGGAGATGCTAGTACTGATATGGAATTCATCACTGCTTCTTCAT 
 
Mm: NM_001081249.1 TTACATTAGATTTAGAGTCTGAAACCAAAGTCAAAAAGGAATTACCCAGTACTCCGTCTCCCAGTGTGGAGATATCA 
RGC5               TTACATTAGATTTAGAGTCTGAAACCAAAGTCAAAAAGGAATTACCCAGTACTCCGTCTCCCAGTGTGGAGATATCA 
Rn: NM_001170558.1 TTACATTAGATTTGGAGTCCGATACCAAAGTCAAAAAAGAATTACCCAGTACTCTGTCTCCCAGTGTGGAGACTTCA 
 
Mm: NM_001081249.1 TCCTCTTTTGAGCCAACAGGATTAACCCCGAGTACTGTACTAGACATAGAAATTGCTGGAGTTATGAGCCAGA 
RGC5               TCCTCTTTTGAGCCAACAGGATTAACCCCGAGTACTGTACTAGACATAGAAATTGCTGGAGTTATGAGSCARA 
Rn: NM_001170558.1 TCCTCCTCTGAGCCAATAGGATTAGCTCCGAGTACTGTATTGGACATAGAAATTGTGGAAGTTATGAATCAGA 
 
 
 
Mm: NM_009851.2    GTGCGAACCAGGACAGTGGAGTGACCACAACTTCTGGTCCTATGAGGAGACCTCAGATTCCAGAATGGCTCATCATCTTGG 
RGC5               CGMMSRRTSACTGAMGTGGAGTGACCACAACTTCTGGTCCTATGAGGAGACCTCAGATTCCAGAATGGCTCATCATCTTGG 
Rn: M61875.1       GTGGGAATCAAGACAGTGGAGTGACCACAACTTCTGGTCCTGCGAGGAGACCTCAGATTCCAGAGTGGCTTATCATCTTGG 
 
Mm: NM_009851.2    CATCTCTCCTGGCACTGGCTCTGATTCTTGCCGTCTGCATCGCGGTCAATAGTAGGAGAAGGTGTGGGCAGAAGAAAAAGC 
RGC5               CATCTCTCCTGGCACTGGCTCTGATTCTTGCCGTCTGCATCGCGGTCAATAGTAGGAGAAGGTGTGGGCAGAAGAAAAAGC 
Rn: M61875.1       CATCCCTCCTGGCGCTGGCTCTGATTCTTGCCGTCTGCATTGCTGTCAACAGTAGGAGAAGGTGTGGGCAGAAGAAGAAGC 
 
Mm: NM_009851.2    TGGTGATCAACGGTGGCAATGGGACGGTGGAAGACAGGAAACCCAGTGAGCTCAACGGGGAGGCCAGCAAGTCTCAGGAAA 
RGC5               TGGTGATCAACGGTGGCAATGGGACGGTGGAAGACAGGAAACCCAGTGAGCTCAACGGGGAGGCCAGCAAGTCTCAGGAAA 
Rn: M61875.1       TGGTGATCAACAGTGGCAATGGAACAGTGGAAGACAGGAAACCAAGTGAACTCAACGGGGAGGCCAGCAAGTCTCAGGAAA 
 
Mm: NM_009851.2    TGGTGCATTTGGTGAACAAGGAACCATCAGAGACCCCGGACCAGTGTATGACAGCTGACGAGACCCGGAATCTGCAGAGTG 
RGC5               TGGTGCATTTGGTGAACAAGGAACCATCAGAGACCCCGGACCAGTGTATGACAGCTGACGAGACCCGGAATCTGCAGAGTG 
Rn: M61875.1       TGGTGCATTTGGTGAACAAGGAACCAACAGAGACTCCGGACCAGTTTATGACAGCTGATGAGACCCGGAATCTGCAGAGTG 
 
Mm: NM_009851.2    TGGACATGAAGATTGGGGTGTAGTGCCTACGCCATTAACTTGAAAAGACAGCACGATTGGAGAC 
RGC5               TGGACATGAAGATTGGGGTGTAGTGCCTACGCCATTAACTTGAAAAGACAGCACGATWRRAGAC 
Rn: M61875.1       TGGATATGAAGATTGGGGTGTAGTGCCTATGCCACTAACTTGAAAAGACACAACAATTGGAGAC 
B 
C 
Figure 3.7: NG2 and CD44 PCR Products and Sequence Alignments. (A.) NG2 and CD44 primers
were used to amplify RGC-5 cDNA in a PCR reacƟon. Clear bands of the correct were present
for both NG2 (≈475 bp) and CD44 (≈381 bp). To conﬁrmmy original ﬁndings, RGC-5 PCR products
were sequenced and aligned using ClustalX alignments for (B.) NG2 and (C.) CD44. Sequence align-
ment also included published genes for NG2 (Mm. NM_001081249.1) (Rn. NM_001170558.1)
and CD44 (Mm. NM_009851.2) (Rn M61875.1). The sequencing data conﬁrms that RGC-5 cells
are derived from mouse. Areas highlighted in green indicate areas of rat homology whereas re-
gions in pink signify areas of mouse homology.
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3.5.2 Primer OpƟmisaƟon
To determine primer speciﬁcity and opƟmum annealing temperature a series of PCR re-
acƟons were performed. The ampliﬁed products were separated on a 1% agarose gel and
visualised by EtBr staining. A series of primers were designed to characterise the RGC-5
cell line and determine its origin. An annealing temperature of 50 C produced a high
degree of smearing and non-speciﬁc ampliﬁcaƟon. As a result, an annealing tempera-
ture of 55 C was selected for all future experiments. Primers which were unsuccessful
at amplifying the desired products were re-designed for use in future experiments.
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Figure 3.8: OpƟmisaƟon of Annealing Temperature. IniƟal primer opƟmisaƟon was performed
onmouse brain cDNA (posiƟve control). The genes of interest were ampliﬁed in a PCR reacƟon for
30 cycles (for reacƟon condiƟons see secƟon 2.1.13) then separated on a 1% agarose gel. An an-
nealing temperature of 50 C produced a high degree of smearing and non-speciﬁc ampliﬁcaƟon.
As a result an annealing temperature of 55 C was selected for all future experiments. This tem-
perature reduced non-speciﬁc annealing and produced clean bands. 1. βIII-Tubulin 2. CD11b 3.
CD44 4. CD68 5. CD113 6. ChAT 7. GFAP 8. NesƟn 9. NeuroD 10. Neurogenin-1 11. Neurogenin-
2 12. Neuroﬁlament-H 13. Neuroﬁlament-L 14. Neuroﬁlament-M 15. NG2 16.Oligodendrocyte
transcripƟon factor-1 (Olig-1) 17. oligodendrocyte transcripƟon factor-2 (Olig-2) 18. Pax-6 19.
RALDH2 20. sex determining region Y box-1 (SOX-1) 21. SOX-2 22. Tau 23. Thy-1 24. Tyrosine
Hydroxylase 25. UCLH 26. GAPDH.
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3.5.3 Determining the exponenƟal phase of the PCR reacƟon
For each primer, the exponenƟal phase of the PCR reacƟon was determined using cDNA
from the posiƟve control groups. The results of which are displayed in appendix A.
3.5.3.1 Neuronal marker expression
Semi-quanƟtaƟve PCR was used to determine whether the RGC-5 cell line has a neuronal
lineage, primers were designed for a selecƟon of neuronal markers (NF-H, NF-M, NF-L,
Tau, Thy-1 and βIII-Tubulin). Mouse brain cDNA was included as a posiƟve control whilst
GAPDH was included as an internal control. Clear bands of the correct size were present
in all mouse brain control posiƟve control groups (conﬁrming primer speciﬁcity) for each
set of markers. RGC-5 cells did not express mRNAs for NF-H, NF-M, NF-L, Tau and Thy-1,
but weakly expressed βIII-Tubulin (see ﬁgure 3.9a).
3.5.3.2 Expression of glial markers
Semi-quanƟtaƟve PCRwas used to establish whether the RGC-5 cell line had a glial origin.
Mouse brain cDNA was included as a posiƟve control whilst GAPDH was included as an
internal control. Clear bands of the correct size were present in all mouse brain control
posiƟve control groups (conﬁrming primer speciﬁcity) for each set ofmarkers. In contrast,
RGC-5 cells did not express mRNAs for the astrocyte marker, GFAP, the ﬁbroblast marker
RALDH2 or the acƟvated microglia marker CD11b (see ﬁgure 3.9b).
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3.5.3.3 Developmental Marker Expression
RGC-5 cells strongly expressed CD44 mRNA (a marker of haematopoieƟc stem cell ori-
gin), NesƟn (an intermediate ﬁlament protein commonly found in progenitors) and PAX-6
(Pax-6, a master control gene for the development of the eye and other sensory organs).
RGC-5 cells did not express CD133 mRNA (a marker found in neuronal, endothelial, glial,
glioblastoma and hematopoieƟc progenitor cells), nor choline acetyltransferase (ChaT)
mRNA (ChaT, an enzyme synthesised by neurons and required for their normal funcƟon)
(see ﬁgure 3.9c). However, RGC-5 cells did weakly express mRNA for SOX-1 (SOX-1, a
marker of cells restricted to the neuroectoderm in embryos) (see ﬁgure 3.9c).
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Figure 3.9: Semi-quanƟtaƟve PCR analysis of selected neuronal, glial and progenitor cell mRNA
markers in RGC-5 cells. Clear bands of the correct size were present in all mouse brain posiƟve
control groups for all mRNAs tested. (A.) RGC-5 cells expressed liƩle or nomRNA for neuronal cell
markers including βIII-Tubulin, Neuroﬁlament-H, Neuroﬁlament-L, Neuroﬁlament-M, Tau and Thy-
1. (B.) RGC-5 cells did not express mRNAs for the astrocyte marker, GFAP, the ﬁbroblast marker
RALDH2, or the acƟvated microglia marker CD11b. (C.) RGC-5 cells were strongly posiƟve for
CD44, NesƟn and Pax-6 – this was indicaƟve of a early progenitor marker cell lineages. However,
RGC-5 cells did not express mRNA for CD133 or ChAT and only very weakly expressed SOX-1. See
ﬁgures A.1, A.2 and A.3 for the opƟmisaƟon processes.
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3.5.4 RGC-5 cells are derived from the oligodendroglial lineage
RGC-5 cells expressedmRNAmarkers consistent with those found in the oligodendroglial
lineage. Clear bands of the correct size were present in all mouse brain posiƟve control
groups. InteresƟngly, RGC-5 cells co-expressed mRNA for markers of mature and imma-
ture oligodendrocytes (see ﬁgure 3.10). For example, RGC-5 cells expressed mRNAs for
NG2, CNPase and GalC, but tested negaƟve for MBP (a marker of mature myelinaƟng
oligodendrocytes). NG2 and CAII expression, was conﬁrmed by immunocytochemistry
(see ﬁgure 3.11) and sequencing (see ﬁgure 3.7b). Since strong immunoreacƟvivity was
seen in all cells (not just a subpopulaƟon) it is unlikely that this consƟtutes a mixed popu-
laƟon of cells. RGC-5 cells also displayed strong homogeneous immunoreacƟvity for CAII
(carbonic anhydrase II, typically expressed at all stages of oligodendrocyte development
(Baumann & Pham-Dinh 2001)). RGC-5 cells did not express mRNA for Olig-1 or -2.
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Figure 3.10: Semi-quanƟtaƟve PCR shows that RGC-5 cells express markers of the oligoden-
droglial lineage. Clear bands of the correct size were present in all mouse brain posiƟve control
groups for all mRNAs tested. RGC-5 cells expressed mRNAmarkers of both mature and immature
oligodendrocytes (GalC and NG2), but tested negaƟve for Olig-1, Olig-2 and MBP. See ﬁgure A.4
for the opƟmisaƟon process.
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Figure 3.11: Immunocytochenistry shows that RGC-5 cells express markers of the oligoden-
droglial lineage. RGC-5 cells co-express NG2 (green), a CSPG and marker of NG2 glia, as well
as CAII (red). Strong immunoreacƟvity was observed in all cells. DAPI stained nuclei are in blue.
Scale bars = 20 µm.
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3.5.5 RGC-5 cells are not derived from cone photoreceptors
To establish whether the RGC-5 cell line was derived from cone photoreceptors of the
reƟna, as suggestedpreviously (Woodet al. 2010), semi-quanƟtaƟvePCR for blue-sensiƟve
opsin was performed and comparedwith cDNA frommouse eyes (posiƟve control). Clear
bands of the correct size were present in all mouse eye control groups, but absent from
the RGC-5 test group (see ﬁgure 3.12). This demonstrates that the RGC-5 cell line is not
derived from blue sensiƟve cone photoreceptors.
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Figure 3.12: RGC-5 cells are not derived from cone photoreceptor cells. Semi-quanƟtaƟve PCR
analysis shows that RGC-5 cells did not express blue-sensiƟve opsin, a marker of cone photore-
ceptor cells. However, a clear band of the correct size was present in the mouse eye posiƟve
control group. See ﬁgure A.5 for the opƟmisaƟon process.
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3.5.6 Densitometry
Densitometric quanƟﬁcaƟon was performed on all of the posiƟve lineage markers ex-
pressed in RGC-5 cells and compared to that of the mouse brain posiƟve controls. Apart
from βIII-Tubulin, all mRNA markers were expressed in greater abundance than mouse
brain posiƟve controls (see ﬁgure 3.13). All the mRNAmarkers were expressed in greater
abundance in RGC-5 cells than in the mouse brain posiƟve controls (see ﬁgure 3.13).
Moreover, RGC-5 cells expressed signiﬁcantly more CD44, CNPase and NesƟnmRNA than
in the mouse brain posiƟve controls. The only excepƟon to this was βIII-Tubulin, which
was weakly expressed in the RGC-5 cell line.
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Figure 3.13: Densitometric Analysis of PCR Products. RGC-5 PCR products were compared
against a mouse brain posiƟve control. All measurements were normalised to GAPDH (internal
control). All lineagemarkers were expressed in greater abundance thanmouse brain posiƟve con-
trols. The only excepƟon to this was βIII-Tubulin, which was weakly expressed in the RGC-5 cell
line. Densitometric analysis was performed on PCR products from 3 independent experiments,
apart from Pax-6 which represents n = 2. ***p ≤ 0.001, **p ≤ 0.01. StaƟsƟcal test = independent
T-test. Due to the low n number, staƟsƟcs were not performed on Pax-6 densitometry measure-
ments.
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3.6 Discussion
3.6.1 Morphological analysis of Staurosporine treated RGC-5 cells
Previous studies (FrasseƩo et al. 2006) have suggested that Staurosporine, a broad spec-
trum protein kinase inhibitor, is capable of diﬀerenƟaƟng the RGC-5 cell line. Accord-
ing to the literature (FrasseƩo et al. 2006), Staurosporine treatment induces cell cycle
arrest, morphological changes, upregulaƟon of neuronal markers (Thymocyte diﬀerenƟ-
aƟon anƟgen 1, microtubule-associated protein 2 (MAP2) and N-Methyl-D-asparƟc acid
(NMDA-R1) and establishment of outward recƟfying channels.
Unfortunately the mechanism by which Staurosporine induces diﬀerenƟaƟon is not yet
fully understood. Its mechanism of acƟon is presumably related to kinase inhibiƟon how-
ever, it's unclear as to which kinases are directly responsible. In 2006 FrasseƩo et al
tested a variety of diﬀerent kinase inhibitors to determine which were involved in the
RGC-5 diﬀerenƟaƟon process (FrasseƩo et al. 2006). Although treatment with H-1152
(a Rho kinase inhibitor) and H-89 (a non-speciﬁc protein kinase-A inhibitor) resulted in
some process formaƟon, however the morphological changes induced were dissimilar
from Staurosporine treated RGC-5 cells (FrasseƩo et al. 2006). Although each kinase in-
hibitor induced RGC-5 process formaƟon, somal roundingwas not evident, irrespecƟve of
whether the kinase inhibitors were added alone or in combinaƟon (FrasseƩo et al. 2006).
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In 2009 Thompson et al took a diﬀerent approach, by comparing Staurosporine against
other structurally related molecules (K252a1, K252b2, K252c3, UCN-014 and PKC-4125)
(Thompson & Levin 2010). RGC-5 cells were treated with each of these compounds and
morphological measurements (somal rounding, process formaƟon, number of processes
etc.) were taken. They found that only Staurosporine and-hydroxystaurosporine (UCN-
01) (the most structurally similar) induced diﬀerenƟaƟon of the RGC-5 cell line – both of
which induced somal rounding and process extension. Since Staurosporine and UCN-01
were the only compounds that contained an accessible methoxy group at the 3ʹ carbon
and a neighbouring amine group, they concluded that these structural groups were re-
sponsible for causing RGC-5 diﬀerenƟaƟon.
One of the limitaƟons of using Staurosporine as a diﬀerenƟaƟng agent is that very liƩle
is known about its mechanism of acƟon. As Staurosporine is a broad spectrum kinase
inhibitor it has mulƟple targets, many of which have not yet been idenƟﬁed. As a result,
Staurosporine should be used with care as it may be diﬃcult to make direct comparisons
between Staurosporine treated cell lines and primary cell cultures.
Although many targets have not yet been idenƟﬁed many have, and these include: PKC
(see secƟon 1.8.3.2), protein kinase A (PKA) and protein kinase G (PKG) (Tamaoki, et al.
1986). In addiƟon to this Staurosporine also inhibits a variety of cell cycle regulators
19,12-epoxy-1H-diindolo[1,2,3-fg:3ʹ,2ʹ,1ʹ-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-
2(5R,6S,8S)-6-hydroxy-5-methyl-13-oxo-6,7,8,13,14,15-hexahydro-5H-16-oxa-4b,8a,14-triaza-5,8-
methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacene-6-carboxylic acid
3Staurosporine aglycone
47-hydroxystaurosporine
54ʹ-N-benzoylstaurosporine
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including cyclin dependent kinase 1 (regulates M phase), cyclin dependent kinase 2 (reg-
ulates G1/S phase) and cyclin dependent kinase 5 (regulates TranscripƟon). AddiƟonal
targets include: janus-kinase 2 (JAK-2) (see secƟon 1.9.2), epidermal growth factor recep-
tor kinase, platelet derived growth factor receptor, myosin-light chain kinase (regulates
cellular morphology), ROCK (see secƟon 1.6.2), MAP/ERK kinase (see secƟon 1.8.3.1) and
Akt (see secƟon 1.8.3.3) (Bain, et al. 2003). Using this diﬀerenƟaƟon agent may present
a number of problems when invesƟgaƟng growth and/or inhibitory signalling pathways,
since staurosporine inhibits key mediators of many of these pathways.
To determine whether Staurosporine did indeed induce morphological changes consis-
tent with that of an RGC phenotype, it was decided to perform a Staurosporine dose
response experiment. In agreement with other published works (Wood et al. 2010, Fras-
seƩo et al. 2006), RGC-5 cells do exhibit disƟncƟve morphological changes aŌer Stau-
rosporine treatment (see ﬁgures 3.1, 3.2 and 3.3). Staurosporine treatment led to in-
creases in the length of the longest process, and processes length/cell, with a concentra-
Ɵon of Staurosporine between 0:1 µÃ to 1:78 µÃ favouring opƟmumprocess outgrowth.
In addiƟon to this, Staurosporine treatment signiﬁcantly enhanced process number (com-
pared to controls), with maximal process number being achieved at 562 nÃ. Process
number declined between 1 µÃ to 3:16 µÃ, this may have been a result of increased cy-
toxicity (see ﬁgure 3.4). Moreover, Staurosporine treatment led to a dose dependent
increase in process branching. Maximal branching was achieved at a dose of 1 µÃ to
1:78 µÃ, the extent of process branching was dramaƟcally reduced by concentraƟons
higher than this, presumably as a result of cytotoxicity (see ﬁgure 3.4).
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In order to establish a suitable concentraƟon to induce diﬀerenƟaƟon whilst keeping tox-
icity to aminimum, a cell viability assay was performed. In retrospect this wasn’t the best
approach to take since comparisons can’t be easily made between loss of viability and re-
duced cell number due to cell cycle arrest. Ideally I should have combined this approach
with direct cell counts and BrdU or Tunnel immuno-labelling, as this would have allowed
me to disƟnguish between mitoƟc and post-mitoƟc cells. This would have allowed me to
more accurately disƟnguish between toxicity and cell cycle arrest.
The results show that there was a signiﬁcant reducƟon in mean ATP content aŌer treat-
ment with high doses of Staurosporine (1 µÃ, 1:78 µÃ or 3:16 µÃ) compared to all other
treatment groups (see ﬁgure 3.4). Although this indicates that Staurosporine could have
caused some toxicity, addiƟonal experiments would need to be performed to conﬁrm
this (see previous). InteresƟngly, a number of other studies (Thompson & Levin 2010)
(FrasseƩo et al. 2006) have shown that Staurosporine does indeed cause toxicity at doses
higher than 316 nÃ, aŌer direct cell counƟng. This suggests that the reducƟon of ATP
seen in ﬁgure was likely a result of toxicity.
Treatment with 0.1%, 1% and 2% DMSO did not cause signiﬁcant toxicity compared to
the untreated control. I am fairly conﬁdent that this was the case, since all of the cells
present within these groups were sƟll acƟvely dividing, however this would sƟll need to
be conﬁrmed by addiƟonal experiments.
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3.6.2 RGC-5 sequencing
Sequencing analysis of GAPDH (see ﬁgure 3.6), CD44 and NG2 (see ﬁgure 3.7) has re-
vealed that the cells in my possession are derived from mice (Mus musculus) not rats
(RaƩus norvegicus). The distribuƟon of this misidenƟﬁed and/or cross-contaminated
cell does not appear to be an isolated occurrence — two other laboratories have cor-
roborated these ﬁndings (Bergen et al. 2009). However this in itself does not exclude
the use of the RGC-5 cell line as an appropriate alternaƟve for primary reƟnal culture. To
assess this, it was necessary to look at the expression proﬁle of the RGC-5 cell line.
3.6.3 RGC-5 expression proﬁle
Semi-quanƟtaƟve PCR analysis has revealed that the RGC-5 cell line does not express
mRNA for markers of mature RGC, (Thy1, NF-M, NF-L, NF-H and Tau) and only weakly
expressed the neuronal marker βIII-Tubulin (see ﬁgure 3.9a). As a result the RGC-5 cell
line is unlikely to be derived from mature RGC. Furthermore, RGC-5 cells did not express
markers of ﬁbroblasts (RALDH2), acƟvatedmicroglia (CD11b) ormacrophages (CD68) (see
ﬁgure 3.9b).
Since the original report of the generaƟon of the RGC-5 cell line (R.R.Krishnamoorthy
et al. 2000), many discrepancies with primary RGC have been idenƟﬁed. For example,
there has been marked decrease in glutamate sensiƟvity suggesƟng that the RGC-5 cells
were pharmacologically less ganglion-cell like (Bergen et al. 2009, Fan, et al. 2005, Maher
& Hanneken 2005).
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Contrary to previously published works (Wood et al. 2010), the RGC-5 cell line does not
express mRNA for blue-sensiƟve Opsin, a marker of cone photoreceptors. In this study
(Wood et al. 2010), Opsin expression was determined through the use of western blot-
Ɵng and immunostaining. This discrepancy may have been due to a problem with anƟ-
body speciﬁcity. It is possible that the anƟbody exhibited cross-reacƟvity with an anƟgen
present on the RGC-5 cell line.
However, in agreement with this study (Wood et al. 2010), RGC-5 cells expressed βIII-
Tubulin but did not express Thy-1, NF-H, NF-M or NF-L – even aŌer treatment with any
of the known RGC-5 diﬀerenƟaƟng agents (Staurosporine, Succinyl-concanavalin A and
TrichostaƟn).
RGC-5 cells expressed mRNAs for NG2, CNPase and GalC (oligodendroglial lineage mark-
ers) but tested negaƟve forMBP (amarker ofmaturemyelinaƟng oligodendrocytes). NG2
expression (a marker of oligodendrocyte progenitors / NG2 glia) was further conﬁrmed
by immunocytochemistry and sequencing analysis (see ﬁgure 3.7). In light of this infor-
maƟon, it seems unlikely that these cells were even derived from the eye, since oligo-
dendrocyte progenitors are typically absent from the reƟna.
InteresƟngly, RGC-5 cells did not express oligodendrocyte transcripƟon factor 1 and 2
(Olig- 1, Olig-2) (see ﬁgure 3.10). These genes encode basic helix-loop helix transcripƟon
factors and are expressed exclusively by oligodendrocytes and NG2 glia/oligodendrocyte
progenitors. Furthermore, RGC-5 cells strongly express the neural stem cell marker Pax-6
(see ﬁgure 3.9c). This was surprising since RGC-5 cells express many markers consistent
with an oligodendroglial lineage. This may in some way explain the absence of Olig-2
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expression since It has been well documented that (Agarwal et al. 2007) there is an in-
verse correlaƟon between Olig-2 and Pax-6 expression — over expression of Pax-6 gen-
erally leads to down regulaƟon of Olig-2 and progression towards a neuronal fate (Jang &
Goldman 2011). It is also possible that these cells may be derived from a subpopulaƟon
of NG2 glia which expresses Pax-6, or that these cells have not yet commiƩed themselves
to a parƟcular cell fate.
InteresƟngly, RGC-5 cells highly expressed mRNA for both CD44 and NesƟn (see ﬁgure
3.9c)— thiswas not surprising since both aremarkers ofmulƟlineage progenitors (Wiese,
et al. 2004). NesƟn is highly upregulated in proliferaƟng oligodendrocyte progenitors
(Gallo & Armstrong 1995). Moreover, NesƟn and CD44 are upregulated in response to
injury, so it is also possible that thismay have been a consequence of the isolaƟon process
(Frisen, et al. 1995, Moon, et al. 2004).
The wide range of dispariƟes in RGC-5 cell phenotypes, which encompass the original
characterisƟcs given by Agarwal and colleagues (R.R.Krishnamoorthy et al. 2000, Agar-
wal et al. 2007) and more recent re-evaluaƟons (Bergen et al. 2009, Wood et al. 2010),
are probably explained by inadequate isolaƟon during passage (American Type Culture
CollecƟon Standards Development OrganizaƟonWorkgroup ASN-0002 2010), diﬀerenƟal
methods of screening and misidenƟﬁcaƟon (MacLeod, et al. 1999, Masters, et al. 2001,
Thompson, et al. 2004) throughmislabelling (American Type Culture CollecƟon Standards
Development OrganizaƟon Workgroup ASN-0002 2010) and cross-contaminaƟon with
other cell lines. For example, phenotypic screening may yield divergent results when
using speciﬁc anƟbody marker techniques compared to DNA ampliﬁcaƟon, restricƟon
digest and sequencing analyses. Once contaminated, invading cells can swiŌly over-ride
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and eventually replace the resident cell line (Nims, et al. 1998). For example, a study con-
ducted by the american Type Culture CollecƟon (ATCC) found that 27 out of 56 cell lines
were contaminated by the HeLa cell line (Lavappa, et al. 1976), while another found that
ECV304 (Dirks, et al. 1999), a normal human endothelial cell line, had become contam-
inated by the bladder cancer derived T24 cell line, and two human prostate cancer cell
lines, TSU-Pr1 and JCA-1 (van Bokhoven, et al. 2001). Despite the applicaƟon of genotyp-
ing, karyotyping and cell marker idenƟﬁcaƟon, the use ofmisidenƟﬁed and contaminated
cell lines conƟnues to invalidate results, waste Ɵme and resources, andmake comparison
between published works impossible.
3.7 Conclusions
The overall aim of this study was to establish whether the RGC-5 cell line could be used
as a subsƟtute for primary RGC. From the current data it is evident that the RGC-5 cell
line is not what it was originally reported to be. The RGC-5 cells in our laboratory were
derived from a mouse oligodendroglial lineage and were not ganglion or cone photore-
ceptor cells.
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CHAPTER 4
IN VITRO EFFECTS OF CNTF IN PRIMARY
RETINAL CULTURE
Page | 131
4.1 TesƟng the eﬀecƟveness of CNTF in primary reƟnal culture
Before a long term in vivo delivery strategy was undertaken, it was decided to look at
the eﬀecƟveness of CNTF treatment on primary reƟnal cultures. It was also necessary
to conﬁrm that CNTF could disinhibit RGC neurite outgrowth whilst in an inhibitory en-
vironment. To this end, a dose response experiment was performed to determine the
opƟmum CNTF concentraƟon for RGC.
Having determined the opƟmum CNTF concentraƟon, it was necessary to test this dose
in the presence of a growth inhibitory ligand. To achieve this, the recombinant Nogo-P4
pepƟde was chosen to crudely mimic the inhibitory CNS environment aŌer injury. Nogo-
P4 was selected in preference to central myelin extract for a number of reasons. Firstly,
the recombinant protein is soluble, allowing the dose to be easily modiﬁed if opƟmisa-
Ɵon was required. In contrast, central myelin extract is lipid rich and contains an array of
inhibitory ligands, therefore it would be necessary to fully characterise and Ɵtrate each
batch of central myelin extract before use. This is a Ɵme consuming and expensive pro-
cess which is further impeded by the presence of contaminaƟng growth factors, such as
ﬁbroblast growth factor 2 (FGF2). Secondly, Nogo has a well deﬁned signalling proﬁle
which has been extensively characterised — this would make it easier to monitor CNTF
and/or Nogo dependent signalling mechanisms. Once opƟmised, this neurite growth
inhibitory assay could be used to reproducibly inhibit RGC neurite outgrowth. Further-
more, this assay could be used to test a variety of neuritogenic and/or neuroprotecƟve
therapeuƟcs in vitro.
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Several studies suggest that CNTF is ineﬀecƟve at directly sƟmulaƟng RGC axon growth
(Cui, et al. 2008), whilst others suggest that cAMP elevaƟon is required for CNTF to be
eﬀecƟve (Müller, et al. 2009). Furthermore, it was recently proposed that CNTF exerts
its eﬀects indirectly through the acƟvaƟon of macrophages/microglia (Cen, et al. 2007).
As there has been some controversy regarding the eﬀecƟveness of CNTF in vitro (Müller
et al. 2009) and in vivo (Müller et al. 2009). It was also necessary to establish whether an
addiƟonal elevaƟon in cAMP was required to sƟmulate neurite outgrowth. To establish
this it was decided to test each CNTF dose in the presence of a cAMP elevator, namely
Forskolin (an acƟvator of adenylate cyclase).
As already discussed, cAMP is important both developmentally and aŌer injury. cAMP
levels not only modulate neuronal responsiveness to myelin inhibitory ligands, but can
also inﬂuence their capacity for regrowth (Cai et al. 2001, Cai, et al. 1999). cAMP acƟvates
PKA to exert many of its biological eﬀects and acts independently to that of the JAK/STAT,
MAPK/ERK and PI3-K/Akt signalling pathways (Li, et al. 2000).
4.2 Aims
1. Develop an assay for assessing whether recombinant CNTF can disinhibit RGC neu-
rite outgrowth in vitro in the presence of a growth inhibitory ligand.
2. Determine whether an elevaƟon in cAMP is required for CNTF to eﬀecƟvely sƟmu-
late RGC neurite outgrowth.
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3. Determine whether AAV2-CNTF-hrGFP, AAV2-CNTF-FLAG and AAV2-CNTF-shRhoA-
hrGFP constructs produce biologically relevant levels of CNTFwhen transfected into
HEK-293 cells.
4.3 Results
4.3.1 Primary reƟnal cultures
Primary reƟnal cultures were prepared as in secƟon 2.1.1 and incubated for 4 d. Cul-
tures contained a mixed populaƟon of cells comprising of both reƟnal neurons and glia.
RGCmake up approximately 1% of the total cell populaƟon in mixed reƟnal cultures. The
remaining cell populaƟon is made up of reƟnal neurons (e.g. amacrine cells, photore-
ceptors, bipolar cells and horizontal cells), reƟnal glia (e.g. Müller glia and astrocytes),
and endothelial cells. Primary RGC were idenƟﬁed from other cell types by size, mor-
phology and βIII-Tubulin (a neuronal marker which is highly expressed in mature RGC)
immunoreacƟvity (see ﬁgure 4.1). The size criterion was based on the assumpƟon that
RGC typically have a cell diameter of 12 µm or less (Guenther, et al. 1994) (see ﬁgure 4.1).
Primary RGC were incubated for 24 h to allow the cells to adhere to the plate — the test
reagents (Nogo-P4 pepƟde and CNTF) were then added. RGC survival and neurite exten-
sion were assessed 3 d later (96 h aŌer plaƟng). A yield of approximately 1 106 reƟnal
cells were extracted from each reƟna and plated at a density of 130 000 cells well 1.
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Figure 4.1: RepresentaƟve bright ﬁeld images of control primary reƟnal cultures. Primary RGC
were idenƟﬁed in culture by their disƟncƟve morphology and size. ReƟnal cells were incubated
for 24 h to allow the cells to adhere to the plate, all test reagents were added at this Ɵme point.
Primary RGC typically have a cell diameter of 12 µm or less (Guenther et al. 1994) and tend to
extend neurites within 96 h of plaƟng. Figture shows control reƟnal cultures (A.) 24h (B.) 48h (C.)
72h (D.) 96h aŌer plaƟng. Black arrows point to the soma of primary RGC, whilst red arrows point
to the neurites.
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4.3.2 Forskolin and recombinant CNTF promotes reƟnal ganglion cell
neurite outgrowth in vitro
A range of CNTF concentraƟons was applied to adult rat primary reƟnal cultures to de-
termine whether recombinant CNTF was capable of promoƟng RGC neurite outgrowth
(see ﬁgure 4.2) and survival (see ﬁgure 4.4) in vitro.
Approximately 130 000 cells well 1were plated and given 24 h to adhere to the plate aŌer
which treatment was applied. AŌer a further 72 h the cells were ﬁxed and analysed for
mean length of longest neurite (ﬁgure 4.2a) and mean neurite length (ﬁgure 4.2b).
Results indicate that CNTF is capable of promoƟng neurite outgrowth in culture (see ﬁg-
ure 4.2a) and that this eﬀect can be augmented with increasing concentraƟons of pro-
tein. The opƟmal dosewas deemed to be 100 ngml 1 as applicaƟon of this concentraƟon
elicited the greatest eﬀect in terms of mean neurite length and mean length of longest
neurite. Treatment with 100 ngml 1 CNTF signiﬁcantly increased the mean length of
longest neurite from 18:83 µm± 1.67 (untreated control) to 33:89 µm± 2.41 (100 ngml 1
CNTF) and mean neurite length from 17:3 µm ± 0.07 (untreated control) to 29:97 µm ±
0.07 (100 ngml 1 CNTF). See ﬁgure 4.5 for representaƟve images of this experiment.
Maximal RGCneurite outgrowthwas achievedwhen Forskolinwas added alone (Forskolin
control). Treatmentwith 15 µÃForskolin signiﬁcantly increased themean length of longest
neurite from 18.82 ± 1.67 (untreated control) to 33.66 ± 2.97 (15 µÃ Forskolin) andmean
neurite length from 17.36 ± 1.43 (untreated control) to 28.21 ± 2.22 (15 µÃ Forskolin).
Similar neurite outgrowthmeasurements (meanneurite length andmean length of longest
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neurite) were obtained when CNTF (10 ngml 1, 50 ngml 1 and 100 ngml 1) was added
in combinaƟon with 15 µÃ Forskolin. However, there was no staƟsƟcally signiﬁcant dif-
ference in neurite length irrespecƟve of whether Forskolin was added alone (Forskolin
control) or in combinaƟon with CNTF (10 ngml 1, 50 ngml 1 or 100 ngml 1, see ﬁgure
4.2b).
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(a) Length of longest neurite
(b)Mean neurite length
Figure 4.2: CNTF and Forskolin promotes neurite outgrowth in vitro. ReƟnal cultures were
treated with increasing doses of CNTF. Each dose was administered alone or in combinaƟon with
15 µÃ Forskolin aŌer 24 h had passed (to allow the cells to adhere to the plate). The cells were
ﬁxed aŌer a further 72 h for analysis. When CNTF was administered alone a dose of 100 ngml 1
induced opƟmal neurite outgrowth— however, when given in combinaƟon with Forskolin a dose
of 10 ngml 1 was deemed to be opƟmal. Error bars represent the SEM. n = 3 for all treatment
groups. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, staƟsƟcal test = one-way ANOVA.
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4.3.3 CNTF and Forskolin treatment has a minimal aﬀect on neurite
number
Forskolin (15 µÃ) treated RGC possessed more neurites both with and without CNTF as
shown in ﬁgure 4.3. Primary reƟnal cells (130 000) were plated at the beginning of the
experiment, CNTF (10 ngml 1, 50 ngml 1 or 100 ngml 1) and/or Forskolin (15 µÃ) was
added 24 h later (to allow Ɵme for the RGC to adhere to the plate) and cells were ﬁxed
and analysed 72 h aŌer treatment was applied.
In most cases there was no signiﬁcant change in neurite number (ﬁgure 4.3), irrespecƟve
of whether CNTF was administered alone or in combinaƟon with Forskolin. Cells treated
with Forskolin alone (Forskolin control, 1.23 ± 0.10) had signiﬁcantly more neurites than
those treated with 100 ngml 1 CNTF (0.82 ± 0.07). RGC were idenƟﬁed by morphology
and βIII-Tubulin staining whilst neurite number was quanƟﬁed by directly counƟng the
number of RGC (secƟon 2.1.1.1 describes the sampling technique used). Figure 4.5 shows
representaƟve images of this experiment.
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Figure 4.3: CNTF and Forskolin had a minimal aﬀect on neurite number. In most cases, there
was no signiﬁcant change in neurite number. RGC within the 15 µÃ Forskolin treatment group
(Forskolin control) had signiﬁcantly more neurites than those in the 100 ngml 1 CNTF treatment
group. All Forskolin treatment groups possessed more neurites than their CNTF-treated counter-
parts. The control groups consist of an untreated (negaƟve) control and a 15 µÃ Forskolin control.
Error bars represent the SEM. n = 3 for all treatment groups. *p ≤ 0.05, staƟsƟcal test = one-way
ANOVA.
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4.3.4 10 ngml 1 and 50 ngml 1 CNTF caused minor toxicity
Toxicity was seen 72 h aŌer treatment with 15 µÃ Forskolin alone (Forskolin control)
compared to the untreated (negaƟve) control (RGC number was reduced by 23.96%).
Similar levels of toxicity were observed when Forskolin was administered together with
10 ngml 1 CNTF or 50 ngml 1 CNTF — each of which had a 22.23% reducƟon in RGC
cell number compared to untreated controls. There was no signiﬁcant change in RGC
cell number between 100 ngml 1 CNTF treated and untreated controls. Primary reƟnal
cultures were ﬁxed and analysed 96 h aŌer plaƟng (72 hour aŌer CNTF and/or Forskolin
addiƟon). RGCwere visualised by βIII-Tubulin immunostaining and idenƟﬁed by their dis-
ƟncƟve morphology (see secƟon 4.3.1). Cell survival was assessed by directly counƟng
the βIII-Tubulin posiƟve (red) RGC (see secƟon 2.1.1.1 for details of the sampling tech-
nique). As 100 ngml 1 has been shown to be an opƟmal dose for RGC neurite outgrowth,
survival and toxicity, I decided to use this dose for all future experiments. See ﬁgure 4.5
for representaƟve images of this experiment.
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Figure 4.4: Minor cytotoxicity was seen aŌer treatment with 15 µÃ Forskolin compared to un-
treated controls. 130 000 reƟnal cells were plated on day 0, treatmentwas applied 24 h aŌer plat-
ing and cell number was then assessed 96 h aŌer plaƟng by directly counƟng βIII-Tubulin posiƟve
(red) RGC. There was no signiﬁcant change in RGC number between 100 ngml 1 CNTF treated
and the untreated controls. The error bars represent the SEM from 3 independent experiments.
**p ≤ 0.01, *p ≤ 0.05, staƟsƟcal test = one-way ANOVA.
Page | 142
Figure 4.5: CNTF dose response experiment. ReƟnal cells (130 000) were treated with either
Forskolin (15 µÃ) and/or increasing concentraƟons (10 ngml 1, 50 ngml 1 and 100 ngml 1) of
CNTF 24 hour aŌer plaƟng. Cells were ﬁxed 72 h later for analysis and quanƟﬁcaƟon of cell num-
ber, neurite number and neurite length (see secƟon 2.1.1.1). Treatment with Forskolin and/or
CNTF sƟmulated RGC neurite outgrowth (highlighted in ﬁgure with red arrows). RGC were iden-
Ɵﬁed by morphology, cell soma size and βIII-Tubulin immunoreacƟvity (red). DAPI stained nuclei
are shown in blue (highlighted in ﬁgure with white arrows). Scale bar = 50 µm.
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4.3.5 100 ngml 1 CNTF increases neurite number and abolishes the
Nogo-P4 induced inhibitory eﬀect
Primary reƟnal cultures were treated with 25 µÃ Nogo-P4 pepƟde to inhibit neurite out-
growth (see ﬁgure 4.7) andneurite number (see ﬁgure 4.6). A posiƟve control of 100 ngml 1
CNTF was also included in the experiment. 25 µÃ Nogo-P4 signiﬁcantly inhibited neurite
number (0.61 ± 0.04) when compared to the untreated control (0.91 ± 0.04). A dose
of 100 ngml 1 CNTF abolished this eﬀect, increasing neurite number from 0.61 ± 0.04
(Nogo-P4 treated) to 0.84 ± 0.06 (25 µÃ Nogo-P4 and 100 ngml 1 CNTF treated). Inter-
esƟngly, there was no signiﬁcant diﬀerence between 100 ngml 1 CNTF (0.93 ± 0.05) and
untreated controls (0.91 ± 0.04). For consistency, 130 000 reƟnal cells were plated at the
start of the experiment. Treatment with Nogo-P4 pepƟde and/or CNTF was applied aŌer
24 h and cells were ﬁxed and analysed 72 h later. Neurite number was established by
directly counƟng βIII-Tubublin posiƟve RGC. Figure 4.9 shows representaƟve images of
this experiment.
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Figure 4.6: 100 ng CNTF increased neurite number and abolished the Nogo-P4 induced in-
hibitory eﬀect. Treatment with 25 µÃ Nogo-P4 pepƟde signiﬁcantly inhibited neurite number,
whereas applicaƟon of 100 ng CNTF reversed this eﬀect. This reversal brought neurite number
back in line with untreated controls. Control groups consisted of 100 ngml 1 CNTF (posiƟve con-
trol) and an untreated control (negaƟve control, labelled as `Control' in ﬁgure). Error bars repre-
sent the SEM from 3 independent experiments. ***p ≤ 0.001, staƟsƟcal test = one-way ANOVA.
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4.3.6 100 ngml 1 CNTFdisinhibitsNogo-P4 treated reƟnal ganglion cells
Primary reƟnal cultures were treated with a 25 µÃ Nogo-P4 inhibitory pepƟde to in-
hibit neurite outgrowth and to crudely mimic the inhibitory environment seen in vivo.
This dose was previously opƟmised by Dr Kevin Morrison (personal communicaƟon) and
the results obtained were consistent with his ﬁndings (see secƟon 4.4.5). A dose of
100 ngml 1 recombinant CNTF was capable of reversing Nogo-P4 induced inhibiƟon (see
ﬁgure 4.7), increasing mean length of longest neurite (see ﬁgure 4.7a) from 18:69 µm ±
1.44 (Nogo-P4 treated) to 39:46 µm±3.53 (25 µÃNogo-P4 and100 ngml 1 CNTF treated).
Furthermore, 100 ngml 1 CNTF increased mean neurite length (see ﬁgure 4.7b) from
25:58 µm ± 1.26 (Nogo-P4 treated) to 53:29 µm ± 3.34 (25 µÃ Nogo-P4 and 100 ngml 1
CNTF treated), bringing it in line with the value of the untreated control (47:07 µm ±
2.35). InteresƟngly, CNTF alone only caused a minimal increase in mean neurite length
(40:16 µm ± 3.82) and mean length of longest neurite (45:17 µm ± 4.00) compared to
untreated controls (34:84 µm ± 2.35 and 39:48 µm ± 2.71 respecƟvely), although this
eﬀect did not reach staƟsƟcal signiﬁcance. See ﬁgure 4.9 for representaƟve images of
this experiment.
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(a)Mean length of longest neurite
Figure 4.7: Eﬀect of CNTF on Nogo-P4 treated primary reƟnal culture. 130 000 reƟnal cells were
plated at the start of the experiment, 100 ng CNTF and/or 25 µÃ Nogo-P4 was added 24 h later
and results were assessed 72 h post-treatment. ApplicaƟon of 25 µÃ Nogo-P4 pepƟde signiﬁ-
cantly inhibited mean length of longest neurite and mean neurite length. ApplicaƟon of 100 ng
CNTF reversed this eﬀect, bringing measurements back in line with untreated control values. βIII-
Tubulin posiƟve neurites were measured using Image Pro® soŌware. Control groups consisted of
100 ngml 1 CNTF (posiƟve control) and an untreated control (negaƟve control, labelled as `Con-
trol' in ﬁgure). Error bars represent the SEM from 3 independent experiments. ConƟnued on next
page. ***p ≤ 0.001, staƟsƟcal test = one-way ANOVA.
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(b)Mean neurite length
Figure 4.7: Eﬀect of CNTF on Nogo-P4 treated primary reƟnal culture. ConƟnued from previous
page. Control groups consisted of 100 ngml 1 CNTF (posiƟve control) and an untreated control
(negaƟve control, labelled as `Control' in ﬁgure). Error bars represent the SEM from3 independent
experiments. ***p ≤ 0.001, staƟsƟcal test = one-way ANOVA.
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4.3.7 Nogo-P4 treatment had no eﬀect on RGC survival
Results show that there was no signiﬁcant diﬀerence in RGC survival between the un-
treated control (negaƟve control) and each of the treatment groups aŌer 72 h, see ﬁgure
4.8. RGC were visualised by βIII-Tubulin immunostaining and idenƟﬁed by their disƟnc-
Ɵve morphology (see secƟon 4.3.1). Cell survival was assessed by directly counƟng βIII-
Tubulin posiƟve (red) RGC (see secƟon 2.1.1.1 for details of the sampling technique). See
ﬁgure 4.9 for representaƟve images of this experiment.
Figure 4.8: Nogo-P4 treatment had no eﬀect on RGC survival. RGC were plated (at a density
of 130 000 cells well 1) and incubated for 24 h, treatment was then applied. AŌer a further 72 h
(96 h aŌer plaƟng) the cells were ﬁxed and analysed. RGC survival was not aﬀected by any of
the treatment groups. No signiﬁcant diﬀerence was observed in RGC number between treatment
groups and the untreated control (negaƟve control). Control groups consisted of 100 ngml 1
CNTF (posiƟve control, labelled as `Control' in ﬁgure) and untreated cells served as a negaƟve
control. Error bars represent the SEM from 3 independent experiments. StaƟsƟcal test = one-
way ANOVA.
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Figure 4.9: Nogo-P4 inhibitory assay. Immunostaining for the RGC marker βIII-Tubulin (red) in
Nogo-P4 pepƟde and CNTF treated reƟnal cultures. DAPI stained nuclei are blue. Treatment with
(C.) 25 µÃ Nogo-P4 signiﬁcantly inhibited RGC neurite outgrowth. Scale bar = 50 µm
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4.3.8 Summary of results
A range of CNTF concentraƟons (10 ngml 1, 50 ngml 1 and 100 ngml 1) were applied to
adult primary reƟnal cultures to determine whether recombinant CNTF could promote
RGC neurite outgrowth and survival in vitro. A dose of 100 ngml 1 CNTF was found to be
opƟmum since this concentraƟon induced maximal neurite outgrowth and survival.
In addiƟon to this, each concentraƟon of CNTF was tested in the presence of Forskolin
(15 µÃ) – this was done to ﬁnd out whether cAMP elevaƟonwas required to enhance the
neuritogenic eﬀects of CNTF. InteresƟngly, the addiƟon of CNTF (10 ngml 1, 50 ngml 1
or 100 ngml 1) did not signiﬁcantly augment neurite outgrowth measurements com-
pared to treatment with Forskolin alone (this is discussed in secƟon 4.4.1). In most cases
there was no signiﬁcant change in neurite number, irrespecƟve of whether Forskolin
(15 µÃ) was administered alone or in combinaƟonwith CNTF. Minor toxicity was induced
by 15 µÃ Forskolin when given in combinaƟon with 10 ngml 1 and 50 ngml 1 CNTF.
The opƟmised dose of 100 ngml 1 CNTFwas then tested in a Nogo-P4 neurite outgrowth
inhibitory assay. Nogo-P4 was added to primary reƟnal cultures to inhibit RGC neurite
outgrowth. Results show that CNTF (100 ngml 1) was capable of disinhibiƟng RGC neu-
rite outgrowth when given in combinaƟon with Nogo-P4 (25 µÃ). In this experiment,
treatment with 100 ngml 1 CNTF alone did not signiﬁcantly enhance RGC neurite out-
growth compared to the untreated control.
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4.4 Discussion
4.4.1 Forskolinwas eﬀecƟve at sƟmulaƟngRGCneurite outgrowthwhen
administered alone or in combinaƟon with a low dose of CNTF
Treatment with Forskolin (a cAMP elevator) alone signiﬁcantly enhanced mean RGC neu-
rite length and mean length of longest neurite compared to untreated controls. This was
hardly surprising since cAMP elevaƟon can sƟmulate RGC neurite outgrowth in vitro (Cai
et al. 1999) and can promote RGC axon regeneraƟon in vivo (Monsul, et al. 2004). A
similar eﬀect was observed when Forskolin was applied in combinaƟon with 10 ngml 1
CNTF.
InteresƟngly, when 10 ngml 1 CNTF was added alone the neuritogenic eﬀects were at-
tenuated. This phenomenon is consistent with previous studies that suggest treatment
with low doses of CNTF (e.g. 10 ngml 1) is insuﬃcient to promote signiﬁcant RGC neurite
outgrowth (Jo, et al. 1999).
Maximal eﬀects in terms of mean neurite length and mean length of longest neurite
were achieved using Forskolin alone or 100 ngml 1 CNTF alone. SupplementaƟon with
Forskolin caused a modest increase in RGC mean neurite length and mean length of
longest neurite — however, this eﬀect decreased with higher concentraƟons of CNTF
(50 ngml 1, 100 ngml 1).
This result may have been a consequence of CNTF receptor saturaƟon and/or CNTF re-
ceptor down-regulaƟon/desensiƟsaƟon. It is well documented that prolonged exposure
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to agonists can lead to receptor down-regulaƟon. This is certainly true in the case of
BDNF, where it has been demonstrated that conƟnuous sƟmulaƟon with recombinant
protein leads to a reducƟon in TrkB protein and mRNA levels in rat hippocampal neurons
(Frank, et al. 1996).
Furthermore, aŌer ON injury RGC begin to lose their ability to respond to NTFs, pre-
sumably through the loss of their respecƟve receptors and/or perturbaƟon of protein
traﬃcking. Like BDNF, a similar decline in responsiveness has been seen aŌer CNTF ad-
ministraƟon and this decline has been associated with a reducƟon in CNTFRɑ expression
(Miotke, et al. 2007). This is important since CNTFRɑ is a major component of the CNTF
triparƟte receptor complex. Likewise, it is possible that CNTFRɑ expression may be af-
fected by reƟnal dissociaƟon, since this process eﬀecƟvely disconnects RGC from their
respecƟve targets. However this seems unlikely since all RGCs were isolated using the
same process, and were responsive to CNTF treatment when given at the correct dose
(100 ngml 1 CNTF).
AlternaƟvely, a lower concentraƟon of Forskolin may be required to opƟmally sƟmulate
neurite outgrowthwhen high concentraƟons of CNTF are present. Whilst 15 µÃ Forskolin
may be adequate to sƟmulate signiﬁcant neurite outgrowth when supplied alone, it may
be too highwhen given in combinaƟonwith 50 ngml 1 or 100 ngml 1 CNTF. It is also pos-
sible that this dose of Forskolin (15 µÃ) saturated the system, prevenƟng further neurite
outgrowth from being achieved. Ideally I should have performed a Forskolin dose re-
sponse experiment to determine whether this was case, and to ﬁnd out whether 15 µÃ
Forskolin was indeed the opƟmum concentraƟon.
Page | 153
Since reƟnal cultures contain a variety of diﬀerent cell types one must also consider the
resident glial populaƟon. CNTF and/or Forskolin treatment may, to a greater or lesser ex-
tent, have an eﬀect on this populaƟon. This eﬀect maymanifest itself through changes in
metabolism, energy consumpƟon, neurotrophic factor producƟon or neurotrophic factor
release (Park, et al. 2004). Any of which may directly or indirectly have an eﬀect on RGC
neurite outgrowth.
4.4.2 100 ngml 1 CNTF signiﬁcantly increased mean neurite length
OpƟmal neurite outgrowth was achieved when 100 ngml 1 CNTF was added alone. This
suggests that CNTF treatment is capable of sƟmulaƟng neurite outgrowth without the
need for exogenous cAMP elevaƟon, a ﬁnding consistent with that of Müller et al (Müller
et al. 2009). Treatment with 100 ngml 1 CNTF was deemed to be opƟmal in terms of
mean neurite length and mean length of longest neurite.
InteresƟngly Müller et al tested much higher doses of recombinant CNTF compared to
those tested in chapter 4 (10 ngml 1, 50 ngml 1 and 100 ngml 1). Müller et al found
that a concentraƟon of 10 ngml 1 CNTF was suﬃcient to promote signiﬁcant RGC neu-
rite outgrowth (Müller et al. 2009). In contrast, no signiﬁcant increase in RGC neurite
outgrowth was documented at this concentraƟon in ﬁgure 4.2. This outcome could have
been due to diﬀerences in reƟnal cell preparaƟon or plaƟng density. The enhanced neu-
ritogenic eﬀects, seen at 10 ngml 1 CNTF, could be explained by diﬀerences in glial num-
ber and/or contact dependent neurotrophic support.
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Müller et al found opƟmum RGC neurite outgrowth was achieved at much higher con-
centraƟons of CNTF (200 ngml 1 CNTF) (Müller et al. 2009) — this was exactly double
the concentraƟon of my opƟmum (100 ngml 1). It is possible that recombinant CNTF is
much more eﬀecƟve at sƟmulaƟng RGC neurite outgrowth at higher concentraƟon (e.g.
at 200 ngml 1 CNTF). However, higher doses (e.g. concentraƟons >100 ngml 1) of CNTF
would need to be tested to determine whether this was the case. Unfortunately direct
comparisons in RGC neurite outgrowth could not bemade at 100 ngml 1 CNTF, since this
concentraƟon was not tested in the publicaƟon.
InteresƟngly, Müller et al used the same concentraƟon of Forskolin (15 µÃ) to deter-
mine whether a rise in cAMP was required for CNTF to be eﬀecƟve at sƟmulaƟng RGC
neurite outgrowth (Müller et al. 2009). In agreement with my results, Forskolin (15 µÃ)
was capable of sƟmulaƟng signiﬁcant RGC neurite outgrowth, when administered alone.
However, it was not required for CNTF to promote signiﬁcant neurite outgrowth in vitro.
In terms of RGC survival Forskolin groups could not be compared since survival data was
not shown in this study (for these groups) and as a result it’s impossible to tell whether
the same levels of RGC toxicity were observed. The CNTF-alone groups can be compared
and agree with my data (see ﬁgure 4.4), there was no signiﬁcant change in RGC number
aŌer treatment with increasing doses of CNTF (without Forskolin) (Müller et al. 2009).
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4.4.3 Treatment with Forskolin led a to a small reducƟon in RGC num-
ber
Cytotoxicity was seen aŌer treatment with 15 µÃ Forskolin, compared to untreated con-
trols. Similar levels of toxicity were observed when Forskolin was administered together
with 10 ngml 1 or 50 ngml 1 CNTF. Since cell counts were not performed for other reƟ-
nal cell populaƟons, it is unclear as towhether Forskolin caused the death of any other cell
types. As a result, it is diﬃcult to establish whether RGC cell death was induced directly
through exposure to Forskolin or indirectly — through the loss of glial cells (and contact
dependent neurotrophic support). It is possible that Forskolin had an adverse eﬀect on
glial cell funcƟon and that this may have contributed to the cytotoxicity seen. There was
no signiﬁcant change in RGC cell number between the 100 ngml 1 CNTF treatment group
and untreated controls. 100 ngml 1 CNTF was deemed to be opƟmal in terms of RGC
neurite outgrowth and survival. As a result this dose was used in all future experiments.
4.4.4 CNTF and Forskolin had aminimal eﬀect onmeanneurite number
Treatment with CNTF and/or Forskolin had no signiﬁcant eﬀect on RGC neurite number
compared to untreated controls. The CNTF plus Forskolin treated groups tended to have
more neurites than their CNTF alone treated counterparts, although this did not reach
staƟsƟcal signiﬁcance. It is important to note that this experiment had a relaƟvely low n
number (n = 3) and it is possible that this trendmay have reached staƟsƟcal signiﬁcance
with further repeƟƟon. In the visual systemRGC typically possess a single long axonwhich
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degenerates aŌer ONC. Consequently neurite length and RGC number were considered
to be a more important measure of axogenic and/or survival response.
4.4.5 25 µÃ Nogo-P4 pepƟde signiﬁcantly inhibited RGC neurite out-
growth
Treatment of RGC with 25 µÃ recombinant Nogo-P4 pepƟde signiﬁcantly inhibited neu-
rite outgrowth whilst causing minimal toxicity. This factor was important as we needed
to be able to diﬀerenƟate between cells lacking neurites as a consequence of apop-
tosis/necrosis and those lacking neurites as a result of Nogo-P4 induced inhibiƟon. A
dose of 25 µÃ Nogo-P4 was selected based upon previous work from our laboratory
(Morrison 2011). In his 2010 study, Dr Kevin Morrison found that doses higher than
25 µÃ caused similar levels of RGC neurite inhibiƟon, but induced signiﬁcant cell death
(Morrison 2011). In a similar study (Wang & Zhu 2008), Wang et al used Nogo-P4 to in-
hibit neuronal stem cell diﬀerenƟaƟon. They found that a dose of 4 µÃ Nogo-P4 was suf-
ﬁcient to signiﬁcantly inhibit neurite outgrowth, however, it is important to note that the
cells under invesƟgaƟonwere neural stem cells that may bemore suscepƟble to Nogo-P4
treatment than mature RGC.
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4.4.6 Treatment with 25 µÃ Nogo-P4 pepƟde had no impact on RGC
survival
Therewas no staƟsƟcally signiﬁcant diﬀerence in RGCnumber aŌer treatmentwith 25 µÃ
Nogo-P4, a ﬁnding that is consistentwith previouswork (Morrison 2011). As this dose did
not cause signiﬁcant cell death it was concluded that the growth inhibiƟon observed was
due to growth cone collapse and not a consequence of RGC necrosis and/or apoptosis.
4.4.7 Treatment with 100 ngml 1 CNTF disinhibited Nogo-P4 pepƟde
treated RGC
Treatment with 100 ngml 1 recombinant CNTF abolished the inhibitory eﬀects of Nogo-
P4 pepƟde and brought neurite measurements back in line with untreated controls. In-
teresƟngly 100 ngml 1 CNTF did not signiﬁcantly sƟmulate neurite outgrowth above that
of untreated controls. It is possible that signiﬁcance may be achieved with further repe-
ƟƟon since this experiment has a relaƟvely low n number (n = 3).
4.5 Conclusions
The purpose of this chapter was to invesƟgate the neuritogenic and/or neuroprotecƟve
eﬀects of CNTF in vitro. To this end, a dose response experiment was performed to deter-
mine the opƟmum CNTF dose. A concentraƟon of 100 ngml 1 CNTF was deemed to be
opƟmal since it signiﬁcantly enhanced neurite outgrowth compared to other CNTF con-
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centraƟons tested. Upon ﬁnding an appropriate concentraƟon, the disinhibitory proper-
Ɵes of CNTF could then be invesƟgated. To accomplish this, Nogo-P4 pepƟde was used
to inhibit RGC neurite outgrowth. Results show that Nogo-P4 pepƟde reproducibly inhib-
ited RGC neurite outgrowth, this result was consistent with previous ﬁndings fromour lab
(Morrison 2011). The use of such an inhibitory assay has many applicaƟons and could be
used to test a host of potenƟal therapeuƟcs in vitro. CNTF (100 ngml 1) was capable
of enhancing RGC neurite outgrowth when administered alone (in some circumstances),
but had a disinhibitory eﬀect when given in combinaƟonwith Nogo-P4 pepƟde. Forskolin
signiﬁcantly enhanced RGC neurite outgrowth when given alone or in combinaƟon with
a low dose of CNTF, however it was not required to potenƟate the neuritogenic eﬀects
of CNTF.
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CHAPTER 5
AAV2 AS A VECTOR FOR DELIVERING
CNTF TO THE VISUAL SYSTEM
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5.1 IntroducƟon
In the previous chapter it was established that recombinant CNTF could be used to disin-
hibit neurite outgrowth inNogo-P4 treatedprimary RGC. Itwas also shown that 100 ngml 1
CNTF could signiﬁcantly enhance RGC neurite outgrowth in a dose response experiment.
Having established the eﬀecƟveness of recombinant CNTF in vitro, the next step would
be to develop and test a viral vector CNTF gene delivery system. To accomplish this AAV2-
CNTF-hrGFP constructs were provided by Dr. Michael Douglas (Molecular Neuroscience
Group, University of Birmingham) to be used in a series of transfecƟon experiments. As
CNTF does not have a classical secretory sequence the CNTF transgene was modiﬁed
to include the ﬁrst 20 amino acids of the rat ppNGF. This region of the NGF gene con-
tains a classical secreƟon sequence, allowing CNTF to be released from HEK-293 cells
aŌer transfecƟon. CNTF ELISAs could then be performed on HEK-293 condiƟoned media
to determine whether the constructs produce CNTF. It was decided to include a FLAG-
tagged construct as it would allow discriminaƟon between CNTF transgene products and
endogenous CNTF levels in vivo (since the transgene was designed using a rat CNTF se-
quence). Secondly, the presence of a FLAG-tag would facilitate any puriﬁcaƟon aƩempts.
The ﬁnal CNTF construct included an shRNA to knockdown RhoA and silence the growth
inhibitory signalling cascade (for details on RNAi see secƟon 1.16). The aim of this was
to launch a two pronged aƩack on RGC axons — driving growth through the secreƟon of
CNTF whilst prevenƟng growth cone collapse through the knockdown of RhoA.
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The main objecƟve of this chapter was to test each AAV2 virus in vivo and to determine
whetherAAV2-CNTF-hrGFP andAAV2-CNTF-shRhoA-hrGFP could promote RGC axonal re-
generaƟon and survival.
5.1.1 Barriers to AAV2 transducƟon
TargeƟng recombinant AAV2 can be diﬃcult when the route of delivery is impeded by the
presence of other structures.
This was clearly demonstrated by Dalkara et al, who idenƟﬁed the ILM as an important
barrier of AAV reƟnal transducƟon aŌer intravitreal injecƟon. In 2009 a series of AAV
targeƟng experiments were performed to idenƟfy any potenƟal barriers and to improve
AAV transducƟon eﬃciency (Dalkara, et al. 2009). To accomplish this, they injected Cy3-
labelled AAV parƟcles (Cy3-labelled AAV1, AAV2, AAV5, AAV8 and AAV9) into the vitreous
of the eye and found that some of these serotypes accumulated at the ILM. AccumulaƟon
of AAV parƟcles seemed to be serotype speciﬁc, with AAV2 and 9 showing the greatest
level of accumulaƟon in this region. In contrast accumulaƟon at the ILM was not readily
apparent aŌer intravitreal injecƟon of AAV1-Cy3 and AAV5-Cy3. AccumulaƟon of AAV2
parƟcles are shown in ﬁgure 5.1.
To overcome this barrier Dalkara et al used Pronase-E (a non-speciﬁc protease) to punch
holes in the ILM (as shown in ﬁgure 5.2) and to increase AAV2 transducƟon eﬃciency.
Laminin immunostaining was performed to idenƟfy the ILM and tomonitor its' structural
integrity. Pronase-E disintegraƟon of the ILM was clearly apparent (see above). At high
concentraƟons (0.01%) Pronase-E treatment perturbed normal reƟnal funcƟon (Dalkara
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Figure 5.1: LocalisaƟon of Cy3-labelled AAV2 parƟcles at the ILM of the reƟna. Dalkara et al in-
jected Cy3-labelled AAV2 parƟcles (2 1012 vg/µl to 5 1012 vg/µl) into the vitreous of Sprague
Dawley rats. Animals were sacriﬁced 3 weeks later and frozen reƟnal secƟons were examined to
determine AAV2 localisaƟon. Clear accumulaƟon of Cy3-labelled AAV2 (shown in red) was readily
apparent at the vitreoreƟnal juncƟon of the eye. ReƟnal neuronswere visualised using a Calbindin
anƟbody (shown in green) and cell nuclei were labelled with DAPI (blue). Figure reproduced from
(Dalkara et al. 2009).
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et al. 2009). A concentraƟon of 0.0002% Pronase-E was found to be opƟmal as it in-
creased AAV2 transducƟon eﬃciency whilst retaining normal reƟnal funcƟon.
Figure 5.2: Pronase-E punches holes in the ILM of the reƟna. The ILM was visualised using an
anƟ-laminin anƟbody (shown in green). (a.) Uninjured / untreated control, ILM can be seen to be
intact (b.) aŌer intravitreal injecƟon of Pronase-E holes can be seen in the ILM. Figure reproduced
from (Dalkara et al. 2009).
As a result it was decided to test whether AAV2-eGFP transducƟon eﬃciency could be
improved by parƟally digesƟng the inner limiƟng membrane using Pronase-E at a con-
centraƟon of 0.0002%.
Another potenƟal barrier to viral transducƟon is the vitreous body – a transparent gel
which occupies the posterior compartment of the eye and is located between the lens
and the reƟna. Although the vitreous is primarily composed of water (99%) (Forrester,
et al. 2002), it is also occupied bymacromolecules (0.1%) such as collagen, hyaluronic acid
and CSPGs, with salts (0.9%)making up the remaining element of the intravitreal environ-
ment (Forrester et al. 2002). Collagen (predominantly type-II) forms a complex network
of ﬁbrils (10 nm to 20 nm) and gives the vitreous body its characterisƟc gelaƟnous prop-
erƟes (Forrester et al. 2002). This collagen meshwork is surrounded by hyaluronic acid
which can hinder (to a greater or lesser extent) the diﬀusion of substances throughout
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the vitreous (Forrester et al. 2002). This largely depends on the size (which can vary)
and the properƟes of the GAG (Forrester et al. 2002). The vitreous also contains a sec-
ond type of collagen, type IX, which contains three collagenous and four non-collagenous
domains. As a result of this it can interact with hyaluronic acid and collagen ﬁbrils to pro-
vide structural support (Forrester et al. 2002). Since collagen is highly hydrophobic in
nature these collagen ﬁbres conƟnually associate and dissociate to form protein aggre-
gates (Bos, et al. 2001). Therefore, the structural makeup of the vitreous is constantly
changing and this may also be a major impediment to AAV2 transducƟon. It is possible
that this network of collagen ﬁbres may entrap the AAV2 virus and prevent its diﬀusion
and subsequent infecƟon of RGC, as a result it is possible that parƟal digesƟon of these
proteins might also aid AAV2 transducƟon.
The use of proteolyƟc enzymes to permeabilise the ILMmay seem like an extreme course
of acƟon, considering that the intenƟon is to eventually develop a therapeuƟc. Although
the ILM is essenƟal during development (HalŌer 1998, Semina, et al. 2006), it is not
needed during adulthood and is oŌen removed by ophthalmic surgeons during macular
hole surgery (Dalkara et al. 2009, Mester & Kuhn 2000). Since this procedure is unfea-
sible in rodents, proteolyƟc digesƟon may serve as an appropriate alternaƟve and form
the basis for a proof of concept experiment. Due to Ɵme constraints I was unable to op-
Ɵmise the dose of Pronase-E and so it was decided to use the dose which was opƟmised
by Dalkara et al (Dalkara et al. 2009).
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5.2 Hypothesis
1. Intravitreal delivery of AAV2-CNTF-hrGFP and AAV2-CNTF-shRhoA-hrGFP will pro-
mote increased RGC survival and axonal regeneraƟon aŌer ONC.
2. Co-administraƟon with Pronase-E will enhance AAV2 transducƟon eﬃciency.
5.3 Aims
1. To promote RGC axonal regeneraƟon and survival through the delivery of AAV2-
CNTF-hrGFP and AAV2-CNTF-shRhoA-hrGFP
2. Determine whether co-injecƟon with 0.0002% Pronase-E can increase AAV2-eGFP
transfecƟon eﬃciency.
5.4 Results
5.4.1 Design and validaƟon of shRhoA containing constructs
The biological acƟviƟes of shRNA containing constructs were designed and validated by
Dr. Mike Douglas. As well as providing the shRhoA sequence present within the AAV2-
CNTF-shRhoA-hrGFP plasmid, Dr. Douglas also designed the primers required to deter-
mine the orientaƟon of the shRhoA insert. To establish biological acƟvity, Dr. Douglas
performed a series of COS-1 cell transfecƟon experiments. Plasmids containing shRhoA
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or shGFP were transfected into COS-1 cells that overexpressed rat RhoA. The eﬀecƟve-
ness of RhoA gene knockdown was compared against two addiƟonal shRhoA sequences
(see ﬁgure 5.3) – the ﬁrst of which was designed by Ahmed et al (Ahmed, et al. 2005b)
and the second by Pillé et al (Pillé, et al. 2005). At an appropriate Ɵme point, cell lysates
were collected and analysed byWestern Bloƫng. The sequence designed by Dr. Douglas
showed the greatest level of RhoA gene knockdown and was used in the ﬁnal construct.
Figure 5.3: Design and validaƟonof shRhoA containing constructs. shRhoA containing constructs
were desiged and validated by Dr. Mike Douglas. The eﬀecƟveness of RhoA gene knowndownwas
compared against two previously published sequences, (B.) Pillé et al and (C.) Ahmed et al. The
sequence designed by Dr. Douglas (A.) (sequence unavailable) showed the greatest level of gene
knockdown and was used in the ﬁnal AAV2 construct.
5.4.2 HEK-293 cells transfectedwithAAV2-CNTF-hrGFP,AAV2-CNTF-shRhoA-
hrGFP and AAV2-CNTF-FLAG produced detectable levels of CNTF
An ELISA was performed to determine whether AAV2-CNTF-hrGFP, AAV2-CNTF-shRhoA-
hrGFP or AAV2-CNTF-FLAG constructs could produce detectable levels of CNTF 5 d aŌer
transfecƟon. Since all CNTF constructs possessed a GFP reporter, transfecƟon eﬃcien-
cies could bemonitored through the use of ﬂuorescencemicroscopy. CondiƟonedmedia
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was also collected from untransfected (negaƟve control), lipofectamine treated (reagent
control) and AAV2-eGFP transfected (transfecƟon control) HEK-293 cells. CNTF was de-
tected in condiƟoned media obtained from the AAV2-CNTF-hrGFP, AAV2-CNTF-shRhoA-
hrGFP and AAV2-CNTF-FLAG transfecƟon groups — although the concentraƟon of CNTF
produced varied considerably between each of the treatment groups. The concentraƟon
of CNTF in the AAV2-CNTF-hrGFP treatment group was approximately 5x the concentra-
Ɵon of CNTF in theAAV2-CNTF-shRhoA-hrGFP andAAV2-CNTF-FLAG groups. As expected,
CNTF was not detected in any of the control groups.
Figure 5.4: CNTF ELISA on HEK-293 CondiƟoned Media. AAV2-CNTF-hrGFP, AAV2-CNTF-shRhoA-
hrGFP and CNTF-FLAG constructs produce biologically relevant levels of CNTF 7 d aŌer transfec-
Ɵon. TheAAV2-CNTF-hrGFP construct producedmore CNTF thanAAV2-CNTF-FLAGorAAV2-CNTF-
shRhoA-hrGFP, this may have been due to increased toxicity or the presence of the FLAG-tag in-
terfering with secreƟon.
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5.4.3 Co-injecƟonwith 0.0002%Pronase-E signiﬁcantly enhancedAAV2-
eGFP transducƟon, but caused some cell death
Co-administraƟon with 0.0002% Pronase-E signiﬁcantly enhanced RGC GFP transducƟon
compared to AAV2-eGFP (1 1011 vg/10µl) alone in reƟnal wholemount preparaƟons
30 d aŌer intravitreal injecƟon (as in secƟon 2.2.6, see ﬁgure 5.5). When AAV2-eGFPwas
administered alone 17% of the RGC populaƟon was GFP posiƟve, however when deliv-
ered in combinaƟon with 0.0002% Pronase-E, 52% of the surviving RGC populaƟon was
GFP posiƟve. Treatment with 0.0002% Pronase-E caused a signiﬁcant reducƟon (18%,
192:3 RGC/mm2 ± 26 RGC/mm2) in total RGC number. Furthermore GFP expression was
signiﬁcantly weaker in the AAV2-eGFP alone treatment group compared to the AAV2-
eGFP + Pronase-E treatment group (see ﬁgure 5.5).
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Figure 5.5: AAV2-eGFP transducƟon. QuanƟﬁcaƟon of RGC survival and GFP transducƟon 30 d
aŌer 1 1011 vg/10µl AAV2-eGFP intravitreal injecƟon. Co-injecƟon with 0.0002% Pronase-E sig-
niﬁcantly enhanced RGC GFP transducƟon in reƟnal wholemount preparaƟons. However, there
was a signiﬁcant reducƟon in the number of FG posiƟve RGC. The results represent RGC counts
from 3 eyes ± SEM. *p ≤ 0.05, ***p ≤ 0.001. StaƟsƟcal test = one-way ANOVA.
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Figure 5.6: AAV2-eGFP transducƟon representaƟve wholemount images. RepresentaƟve im-
ages of FG-traced (red) and GFP transduced (green) RGC in reƟnal wholemount preparaƟons (30
days aŌer 1 1011 vg/10µl AAV2-eGFP intravitreal injecƟon). FG was colourised red so that RGC
co-localisaƟon (yellow) could be visualised. Scale bar = 50 µm.
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5.4.4 RGC survival was not enhanced byAAV2-CNTF-hrGFP + Pronase-E
or AAV2-CNTF-shRhoA-hrGFP + Pronase-E treatment
Sprague Dawley rats received an intravitreal injecƟon of AAV2 virus 30 d prior to receiv-
ing an ONC injury. RGC counts obtained from H&E stained frozen reƟnal secƟons 23 d
post ONC (see secƟon 2.1.4 for details) demonstrates that all AAV2 treatment groups
(1 1011 vg/10µl (AAV2-eGFP + Pronase-E, AAV2-CNTF-hrGFP + Pronase-E and AAV2-
CNTF-shRhoA-hrGFP + Pronase-E) induced signiﬁcant (***p ≤ 0.001) RGC cell death, caus-
ing ≈40% reducƟon in RGC cell number compared to the uninjured/uninjected control
group (see ﬁgure 5.7). RGC cell loss was accompanied by thinning of the IPL and OPL, this
was parƟcularly evident in AAV2-eGFP injected animals (see ﬁgure 5.8). There was no sig-
niﬁcant change in mean RGC number between all AAV2 treatment groups. As expected
uninjured control reƟnal secƟons retained a normal morphological appearance.
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Figure 5.7: RGC Survival was not enhanced by AAV2-CNTF-hrGFP or AAV2-CNTF-sRhoA Treat-
ment. There was no signiﬁcant diﬀerence in RGC survival between each of the AAV2 treatment
groups, however there was a ≈40% reducƟon in RGC cell number compared to uninjured controls.
The results represent RGC counts from 3 eyes ± SEM. ***p ≤ 0.001. StaƟsƟcal test = one-way
ANOVA.
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5.4.5 AAV2-CNTF-hrGFP and CNTF-shRhoA did not promote extensive
RGC axonal regeneraƟon
Intravitreal injecƟonofAAV2-CNTF-hrGFP (1 1011 vg/10µl) + 0.0002%Pronase-E orAAV2-
CNTF-shRhoA-hrGFP (1 1011 vg/10µl) + 0.0002% Pronase-E 30 d before ONC failed to
promote signiﬁcant axon regeneraƟon (animals were sacriﬁced 23 d aŌer ONC injury)
when compared to the control (AAV2-eGFP + 0.0002% Pronase-E).
Although GAP-43 posiƟve axons (shown in ﬁgure 5.11B and 5.12B) entered the crush site
(*) in both cases, very few entered the distal stump (D) of the ON (see ﬁgures 5.9, 5.11
and 5.12). RGC axons were found, for both treatment groups, to not regenerate beyond
1200 µm (hence why quanƟﬁcaƟon stops at 1200 µm).
A signiﬁcant diﬀerence in the mean number of RGC axons was found at 400 µm for an-
imals treated with AAV2-CNTF-hrGFP + 0.0002% Pronase-E when compared to the con-
trol (AAV2-eGFP + 0.0002% Pronase-E). The mean number of RGC axons was found to
be signiﬁcantly fewer, see ﬁgure 5.9 for quanƟﬁcaƟon. There was no signiﬁcant diﬀer-
ence in mean number of RGC axons at all other distances (100 µm, 200 µm, 800 µm and
1200 µm).
WhenAAV2-CNTF-shRhoA + 0.0002%Pronase-Ewas compared to the control signiﬁcantly
fewer RGC axons (mean of directly counted RGC axons across 3 secƟons per ON and 3 ON
per treatment group) were found at 200 µm from the crush site. There was no signiﬁcant
diﬀerence in mean number of RGC axons at all other distances (100 µm, 400 µm, 800 µm
and 1200 µm).
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InteresƟngly no GFP was seen in any of the secƟons (despite the use of polyclonal anƟ-
bodies to amplify the signal), as a result the lack of regeneraƟon (see ﬁgures 5.9, 5.10,
5.11 and 5.12) or survival (see ﬁgures 5.7 and 5.8) may have been a consequence of in-
eﬀecƟve viral transducƟon.
AAV2-CNTF-hrGFP + Pronase-E and AAV2-CNTF-shRhoA-hrGFP + Pronase-E did not pro-
mote extensive RGC axonal regeneraƟon 23 d aŌer ONC (see ﬁgure 5.12). Although GAP-
43 posiƟve axons entered the crush site (*), very few entered the distal stump (D). From
the examples in ﬁgure 5.11, it appears that there are more GAP-43 posiƟve axons in the
proximal stump compared to the negaƟve control (AAV2-eGFP + Pronase-E), suggesƟng
that AAV2-CNTF-hrGFP + Pronase-E and AAV2-CNTF-shRhoA-hrGFP + Pronase-E could be
neuroprotecƟve. This is clearly not the case, since there was no signiﬁcant diﬀerence be-
tween RGC number in H&E stained reƟnal secƟons (see secƟon 5.4.4). InteresƟngly no
GFP was seen in any of the secƟons, as a result the lack of regeneraƟon (see ﬁgures 5.10,
5.11 and 5.12) or survival (see ﬁgure 5.7) may have been a consequence of ineﬀecƟve
viral transducƟon.
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Figure 5.9: QuanƟﬁcaƟon of RGC axon regeneraƟon. Animals received an intravitreal in-
jecƟon of AAV2-eGFP + 0.0002% Pronase-E, AAV2-CNTF-hrGFP + 0.0002% Pronase-E or AAV2-
CNTF-shRhoA-hrGFP + 0.0002% Pronase-E; aŌer 30 d the animals were given an ON crush in-
jury and aŌer a further 23 d the animals were sacriﬁced. Intravitreal injecƟon of AAV2-CNTF-
hrGFP (1 1011 vg/10µl) + 0.0002% Pronase-E or AAV2-CNTF-shRhoA-hrGFP (1 1011 vg/10µl) +
0.0002% Pronase-E failed to promote signiﬁcant axon regeneraƟon when compared to the con-
trol (AAV2-eGFP + 0.0002% Pronase-E). RGC axons were found to not regenerate beyond 1200 µm
from the centre of the crush site.
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Figure 5.10: Intravitreal injecƟon ofAAV2-eGFP + 0.0002% Pronase-E did not promote RGC axon
regeneraƟon 23 d post-ONC. Although GAP-43 posiƟve (shown in red) axons (see B) entered the
crush site (*) very few entered the distal stump (D) of the ON (see A1). (A.)Merged image show-
ing GAP-43 (red), eGFP (green) and DAPI (blue) staining. (A1.) A magniﬁed secƟon of A showing
some GAP-43 posiƟve axons cross the crush site and enter the distal stump of the injured ON. (B.)
Image showing GAP-43 stained RGC axons only. (C.) eGFP immunostaining was not readily appar-
ent, however autoﬂuorescent macrophages (or eGFP posiƟve debris) can be seen (C1.) shows a
magniﬁed secƟon of C. P = proximal site, * = crush site, D = distal stump. Scale bar = 100 µm
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Figure 5.11: Intravitreal injecƟon ofAAV2-CNTF + 0.0002%Pronase-E did not promote RGC axon
regeneraƟon 23 d post-ONC.GAP-43 posiƟve axons (shown in red) are seen to enter the crush site
(*), however very few enter the distal stump (D) - as can be seen in the magniﬁed image A1. (A.)
Merged image showing GAP-43 (red), eGFP (green) and DAPI (blue) staining. (A1.) A magniﬁed
secƟon of A showing some GAP-43 posiƟve axons cross the crush site and enter the distal stump
of the injured ON. (B.) Image showing GAP-43 stained RGC axons only. (C.) eGFP immunostaining
was not readily apparent. P = proximal site, * = crush site, D = distal stump. Scale bar = 100 µm
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Figure 5.12: Intravitreal injecƟon of AAV2-CNTF-shRhoA + 0.0002% Pronase-E did not promote
RGC axon regeneraƟon 23 d post-ONC. A shows that although GAP-43 posiƟve axons (red) en-
tered the crush site (*), very few entered the distal stump (D). (A.)Merged image showing GAP-43
(red), eGFP (green) and DAPI (blue) staining. (A1.) A magniﬁed secƟon of A showing some GAP-
43 posiƟve axons cross the crush site and enter the distal stump of the injured ON. (B.) Image
showing GAP-43 stained RGC axons only. (C.) eGFP immunostaining was not readily apparent. P
= proximal site, * = crush site, D = distal stump. Scale bar = 100 µm
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5.5 Discussion
5.5.1 CondiƟonedmedia collected fromAAV2-CNTF-hrGFP,AAV2-CNTF-
shRhoA-hrGFP andAAV2-CNTF-FLAG transfectedHEK-293 cells con-
tained detectable levels of CNTF
CondiƟonedmediawas collected fromAAV2-CNTF-hrGFP,AAV2-CNTF-shRhoA-hrGFP and
AAV2-CNTF-FLAG transfected HEK-293 cells. CNTF ELISAs were performed to determine
whether each of the CNTF constructs produced detectable levels of CNTF. InteresƟngly
CNTF levels in the AAV2-CNTF-shRhoA-hrGFP and AAV2-CNTF-FLAG groups were lower
than that ofAAV2-CNTF-hrGFP alone. Cytotoxicitywas apparent in theAAV2-CNTF-shRhoA-
hrGFP transfected cells, this may have also led to a decrease in CNTF secreƟon.
5.5.2 AAV2-eGFP + Pronase-E signiﬁcantly enhanced AAV2-eGFP trans-
ducƟon
Co-administraƟon with 0.0002% Pronase-E signiﬁcantly enhanced RGC GFP transducƟon
compared toAAV2-eGFP alone in reƟnalwholemount preparaƟons (see ﬁgure 5.5). When
AAV2-eGFP was administered alone 17% of the RGC populaƟon was GFP posiƟve, how-
ever, when delivered in combinaƟon with 0.0002% Pronase-E 52% of the surviving RGC
populaƟon was GFP posiƟve. This was probably a direct consequence of digesƟon of the
inner-limiƟng membrane as in (Dalkara et al. 2009) or due to the degradaƟon or dam-
age of AAV2 receptors laminin or HSPG receptors. It is also possible that the presence
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of Pronase-E made the vitreous more permissible, as previously discussed (see secƟon
5.1.1).
5.5.3 AAV2-eGFP + Pronase-E signiﬁcantly reduced RGC number in reƟ-
nal wholemount preparaƟons
Treatment with 0.0002% Pronase-E caused a signiﬁcant reducƟon (18%, 192:3 RGC/mm2
±26 RGC/mm2) in total RGCnumber. FurthermoreGFPexpressionwas signiﬁcantlyweaker
in the AAV2-eGFP alone treatment group compared to the AAV2-eGFP + Pronase-E treat-
ment group (see ﬁgure 5.6). It is possible that the toxicity observed in ﬁgure 5.5 was a
direct consequence of GFP expression. Several studies (Klein, et al. 2006) have shown
a posiƟve correlaƟon between GFP expression and cell death. For example, Klein et al
has demonstrated that neuronal death in the substanƟa nigra aŌer AAV8 injecƟon was
a direct consequence of GFP expression (Klein et al. 2006). Cell death was aƩributed to
GFP expression, since injecƟon of the AAV8 vector alone (absent the GFP reporter) did
not induce cell death (Klein et al. 2006). Moreover, toxicity was ameliorated by a reduc-
Ɵon in viral Ɵtre, presumably as a consequence of reduced infecƟvity (Klein et al. 2006).
Furthermore, GFP toxicity has also been reported in primary neuronal cultures (Detrait,
et al. 2002, Krestel, et al. 2004) and a variety of cell lines (Liu, et al. 1999). Although
the mechanism through which GFP causes cell death remains unclear, several proposals
have been made: It is possible that GFP aﬀects normal cell funcƟoning through the per-
turbaƟon of polyubiquiƟnaƟon (Baens, et al. 2006). This post-translaƟonal modiﬁcaƟon
is parƟcularly important in modulaƟng p53 tumour suppressor acƟvity as well as other
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important signalling events (e.g. NF-κB and JNK signalling) (Baens et al. 2006). Another
possibility is that GFP accumulates and prevents retrograde and anterograde transport
of essenƟal proteins and nutrients. Furthermore it has been documented that conƟnual
sƟmulaƟon of eGFP can cause cell death through the producƟon of free radicals (cited in
(Liu et al. 1999)).
Another potenƟal explanaƟon is that the high viral Ɵtre of theAAV2-eGFP virus (1 1011 vg/10µl)
induced RGC cell death. To establish this it would be necessary to perform a dose re-
sponse experiment. Furthermore it would also be necessary to test diﬀerent doses of
virus using AAV2 vector alone (absent GFP transgene)— thiswould allowme to diﬀerenƟ-
ate between toxicity induced by viral dose and toxicity induced by eGFP expression. Since
an untreated control group wasn't present in the reƟnal wholemount survival counts I
was unable to ascertain whether a dose of 1 1011 AAV2-eGFP virus caused toxicity.
Perhaps one of themore obvious explanaƟons is that Pronase-E directly caused the death
of reƟnal RGC throughprotein degradaƟon. Todeterminewhether thiswas case, a Pronase-
E dose response experiment could be performed. Although Dalkara et al (Dalkara et al.
2009) reported that 0.0002% Pronase-E did not cause RGC cell death, independent con-
ﬁrmaƟon of this would need to be performed.
Due to Ɵme constraints the AAV2-eGFP transducƟon experiments and ON crush exper-
iments were run in parallel. As a result, it was decided to co-inject 0.0002% Pronase-E
with each of the AAV2 treatment groups (i.e. AAV2-eGFP, AAV2-CNTF-hrGFP and AAV2-
CNTF-shRhoA-hrGFP).
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5.5.4 AAV2-CNTF-hrGFP andAAV2-CNTF-shRhoA-hrGFP didnot promote
extensive axonal regeneraƟon
AAV2-CNTF-hrGFP and AAV2-CNTF-shRhoA-hrGFP did not promote extensive axonal re-
generaƟon 23 d post ONC (see ﬁgures 5.11 and 5.12). Although quite a few GAP-43 pos-
iƟve axons (red) were present in the proximal stump (of AAV2-CNTF-hrGFP and AAV2-
CNTF-shRhoA-hrGFP injected animals, see ﬁgures 5.11 and 5.12), very few axons tra-
versed the crush site and entered the distal stump. Due to the low n number (n = 1)
RGC axonal regeneraƟon was not quanƟﬁed.
InteresƟngly no GFP was seen in any of the ON secƟons, this may have been due to a
number of reasons. It is possible that AAV2 had diﬃculty reaching the target cell de-
spite co-administraƟon with Pronase-E. Histological examinaƟon of the ILM would indi-
cate whether this was the case. AlternaƟvely GFP expression may have been too weak to
detect visually, to determine whether this was the case IHC could be performed using an
anƟbody targeted against GFP. This is a possibility since the hrGFP transgene is translated
from the IRES – a process which is less eﬃcient and can result in weaker reporter gene
expression.
Another possibility is that any virally transduced cells were killed oﬀ as a result of vi-
ral Ɵtre or GFP toxicity (as previously discussed in secƟon 5.5.3). Furthermore, since
0.0002% Pronase-E is toxic to RGC, the presence of this enzyme may have also been a
factor, making fewer RGC available for virally mediated transducƟon.
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5.5.5 AAV2-CNTF-hrGFP andAAV2-CNTF-shRhoA-hrGFP did not protect
RGC from cell death
ReƟnal counts (from H&E stained reƟnal secƟons) demonstrate that there was no signiﬁ-
cant diﬀerence in RGC number between each of the AAV2-treatment groups (AAV2-eGFP
+ Pronase-E, AAV2-CNTF-hrGFP + Pronase-E and AAV2-CNTF-shRhoA-hrGFP + Pronase-
E) 23 d post ONC – however signiﬁcant RGC cell death was exhibited compared to un-
treated/uninjured controls, with a ≈40% reducƟon in RGC cell survival. Once more this
may have been a consequence of ineﬀecƟve viral delivery (as previously discussed in
secƟon 5.1.1) or the presence of toxic substances (Pronase-E, see ﬁgure 5.7). Since GFP
expression was not seen in any of the reƟnal secƟons examined, the likelihood of GFP
mediated toxicity was reduced.
5.6 Conclusions
The ILM appears to be a major barrier to AAV2-mediated gene transducƟon via intrav-
itreal injecƟon. Although co-administraƟon with Pronase-E could signiﬁcantly facilitate
this process, it also led RGC cell death. Unfortunately I am unable to make any solid con-
clusions as to the eﬀecƟveness of long term CNTF delivery (and/or RhoA knockdown)
since the AAV2 delivery technique clearly requires further opƟmisaƟon.
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CHAPTER 6
GENERAL DISCUSSION
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6.1 Main Findings and Future Work
The main objecƟve of this invesƟgaƟon was to determine whether CNTF could promote
RGC axonal regeneraƟon and survival aŌer ON transecƟon. In order to determine these
eﬀects in vitro, it was necessary to develop an assay by which neuronal and glial eﬀects
could be monitored independently. As described previously (see secƟon 1.1) the reƟna
contains a variety of diﬀerent cell types. Each of these cell populaƟons can contribute
towards any therapeuƟc outcome through the release of NTF or inhibitory molecules.
Thismakes it diﬃcult to dissect out neuronal and/or glia speciﬁcmechanisms. In an eﬀort
to try and diﬀerenƟate between these mechanisms, it was decided to characterise an
RGC-5 cell line. This was done primarily to determine whether the RGC-5 cell line could
be used as a subsƟtute for primary reƟnal culture. This would be a parƟcularly eﬀecƟve
tool at monitoring the neuronal eﬀects of CNTF since some groups have hypothesized
that CNTF acts indirectly through the acƟvaƟon of macrophages (Cen et al. 2007) and/or
astrocytes (Müller et al. 2009).
Unfortunately the RGC-5 cell line was not what it was originally reported to be, and is
likely derived from a mouse oligodendrocyte progenitor lineage (see chapter 3). As a re-
sult of this, it was decided to test our therapeuƟc agent of interest (e.g. recombinant
CNTF) in primary reƟnal cultures (see chapter 4). Although this assay did not allow for
disƟncƟon between neuronal and glial speciﬁc responses, it allowed me to evaluate the
overall funcƟonal outcome of CNTF treatment. During the course of this invesƟgaƟon it
was established that a dose of 100 ngml 1 CNTF was opƟmum in terms of RGC neurite
outgrowth and survival, and that this dose was capable of disinhibiƟng RGC neurite out-
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growth. Moreover, Forskolin signiﬁcantly enhanced RGC neurite outgrowth when given
alone (or in combinaƟonwith a low dose of CNTF), but was not required to potenƟate the
neuritogenic eﬀects of CNTF. To be able to disƟnguish between neuronal and glial speciﬁc
responses it would be advantageous to be able to assess the eﬀecƟveness of recombinant
CNTF on a relaƟvely pure populaƟon of RGC — to accomplish this, an immunopanning
technique could be used to isolate primary RGC.
6.1.1 Viral Delivery
In agreement with Dalkara et al (Dalkara et al. 2009), the ILM was conﬁrmed to be a
major barrier to AAV2 mediated gene transducƟon when administered intravitreally. To
address this problem, a series of in vivo experiments could be performed to opƟmise viral
transgene delivery. This would involve performing an AAV2 dose response experiment to
ﬁnd an opƟmal viral concentraƟon. To be an eﬀecƟve therapeuƟc vector, this dose would
need to be capable of reproducibly and eﬃciently transducing RGC without causing any
adverse eﬀects (e.g. RGC toxicity). To determine this, each dose would need to be tested
in the presence and absence of a GFP reporter, so that the cause (e.g. viral Ɵtre, GFP ex-
pression) of any toxicity could be easily assessed. A Pronase-E dose response experiment
could also be performed to determine whether 0.0002% Pronase-E was the cause of RGC
cell death in chapter 5. To establish this histological examinaƟon of the ILM would also
be advantageous so that the extent of degradaƟon could be assessed. Although the ILM
seems to be a signiﬁcant structural barrier to AAV2 mediated gene transducƟon, other
potenƟal barriers do exist and it is possible that Pronase-E has aﬀects other than to the
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ILM. For example Pronase-E may degrade proteins of the vitreous making the environ-
ment more permissible to viral entry.
Since only a single injecƟon of virus was administered to Sprague Dawley rats the eﬀect
of mulƟple injecƟons could also be invesƟgated. Furthermore, the use of slow release
devices could be invesƟgated as an alternaƟve to virally mediated gene transfer.
The use of such a device has several advantages:
1. It would eliminate the need of using a virus at all.
2. TherapeuƟc intervenƟon would be instantaneous (i.e. not necessary to wait up to
30 d for suﬃcient transgene expression).
3. The implant could be removed if required.
Intravitreal injecƟon of AAV2-CNTF-hrGFP + 0.0002% Pronase-E or AAV2-CNTF-shRhoA-
hrGFP + 0.0002% Pronase-E did not rescue RGC from cell death 23d post ONC. As dis-
cussed previously, this was probably a result of defecƟve viral delivery. AAV2-CNTF-hrGFP
and AAV2-CNTF-shRhoA-hrGFP failed to promote signiﬁcant RGC axon regeneraƟon 23 d
aŌer ONC. Furthermore, no GFP was detected in the secƟons despite the use of anƟbod-
ies to enhance any signal present. A future experiment would be to replace the AAV2-
eGFP virus (control) with one containing hrGFP, since hrGFP was used in AAV2-CNTF-
hrGFP and AAV2-CNTF-shRhoA-hrGFP viral vectors.
Furthermore it would be necessary to establish whether the shRNA present in the AAV2-
CNTF-shRhoA-hrGFP virus was eﬀecƟve at knocking down RhoA expression in primary
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RGC. To accomplish this, reƟnas could be harvested from intravitreally injected animals,
and RhoA expression assessed through real Ɵme PCR and/or western blot analysis. Fur-
thermore, CNTF over expression could be conﬁrmed using similar techniques.
6.2 Conclusions
The ﬁndings of this thesis provide extensive evidence that the RGC-5 cell line was not
what it was originally reported to be (R.R.Krishnamoorthy et al. 2000, Agarwal et al. 2007)
– and is in fact derived from mouse oligodendrocyte progenitor cells. It was found that
recombinant CNTF could promote RGC neurite outgrowth in vitro, and could disinhibit
Nogo-P4 treated RGC. Although RGC axonal regeneraƟon and survival were not promoted
in vivo (due to ineﬃcient viral delivery) CNTF and/or shRhoA sƟll has the potenƟal to be
an eﬀecƟve therapeuƟc in vivo.
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APPENDIX A
CHARACTERISATION OF THE RGC-5 CELL
LINE
This appendix contains addiƟonal ﬁgures from the characterisaƟon of the RGC-5 cell line
chapter (chapter 3).
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Figure A.1: RGC-5 neuronal marker expression. Complete version of ﬁgure 3.9a showing all the
bands from the opƟmisaƟon of the semi-quanƟtaƟve PCR experiment. RGC-5 cells expressed liƩle
or no mRNA for neuronal cell markers including βIII-Tubulin, Neuroﬁlament-H, Neuroﬁlament-L,
Neuroﬁlament-M, Tau and Thy-1. (A.) βIII Tubulin (B.) Neuroﬁlament H (C.) Neuroﬁlament L (D.)
Neuroﬁlament M (E.) Tau (F.) Thy1 (G.) GAPDH
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Figure A.2: RGC-5 glial marker expression. Complete version of ﬁgure 3.9b showing all the bands
from the opƟmisaƟon of the semi-quanƟtaƟve PCR experiment. RGC-5 cells did not express mR-
NAs for the astrocyte marker, GFAP, the ﬁbroblast marker RALDH2, or the acƟvated microglia
marker CD11b. (A.) RALDH2 (B.) CD11b (C.) CD68 (D.) GAPDH. (E.) GFAP.
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Figure A.3: RGC-5 developmental marker expression. Complete version of ﬁgure 3.9c showing
all the bands from the opƟmisaƟon of the semi-quanƟtaƟve PCR experiment. RGC-5 cells were
strongly posiƟve for CD44, NesƟn (not shown) and Pax-6 – this was indicaƟve of a early progenitor
marker cell lineages. However, RGC-5 cells did not expressmRNA for CD133 or ChAT and only very
weakly expressed SOX-1. (A.) SOX1 (B.) CD44 (C.) CD133 (D.) ChAT (E.) PAX6 (F.) GAPDH.
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Figure A.4: RGC-5 oligodendroglial lineage marker expression. Complete version of ﬁgure 3.10
showing all the bands from the opƟmisaƟon of the semi-quanƟtaƟve PCR experiment. Clear
bands of the correct size were present in all mouse brain posiƟve control groups for all mRNAs
tested. RGC-5 cells expressed mRNA markers of both mature and immature oligodendrocytes
(GalC and NG2), but tested negaƟve for Olig-1, Olig-2 and MBP. (A.) MBP (B.) GalC (C.) NG2 (D.)
Olig-1 (E.) Olig-2 (F.) GAPDH
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Figure A.5: Blue-sensiƟve opsin expression. Complete version of ﬁgure 3.12 showing all the
bands from the opƟmisaƟon of the semi-quanƟtaƟve PCR experiment. Semi-quanƟtaƟve PCR
analysis shows that RGC-5 cells did not express blue-sensiƟve opsin, a marker of cone photore-
ceptor cells. However, a clear band of the correct size was present in the mouse eye posiƟve
control group.
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